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Human Dual specificity tyrosine (Y)-Regulated Kinase 1A (DYRK1A) is a protein kinase 
encoded by a dosage-dependent gene. An extra copy of DYRK1A contributes to Down syndrome 
(DS) pathogenesis while loss of one allele causes severe mental retardation and autism. 
DYRK1A is involved in phosphorylation of several proteins that regulate cell cycle control and 
tumor suppression. However, the function and regulation of this kinase is not well understood 
and current knowledge does not fully explain dosage-dependent function of this important 
kinase. Our previous proteomic studies identified several novel DYRK1A interacting proteins 
including RNF169, FAM117B, TROAP, LZTS1, LZTS2 and DCAF7. In this dissertation, we 




protein interaction network. Firstly, we show that DYRK1A regulates that recruitment of 53BP1 
to DNA double strand breaks (DSBs) in part through its interaction with RNF169. This revealed 
a novel role of DYRK1A in DSB repair pathway choice. Secondly, we identify LZTS1 and 
LZTS2 as novel regulators of DYRK1A activity towards LIN52. Thirdly, we observed that 
DCAF7 interacts with several other DYRK1A-binding proteins including RNF169, TROAP, 
FAM117B, LZTS1 and LZTS2 giving rise to various multi-subunit protein complexes, but it 
does not act as a scaffold for these interactions. We also observed an unexpected role of 
DYRK1A in mediating the interaction between these DYRK1A-binding proteins and DCAF7, 
which could explain some aspects of the dosage-dependent function of DYRK1A.  
As DCAF7 was the most highly enriched DYRK1A-interacting protein, we generated and 
analyzed the DCAF7 interactome in order to understand the functional significance of the 
DYRK1A-DCAF7 interaction. We show that DCAF7 interacts with the components of a multi-
subunit Polycomb Repressive Complex 1.3/5 (PRC1.3/5) independent of DYRK1A, but 
DYRK1A could influence the molecular size of the PRC1.3/5 complex. Furthermore, our data 
suggest that DYRK1A and DCAF7 regulate the monoubiquitination of H2A at K119 by 
PRC1.3/5. Using RNA-seq analysis, we identified a common set of genes regulated by DYRK1A 
and DCAF7. Our data shows that DCAF7 requires DYRK1A for its transcriptional effect. Future 
studies will be focused to determine the molecular mechanism by which DYRK1A and DCAF7 
regulate the transcription of the PRC1.5 target genes.  
In conclusion, DYRK1A interacting proteins could regulate the activity and function of 
DYRK1A and play a role in its biological functions including tumor suppression, the DNA 





CHAPTER 1: GENERAL INTRODUCTION 
 
1.1. The DYRK family 
DYRK, or Dual specificity Tyrosine Regulated Kinases, belong to the CMGC group of 
eukaryotic protein kinases that includes cyclin-dependent kinase [CDK], mitogen-activated 
protein kinase [MAPK], glycogen synthase kinase [GSK3], and CDC-like kinase [CLK] (Aranda 
et al., 2011; Hanks & Hunter, 1995). Based on the degree of conservation in their kinase domain, 
the DYRK family can be further divided into three sub-families: 1) DYRK kinases 2) PRP4s 
(pre-mRNA processing protein 4- kinases) and 3) HIPKs (Homeodomain-interacting protein 
kinases) (Figure 1). Out of these, the DYRK sub-family can be further divided into three 
branches including 1) yeast kinase Yak1p which has no members in animals; 2) DYRK1 and 3) 
DYRK 2. DYRK1 and DYRK2 have members ranging from yeast to humans and are highly 
conserved across evolution (Aranda et al., 2011) (Figure 1). Minibrain in Drosophila is the 
closest homolog of mammalian DYRK1A (Aranda et al., 2011). 
Based on ectopic expression of the DYRK family members in cell lines, they were also classified 
as cytosolic kinases (DYRK2, DYRK3, DYRK4) and nuclear kinases (DYRK1A and DYRK1B) 
(Becker et al., 1998). However, it has been observed that the endogenous expression of these 
proteins varies from this classification. For example, under overexpressed conditions DYRK1A 
localizes to the nuclear speckles while endogenous DYRK1A is observed both in the nucleus and 
cytoplasm (Álvarez et al., 2003; Hämmerle et al., 2003; Martı́ et al., 2003; Wegiel et al., 2004). 
DYRK1B has been found to be predominantly nuclear in some cell lines while it is mostly 
cytoplasmic in muscle fibers as well as in rhabdomyosarcoma and pancreatic ductal carcinoma 
cells (Friedman, 2007).  
 
 2 
DYRK1A is the most ubiquitously expressed member in tissues of adult and fetal origin 
(Guimera et al., 1999; Okui et al., 1999) while DYRK2, DYRK3 and DYRK4 have limited tissue 
distribution (Becker et al., 1998; Sacher et al., 2007).  
Structurally, DYRK family members share a conserved kinase domain and an adjacent DYRK 
homology domain (DH) but differ more towards the N and C terminal regions (Aranda et al., 
2011). In addition to the conserved catalytic kinase domain, DYRK1A has two nuclear 
localization signal sequences (NLSs): a classical bipartite NLS at the N-terminal region of the 
protein and a complex NLS within the catalytic domain (Aranda et al., 2011). The kinase domain 
is followed by a PEST domain and then by a histidine-rich domain that targets DYRK1A to the 
nuclear speckles compartment where it may co-localize with splicing machinery (Figure 2) 
(Álvarez et al., 2003; Aranda et al., 2011). 
DYRKs phosphorylate themselves on tyrosine (Y) and serine/threonine (S/T) residues but 
phosphorylate their substrates only on serine and threonine residues. This is why they are 
referred to as dual specificity tyrosine regulated kinases. The Y autophosphorylation in the 
activation loop on all DYRKs occurs in cis with translation. Specifically, the phosphorylation on 
the second tyrosine (Y) in the YxY motif is required for the activity of all DYRK members 
(Himpel et al., 2001; Li et al., 2002; Lochhead et al., 2003). This phosphorylation on DYRK 
seems to be constitutive unlike the regulatory phosphorylation on the mitogen-activated protein 
kinases (MAPK) (Glenewinkel et al., 2016). Interestingly, in contrast to former observations, it 
has been observed that DYRK1A retains its Y phosphorylation ability even after translation 





Figure 1: The DYRK kinase family.  
A) An unrooted phylogenetic tree depicting the evolutionary divergence of the kinase domain in 
the DYRK family members. The DYRK sub family has members ranging from yeast to humans. 
B) The DYRK sub family members can be classified as Class I and Class II  DYRKs. The 
percentage of conservation at the protein level between orthologues is indicated above the arrows 
and between 2 paralogues is indicated in parentheses within the boxes [Adopted from (Aranda et 
al., 2011)]. 
 
Figure 2: Schematic representation of the domain structure of the 5 mammalian DYRKs. 
Different functional motifs are indicated. Red lines indicate regions of the protein affected by 
alternate splicing events [Adopted from (Aranda et al., 2011)]. 
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1.2. DYRK1A is a dosage sensitive gene 
In humans, DYRK1A protein is encoded by the DYRK1A gene which is located in the ‘Down 
syndrome Critical Region’ on chromosome 21 (Korbel et al., 2009; Ohira et al., 1997). Trisomy 
of this critical region results in Down syndrome (Korbel et al., 2009; Ohira et al., 1997). It was 
suggested that DYRK1A overexpression could contribute to the depletion of neurons in the 
developing brain of the DS fetuses either due to the precocious onset of neurogenesis in 
progenitors leading to the concomitant depletion of the proliferating progenitor pool or by 
inducing a premature cell cycle arrest of the neurogenic progenitors leading to a decrease in the 
number of neurons generated by each progenitor (F. J. Tejedor & Hämmerle, 2011). On the other 
hand, intragenic deletion or loss of one copy of DYRK1A gene has also been recognized as a 
syndrome with characteristic features such as microcephaly, severe mental retardation and 
speech impairment (Bronicki et al., 2015; Ji et al., 2015). As both gain and loss of one allele of 
DYRK1A results in developmental abnormalities, this gene is highly dosage sensitive. This 
dependence on optimum dosage of DYRK1A is conserved across evolution. Mini brain (Mnb) in 
Drosophila is the closest homolog of mammalian DYRK1A (Figure 1b) and is involved in neural 
proliferation and differentiation in Drosophila. It was observed that flies with a Mnb loss of 
function developed a smaller adult brain (Tejedor et al., 1995). Furthermore, in mice, 
homozygous deletion of Dyrk1a is embryonically lethal, whereas mice having only one copy of 
Dyrk1a have reduced brain size and display specific neurological and behavioral defects and 
febrile seizures (Fotaki et al., 2002; Raveau et al., 2018). Moreover, mouse models of Dyrk1a 
trisomy recapitulate some of the DS phenotypes (Ahn et al., 2006; Altafaj et al., 2001; F. J. 
Tejedor & Hämmerle, 2011). DYRK1A also plays a role in neural stem development and is 
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necessary for neurogenesis, neural differentiation, cell death and synaptic plasticity across 
different species (Dierssen & de Lagrán, 2006; F. J. Tejedor & Hämmerle, 2011).   
1.3. DYRK1A in other neurological diseases 
DYRK1A is also implicated in several other neurological diseases like dementia, Alzheimer’s 
disease, Parkinson’s disease and Pick’s disease. DYRK1A is one of the kinases responsible for 
phosphorylation of α-synuclein which is a candidate biomarker of Parkinson’s disease (PD) (E. J. 
Kim et al., 2006; Spillantini et al., 1997). An increase of α-synuclein in the brain, leading to 
aggregation and subsequently sequestration in Lewy Bodies, is a hallmark of PD.   
Alzheimer’s disease pathology includes amyloid‐β (Aβ) accumulation and hyperphosphorylation 
of the microtubule binding protein -Tau (Querfurth & LaFerla, 2010). Hyperphosphorylated Tau 
is pathologic and has lesser affinity to microtubules. Pathological Tau forms neurofibrillary 
tangles (NFTs) and insoluble inclusions which is a feature of Alzheimer’s disease and other 
Tauopathies (Medina et al., 2016). DYRK1A is about 1.5 fold overexpressed in DS (Becker et 
al., 2014). Early onset AD is common in DS patients and one possible reason is the 
hyperphosphorylation of Tau by DYRK1A (F. Liu et al., 2008; Wegiel et al., 2011). Indeed, 
DYRK1A phosphorylates Tau at multiple serine and threonine residues (Azorsa et al., 2010; 
Ryoo et al., 2008). Interestingly, mice overexpressing DYRK1A have increased phosphorylated 
Tau in the brain and crossing the DYRK1A heterozygous mice with DS mice regulates 
phosphorylated Tau and amyloid load (García-Cerro et al., 2017). Furthermore, overexpression 
of DYRK1A was observed in postmortem brains of AD patients, supporting the contribution of 
DYRK1A to tau hyperphosphorylation and accumulation of NFTs (Ferrer et al., 2005). Thus, 
inhibition of DYRK1A is being considered to alleviate problems caused by Tau phosphorylation 
in AD. Furthermore, studies in AD mice models or transgenic mice with Tau pathology have 
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further supported that DYRK1A can be a potential target for AD and other Tauopathies (Branca 
et al., 2017; Melchior et al., 2019).  
1.4. Some of the known DYRK1A substrates 
Several reported substrates of DYRK1A harbor a consensus sequence that includes the R-
X(XX)-S/T-P motif. Analysis of in-vitro phosphorylated synthetic peptide substrates established 
DYRK1A’s preference for arginine residue in the -2 or -3 position and for a proline at the +1 
position (Himpel et al., 2001; Himpel et al., 2000).   
Depending on its cellular localization, DYRK1A is responsible for the phosphorylation of 
several proteins involved in important signaling pathways, such as the cell cycle and 
transcription (Duchon & Herault, 2016; Kaczmarski et al., 2014; Martı́ et al., 2003; Park et al., 
2012). Apart from the substrates already mentioned above, DYRK1A phosphorylates Nuclear 
Factor of Activated T cells (NFAT), cAMP Response Element Binding protein (CREB), Signal 
Transducer and Activator of Transcription 3 (STAT3), Glioblastoma associated oncogene 
protein (GLI1), splicing factors (cyclin L2, SF2, SF3), a translation factor (eIF2Be), 
miscellaneous proteins (glycogen synthase, caspase-9, Notch) and synaptic proteins (dynamin I, 
amphiphysin I, synaptojanin) (Duchon & Herault, 2016). Additional DYRK1A substrates 
include cyclin D1, p53, p27, RNA polymerase II and the LIN52 subunit of the DREAM 
repressor complex, as well as Caspase 9 ((J.-Y. Chen et al., 2013; Di Vona et al., 2015; 
Litovchick et al., 2011; Najas et al., 2015; Park et al., 2009, 2010; Soppa et al., 2014). In addition 
to these substrates, DYRK1A interacts with several proteins that may regulate its function or 
subcellular localization including DCAF7 and 14-3-3 (Alvarez et al., 2007; Glenewinkel et al., 
2016; D. Kim et al., 2004; Miyata & Nishida, 2011; Ritterhoff et al., 2010).  
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1.5. DYRK1A’s role in DREAM complex assembly and cancer 
The activity of E2F transcription factors is regulated by the retinoblastoma (RB) family of 
proteins which includes pRB, p107 and p130 (Cobrinik, 2005). The RB family proteins act as 
tumor suppressors in a hypo-phosphorylated form when they bind E2F transcription factors and 
inhibit E2F mediated transcription. Phosphorylation of RB family members by cyclin-dependent 
kinases (CDKs) in the G-1 phase of the cell cycle relieves the binding and inhibition of E2Fs 
(Cobrinik, 2005; Malumbres & Barbacid, 2009). In cells entering quiescence, p130 accumulates 
in response to serum starvation, confluency or pINK4a expression (Cam et al., 2004; E. J. Smith 
et al., 1996). Furthermore, p130 was found to be the predominant RB family member that 
interacts with MuvB core protein complex consisting of RBBP4, LIN9, LIN37, LIN52 and 
LIN54. Mass spectroscopy proteomic analysis and biochemical validation in human cell lines 
revealed that p130 interacts with E2F4, DP1 and the MuvB core, forming the DREAM complex 
in G0/G1 but not in the S-phase, and subsequently causes repression of DREAM target genes 
(Litovchick et al., 2007; Schmit et al., 2007). In S phase, the MuvB core dissociates from the 
p130-DREAM complex and binds BMYB in order to promote transcription of the MMB (MYB-
MuvB) target genes (Litovchick et al., 2007; Schmit et al., 2007). DYRK1A specifically 
phosphorylates the serine 28 (S28) residue on LIN52 (Figure 3) (Litovchick et al., 2011). This 
phosphorylation of LIN52 at S28 was found to be required for DREAM assembly. Furthermore, 
DYRK1A overexpression was found to inhibit proliferation of several human cancer cell lines 
including T98G, U-2 OS, but not HEK 293T (Figure 3) (Litovchick et al., 2011). 
Further, point mutation of LIN52 at S28 or inhibition of DYRK1A activity disrupts DREAM 
assembly and reduces the ability of cells to enter quiescence or undergo Ras-induced senescence 
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(Litovchick et al., 2011). Thus, DYRK1A has been found to play an important role in the 
regulation of DREAM activity and entry into quiescence. 
 
 
Figure 3: Schematic representation depicting how DYRK1A promotes DREAM complex 
assembly, G0/G1 arrest and senescence. [Adopted from (Litovchick et al., 2007)]. 
Interestingly, DS patients have a lower risk of solid tumors but DS children specifically carry a 
higher risk for developing leukemias (Hasle et al., 2000). DYRK1A is known to influence both 
tumor suppressive and tumorigenic activities by regulating its substrates and hence it has been 
termed as a double edged kinase (Fernández-Martínez et al., 2015). DYRK1A substrates can 
function as pro- or anti-oncogenic factors (Figure 4). 
1.6. DYRK1A inhibitors 
Due to DYRK1As role in human disease, its pharmacological inhibition has been a focus of 
research for several years. Potent plant derived inhibitors of DYRK1A include Harmine and 
Epigallocatechin‐gallate (EGCG), the poly phenolic compound in green tea. Synthetic DYRK1A 
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inhibitors include INDY, proINDY, roscovitine, purvalanol A, pyrazolidine-diones, amino-
quinazolines, meridianins, pyridine and pyrazines, and chromenoidole with varying potencies 
towards DYRK1A (H. Kim et al., 2016; B. Smith et al., 2012). DYRK1A inhibitors can further 
be divided into three major classes.  The type I inhibitors bind the ATP binding site in the kinase 
domain of DYRKs and type II and type III inhibitors are non-ATP mimetics. Harmine, an ATP 
competitive inhibitor of DYRK1A, is a plant alkaloid derivative, whereas EGCG is a non-
competitive ATP inhibitor of DYRK1A (Adayev et al., 2006; Bain et al., 2003; Duchon & 
Herault, 2016; Göckler et al., 2009). The use of EGCG has been limited due to poor 
pharmacokinetic properties and limited bioavailability (Duchon & Herault, 2016). Along with 
effectively inhibiting DYRK1A mediated substrate phosphorylation, Harmine has been found to 
inhibit the autophosphorylation of DYRK1A (Walte et al., 2013). Although very potent, clinical 
use of Harmine is limited because it is also a monoamine oxidase inhibitor (Duchon & Herault, 
2016). Other potent inhibitors of DYRK1A include INDY or proINDY but their use has also 
been limited (Duchon & Herault, 2016). Recently, the well-known ATP competitive casein 
kinase II and CLK inhibitor CX4945 was also found to be a potent inhibitor of DYRK1A (H. 
Kim et al., 2016). This drug has already been successful in clinical trials for cancer treatment 
(Siddiqui-Jain et al., 2010). It has also proven efficient in Drosophila and mouse models of 
DYRK1A overexpression and hence holds promise (H. Kim et al., 2016). Additional novel 
DYRK1A inhibitors have been identified that can induce DYRK1A degradation and are 
supposed to be more potent than the current inhibitors, but further research is required to 
evaluate their potential for therapeutic use (Branca et al., 2017; Melchior et al., 2019; Velazquez 




Figure 4: Pro and anticancer functions of DYRK1A.  
DYRK1A has been associated with pro-tumoral activity (green boxes) by activating (green 
arrows) known oncogenes or by inhibiting (red lines) tumor suppressors (red boxes) [Adopted 
from (Fernández-Martínez et al., 2015)]. 
 
1.7. Understanding the function and regulation of DYRK1A through its interacting 
proteins 
Even though DYRK1A is such an important kinase, its function and regulation is poorly 
understood. Hence, multiple groups have recently studied the proteomic landscape of DYRK1A. 
The BioGrid protein interaction network database lists 90 unique proteins that interact with 
human DYRK1A (thebiogrid.org). Most of these interactors have been identified by high-
throughput affinity-capture mass spectrometric analyzes performed in HEK293T cells. The 
glioblastoma cell line T98G, but not HEK293T, was one of the cell lines whose proliferation was 
suppressed with ectopic expression of DYRK1A (Litovchick et al., 2011). Therefore, we used 
the sensitive MudPIT proteomic approach (Florens & Washburn, 2006; Swanson et al., 2009) to 
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detect DYRK1A interacting proteins in T98G cells. We identified 120 proteins specifically 
detected in at least two out of four biological replicate analyses of DYRK1A 
immunoprecipitates, including 98 novel interactors not reported to bind DYRK1A in the BioGrid 
protein interaction database (Figure 5) (Menon et al., 2019).  
Furthermore, our analysis detected 51 proteins in 3 out of 4 DYRK1A pull-down repeats and 7 
proteins including DYRK1A, DCAF7, FAM117A, FAM117B, LZTS2, RNF169 and TROAP, 
were identified in all 4 biological replicates (Menon et al., 2019).  These interacting proteins 
were also the most enriched in the samples and their interaction with DYRK1A was confirmed 
using reciprocal pull-down assays (Menon et al., 2019). Of note, average enrichment of DCAF7 
in the immunoprecipitated samples (as shown by Normalized Spectrum Abundance Factor, or 
dNSAF (Sardiu et al., 2008), was comparable to that of DYRK1A itself, indicating a potentially 
stoichiometric interaction. Further, bioinformatic analysis of the 51 DYRK1A-binding proteins 
revealed a complex network of interactions of factors involved in different cellular processes, 
with notable enrichment of the mRNA processing, transcription and DNA damage response 
functional categories (Menon et al., 2019). Previous proteomic analysis of DYRK1A in 
HEK293T cells identified 24 interacting proteins, 14 of which were also detected in our study 
(Menon et al., 2019; Varjosalo et al., 2013). Two other groups also subsequently reported the 
DYRK1A interactome in HeLa cells. Interestingly, even with different cell types, there is a 
considerable overlap of DYRK1A interacting proteins found in our study with the proteins 
reported in these studies (Guard et al., 2019; Menon et al., 2019; Roewenstrunk et al., 2019; 
Varjosalo et al., 2013), including DCAF7, RNF169, FAM117B, LZTS2 and TROAP. 
In this thesis, we have focused on characterizing some of the novel DYRK1A protein-protein 




Figure 5: Analysis of the DYRK1A-interacting protein network. 
(A). Purification of DYRK1A for MudPIT proteomic analysis. Top: representative western blot 
showing levels of DYRK1A in T98G cells expressing HA-Flag-tagged DYRK1A (DYRK1A-
FH) and DYRK1A band density relative to Actin (control). Bottom: representative silver stained 
gel containing 10% of HA-peptide eluted control or DYRK1A-FH IP samples analyzed by 
MudPIT. Green arrow indicates DYRK1A. (B) Graph shows relative enrichment (dNSAF) of 
proteins detected in two, three or all four DYRK1A MudPIT experiments. DYRK1A is shown as 
a green circle whereas red and blue circles correspond to interacting proteins either listed in the 
BioGrid database, or new DYRK1A-binding proteins, respectively. (C) dNSAF (corresponds to 
relative enrichment) and molecular weight (MW) of seven proteins specifically detected in four 
DYRK1A-FH MudPIT replicate experiments. (D) Hierarchical network of interactions 
(CytoScape) involving DYRK1A-binding proteins identified in this study, constructed using 
MetaScape analysis tool. Larger nodes correspond to proteins detected in all four replicates, 
smaller nodes correspond to proteins detected in three replicates. Unconnected nodes are not 
known to interact with other factors. Colors, as in panel B (E) Molecular Signature Database 
(MSigDB) annotation of the genes encoding DYRK1A-interacting proteins reveals significantly 
enriched functional gene ontology (GO) categories. Proteins detected in at least 3 DYRK1A 
MudPIT repeats were analyzed using Molecular Signature Database annotation tool to compute 
overlaps with GO Biological Process (GO_BP) and GO Cellular Component (GO_CC) gene sets 




CHAPTER 2: CHARACTERIZATION OF THE DYRK1A-RNF169 INTERACTION 
AND ITS FUNCTION IN THE DNA DAMAGE RESPONSE PATHWAY 
(Adapted from Menon V, Ananthapadmanabhan V et al., 2019) 
 
2.1. INTRODUCTION TO THE CHAPTER 
MudPIT analysis carried out to identify DYRK1A interacting proteins detected RNF169 (Ring 
Finger protein 169) in all four biological replicates (Figure 5) (Menon et al., 2019). RNF169 
plays a role in the DNA damage response (An et al., 2018; Poulsen et al., 2012) while DYRK1A 
had no known role in this process. We therefore carried out a functional characterization of the 
DYRK1A-RNF169 interaction in this chapter. 
2.1.1. The DNA damage response 
Cellular exposure to various DNA damaging agents, be it environmental or endogenous, is 
harmful and leads to impaired DNA integrity and genomic instability leading to disease. Of the 
many types of DNA lesions, DNA double strand breaks (DSBs) are considered the most harmful. 
This is because a single DSB is sufficient to cause growth arrest and cell death (Bennett et al., 
1993; Panier & Boulton, 2014; Sandell & Zakian, 1993). Whenever there is a DNA DSB, the 
MRE-11-RAD 50-NBS1 (MRN) complex senses the break. This leads to recruitment of the 
serine/threonine kinase Ataxia Telangiectasia Mutated (ATM) which phosphorylates itself and 
becomes activated (Panier & Boulton, 2014; Paull, 2015). At the break site, ATM in turn 
phosphorylates H2A.X at ser 139 (γH2AX) (Panier & Boulton, 2014; Rogakou et al., 1998).  
γH2AX is used as an early marker of the DNA DSB response. γH2AX is recognized by Mediator 
of DNA Damage Checkpoint protein 1 (MDC1), leading to the sequential recruitment of E3 
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ubiquitin ligases RNF8 and RNF168. RNF8, RNF168 and an E2 conjugating enzyme UBC13 
together regulate the ubiquitination of histones surrounding the DSB sites. One of the outcomes 
of RNF8 and RNF168-mediated chromatin ubiquitylation is a stable recruitment of oligomerized 
p53-binding protein 1 (53BP1), which directly binds to RNF168-ubiquitylated H2AK15 and to 
mono- and di-methylated H4K20 (Panier & Boulton, 2014). 53BP1 is a key factor that can 
influence pathway choice during the repair process. Specifically, 53BP1 phosphorylation by 
ATM leads to recruitment of RIF1, and the 53BP1-RIF1 complex promotes the DNA repair via 
the Non-Homologous End Joining pathway or NHEJ (Escribano-Díaz et al., 2013). This pathway 
can introduce errors in the genome as it involves minor processing of the DNA ends prior to the 
direct ligation of the DSB. In the S-G2 phase of the cell cycle, BRCA1 antagonizes the 53BP1-
RIF1 complex and promotes the more accurate HRR (Homologous Recombination Repair) 
facilitated by end resection via Mre11 and C-terminal binding protein-interacting protein (CtIP) 
(Escribano-Díaz et al., 2013). 
 
 
Figure 6: The complexity of signal transduction pathway following a DNA DSB break. 
DNA damage response elicits a sequential cascade leading to accumulation of 53BP1 at the 
damage sites [Adopted from (Panier & Boulton, 2014)]. 
RNF169 has been reported to be a negative regulator of 53BP1 accumulation at the sites of DNA 
DSBs (Poulsen et al., 2012). RNF169 binding thereby promotes cells to favor HR repair instead 
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of NHEJ (An et al., 2018). The role of DYRK1A in the DNA damage response was poorly 
studied and this chapter will highlight our findings on the role of the DYRK1A-RNF169 
interaction in the DNA DSB response pathways.  Notably, post the publication of our study, two 
other groups also reported the DYRK1A-RNF169 interaction and its role in the DNA damage 
response (Guard et al., 2019; Roewenstrunk et al., 2019).  
2.2. RESULTS  
2.2.1. DYRK1A and RNF169 interact at the endogenous level and co-fractionate together 
First, we confirmed the interaction between exogenously expressed HA-tagged RNF169 and 
endogenous DYRK1A in T98G cells using immunoprecipitation and Western blot analysis 
(IP/WB) (Figure 7A). Using reciprocal IP/WB analysis, interaction between DYRK1A and 
RNF169 was also confirmed at the endogenous level in both T98G and U-2 OS cell lines (Figure 
7B, C). We also observed that the kinase activity of DYRK1A was not required for the 
DYRK1A-RNF169 interaction (Figure 7D).  Furthermore, we found that DYRK1A and RNF169 
co-fractionated together in T98G cell lysates subjected to glycerol gradient ultracentrifugation, 
and the estimated approximate size of the DYRK1A-RNF169 complex was 280 kDa (Figure 7E).  
2.2.2. DYRK1A and RNF169 regulate the recruitment of 53BP1 at sites of DNA DSBs 
U-2 OS cells retain wild type p53 making this cell line a common model for DNA damage-
focused studies. Moreover, these cells have also been used to characterize the regulatory role of 
RNF169 towards 53BP1 recruitment into γ-irradiation induced foci (IRIF). In preliminary 
experiments, we observed that U-2 OS cells displayed the maximum number of distinct 53BP1 
IRIF at 3h post γ-irradiation (5Gy, data not shown). We therefore decided to induce DNA 
damage using γ-irradiation followed by analysis of foci accumulation 3 hours post irradiation in 
our subsequent experiments. We used U-2 OS cell lines stably expressing either wild type or 
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kinase inactive DYRK1A-K188R mutant under control of a doxycycline (dox)-inducible 
promoter to analyze the role of DYRK1A in the regulation of 53BP1 upon DNA damage 
(Himpel et al., 2001; Litovchick et al., 2011). Interestingly, induced expression of WT but not 
kinase-inactive DYRK1A resulted in significantly decreased number of cells displaying more 
than 10 53BP1 IRIF compared to the un-induced control (Figure 8A, B and 9A). In order to 
analyze if RNF169 was required for this effect, we transiently knocked down RNF169 and 
observed that recruitment of 53BP1 into IRIFs in the WT DYRK1A overexpressing cells was 
rescued to the control cell levels (Figure 8C, D and 9B).  
We further investigated the role of DYRK1A kinase activity by using the DYRK1A inhibitor 
Harmine. U-2 OS cells were treated with 10μM of Harmine for 16 hours prior to γ-irradiation 
and the accumulation of 53BP1 IRIFs was quantified. Interestingly, recruitment of 53BP1 to foci 
was increased with Harmine pre-treatment as compared to vehicle treated controls (Figure 10A, 
B). For most accurate quantification of our observations, we calculated both the percentage of 
cells containing more than ten IRIF, as well as an average number of IRIF per nucleus, using 
ImageJ software (Schneider et al., 2012). Consistent with previous reports, with stable HA-
RNF169 overexpression, we also observed a 50% reduction in the number of cells with more 
than 10 53BP1 IRIFs as well as fewer IRIFs per nucleus (compare grey bars, figure 10C). 
Harmine treatment of HA-RNF169- expressing cells resulted in increase in 53BP1 foci formation 
although it was not fully rescued to the control levels (red bars and graph on the right Y-axis). 
Interestingly, in the cells treated with Harmine, HA-RNF169 foci formation was reduced by 
approximately 30% as compared to controls (compare green bars, figure 10C). This could 
explain the increase in 53BP1 IRIFs with Harmine treatment. We also analyzed the binding 
between DYRK1A and RNF169 after the cells were treated with Harmine. Similar to kinase-
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dead DYRK1A, RNF169 from Harmine treated cells also bound endogenous DYRK1A 
efficiently (Figure 10D). These results demonstrate that RNF169 and DYRK1A interact at the 
endogenous level in human cells and that DYRK1A facilitates RNF169’s limiting function 
towards 53BP1 IRIF recruitment. 
 
Figure 7: DYRK1A and RNF169 interact at the endogenous level and co-fractionate 
together. 
(A) IP/WB assay shows binding between transiently expressed HA-tagged RNF169 and 
endogenous DYRK1A in T98G cells. (B, C) IP/WB analyzes of the interaction between the 
endogenous RNF169 and DYRK1A in T98G and U-2 OS cells. RNF169-depleted cell extract 
(siRNF169) is included to identify the RNF169-specific protein band. IgG, negative control. (D) 
IP/WB assay shows interaction between the wildtype and the kinase-inactive DYRK1A (Y321F) 
and the endogenous RNF169 in U-2 OS cells.  (E) WB of the U-2 OS cell extract separated by 
5–45% glycerol gradient ultracentrifugation shows co-fractionation of RNF169 and DYRK1A. 
Black arrows indicate the positions of the molecular weight markers. Red arrow indicates 





Figure 8: DYRK1A and RNF169 regulate 53BP1 recruitment at DNA DSB. 
(A) WB shows the DYRK1A levels in the inducible U-2 OS cell lines under un-irradiated 
conditions before and after doxycycline (Dox) treatment for 12h. Actin is shown as loading 
control. (B) The inducible U-2 OS cell lines were pre-incubated with or without Dox for 12h, 
treated with radiation (5 Gy) and processed for 53BP1 staining after 3h. Induced expression of 
active but not kinase-inactive (KD) DYRK1A (K188R) inhibits 53BP1 IRIF formation. Graph 
shows quantification of cells with 53BP1 foci in cell lines with (+) or without (-) Dox induction 
of 3 biological replicate experiments. Error bars show standard deviation. Red and black dots 
indicate quantifications by two independent observers. p-values were calculated using Student’s 
two-tailed t-test and are indicated on the graphs. (C, D) Knockdown of RNF169 rescues 
DYRK1A-mediated inhibition of 53BP1 foci formation. Inducible U-2 OS cell lines were 
transfected with non-targeting (siControl) or RNF169-specific siRNA and treated with 
doxycycline as in panels A, B to induce expression of DYRK1A. WB in panel C shows 
expression of proteins of interest. Panel D shows quantification of the 53BP1 foci in cells. 
Samples were processed in the same way as in B. Graph shows average of 3 biological 
replicates. Error bars show standard deviation. Red and black dots same as in B and p-values 





Figure 9: Induced expression of DYRK1A inhibits 53BP1 accumulation at the DSB sites. 
(A) Representative images of inducible U-2 OS cell lines expressing wild-type DYRK1A (WT) 
or kinase inactive mutant (KD), with or without treatment with doxycycline for 16h.  Cells were 
γ-irradiated (5Gy) and incubated for 3h before staining with anti-53BP1antibody and DAPI. (B) 
Representative images of U-2 OS cells with induced expression of the wild-type DYRK1A, 
transfected with either non-targeting (siControl) or RNF169-specific siRNA, γ-irradiated (5Gy) 
and incubated for 3h before staining with anti-53BP1antibody and DAPI. See Figure 8 for 





Figure 10: Inhibition of DYRK1A increases 53BP1 recruitment to IRIF. 
(A) Representative images of HA-RNF169 and 53BP1 irradiation induced foci in U-2 OS cells 
stably expressing HA-RNF169 that were either untreated (Mock), or pre-treated with 10 μM 
Harmine or DMSO (vehicle) for 16h before irradiation (5 Gy) and processed for staining after 
3h. (B, C) Graphs show quantification of the 53BP1 or HA-RNF169 IRIF from 4 biological 
replicate experiments. Error bars show standard deviation. p-values were calculated using 
Student’s two-tailed t-test and are indicated on the graphs in panels B and C. (D) IP/WB shows 




2.2.3. DYRK1A phosphorylates RNF169 at functionally important Ser368 and Ser403 
residues  
By scanning through the RNF169 protein sequence, we found that RNF169 contains two 
predicted DYRK1A consensus phosphorylation sites (Menon et al., 2019). These sites were 
identified at positions S386 and S403 in the human RNF169 protein sequence. The region in 
RNF169 encompassing these sites was found to be highly conserved but had no known function. 
Both of these sites were reported in Phosphosite plus database as detected in several high 
throughput phosphoproteomic studies (Hornbeck et al., 2012). Using stable cell lines expressing 
mutants of RNF169, and in-vitro kinase assays with recombinant DYRK1A, we found that 
DYRK1A indeed phosphorylates RNF169 at both the predicted sites - S386 and S403 (Menon et 
al., 2019). 
To characterize the functional significance of DYRK1A phosphorylation sites in RNF169, we 
analyzed accumulation of 53BP1 and RNF169 after induction of DNA damage by γ-irradiation 
in U-2 OS cell lines stably expressing either wild type HA-RNF 169, non-phosphorylatable 
S368A/S340A (RNF169-AA) mutant, or phospho-mimetic S368D/S340D (RNF169-DD) mutant 
(Figure 11). Interestingly, there was approximately two-fold higher number of cells with more 
than ten 53BP1 foci in either RNF169-AA or RNF169-DD-expressing cells compared to the wild 
type HA-RNF169 cell line (Figure 11A, B). As compared to the wild-type expressing cells, there 
was a modest but significant increase in the number of 53BP1 foci per nucleus in the cells 
expressing mutant RNF169 alleles, indicating that phospho-site mutant RNF169 proteins inhibit 
accumulation of 53BP1 at DSB sites to a significantly lesser extent than the wild type RNF169 
(Figure 11A, B). This result is consistent with the effect of Harmine, supporting the contribution 
of DYRK1A to the RNF169-mediated inhibition of 53BP1 accumulation at the DSB sites. 
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Next, we analyzed the recruitment of the HA RNF169-AA and DD mutants to DSB sites in γ 
irradiated U-2 OS cell lines. Interestingly, there was a slight but significant decrease in the 
number of HA positive foci in the cells expressing the mutant proteins as compared to the wild 
type RNF169 (Figure 11A, C). Despite the differences observed with accumulation of 53BP1 
and HA-RNF169 at IRIF between the wild type and RNF169 mutant expressing cell lines, the 
expression levels of the respective HA-RNF169 or 53BP1 proteins were similar across the cell 
lines (Figure 11E). We also observed that IRIF formed by the mutant HA-RNF169 proteins 
appeared to be larger in size than in case of the wild type protein (Figure 11D). Indeed, analysis 
of the foci size using ImageJ software revealed a significant increase of the mean size of the 
RNF169- AA and DD foci compared to the wild type control. Of note that the phenotype we 
observed with the phosphomimetic mutant of RNF169 (RNF169-DD) was very similar to that of 
the phospho deficient (RNF169-AA) mutant. This could mean that the phosphomimetic mutant 
of RNF169 does not accurately represent a constitutively phosphorylated state of the protein. It 
appears that it instead disrupts the same function. Therefore, it was important to test the impact 
of the mutation of DYRK1A phosphorylation sites on some other known function of RNF169.  
The ubiquitin-binding MIU domain of RNF169 recognizes RNF168-polyubiquitylated histones. 
This recognition has been found to be required for the recruitment of RNF169 at the DSB sites 
and for the displacement of 53BP1 (J. Chen et al., 2012; Panier & Boulton, 2014; Poulsen et al., 
2012). Interestingly, we observed that RNF169-AA and RNF169-DD mutants were able to bind 
polyubiquitin chains similar to the wild type RNF169, further supporting our conclusion that 
S368 and S403 sites do not play a significant role in RNF169’s accumulation at the DSB sites 
(Menon et al., 2019). USP7 (Ubiquitin Specific protease 7) has been reported to be important for 
RNF169 function in DNA repair (An et al., 2018). We found that mutations of DYRK1A 
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phosphorylation sites on RNF169 did not affect the interaction between RNF169 and USP7 
(Menon et al., 2019). However, we found that both mutants showed a dramatically reduced 
binding to DYRK1A, both in the un-irradiated controls or post treatment with γ-irradiation 
(Menon et al., 2019). Therefore, these RNF169 mutants not only lack DYRK1A mediated 
phosphorylation but also bind less to DYRK1A. We were therefore able to support the 
conclusion that DYRK1A binding and phosphorylation of RNF169 increases its ability to limit 




Figure 11: The functional significance of S368 and S403 residues in RNF169. 
(A) Representative images of the HA-RNF169 (green) and 53BP1 (red) foci 3h after γ-radiation 
(5 Gy). U-2 OS stable cell lines expressing HA-RNF169 (WT), or the S368A/S403A (AA), or 
S368D/S403D (DD) mutants were stained using anti-HA and 53BP1 antibodies, and DAPI. (B) 
Graph shows quantification of the 53BP1 IRIF from 4 biological replicate experiments shown in 
panel A. All cells were scored in the control U-2 OS cells (Mock, shown as reference) whereas 
only HA-positive cells were scored in the HA-RNF169, RNF169-AA or RNF169-DD expressing 
cell lines. Here and below, error bars show standard deviation and p-values calculated using 
Student’s two-tailed t-test are shown on the graphs. (C) Graph shows quantification of HA-
RNF169 IRIF from 4 experiments in A. Red and black dots indicate values scored by two 
independent observers. (D) Quantification (average foci sizes, left Y-axis and size distribution, 
right Y-axis) of HA-RNF169 foci sizes measured in 4 biological replicate experiments. (E) WB 




2.2.4. Loss of DYRK1A causes a decreased DSB recruitment of RNF169 and 53BP1 
In order to investigate the effects of loss of DYRK1A on 53BP1 and RNF169 IRIF, we 
generated U-2 OS cell lines with CRISPR Cas-9 mediated KO of DYRK1A in the lab [(Menon 
et al., 2019)., and the Methods section].  The KO clones were analyzed for DYRK1A protein 
expression using WB with DYRK1A antibodies targeting different regions of the protein [Figure 
12A (Menon et al., 2019)]. Two independent U-2 OS DYRK1A-KO clones were expanded and 
further validated by WB and genomic DNA sequencing (Menon et al., 2019). We have 
developed an in-vitro kinase assay in the lab to analyze DYRK1A activity in cell extracts.  
Purified LIN52 is used as a substrate and incubated with cell lysates with or without DYRK1A 
(Menon et al., 2019). Using this assay, we confirmed that there was a significant loss of 
DYRK1A kinase activity in the U-2 OS DYRK1A- KO cell lines (Menon et al., 2019). 
Therefore, we chose to use these DYRK1A KO cell lines in our subsequent assays because 
transient siRNA knockdown or stable shRNA knockdown of DYRK1A resulted in significantly 
higher residual LIN52 kinase activity (data not shown). 
Using transiently transfected HA-RNF169 or GFP-RNF169, we compared the recruitment of 
RNF169 into the IRIF in the control and the DYRK1A-KO U-2 OS cells. Similar to the 
phenotype observed with Harmine treatment, both HA-RNF169 and GFP-RNF169 displayed a 
modest but significant decrease in DSB recruitment in γ-irradiated U-2 OS DYRK1A-KO cell 
lines compared to controls (Figure 12B, C). However, unlike Harmine-treated cells, DYRK1A-
KO cell lines showed significantly reduced 53BP1 IRIF formation at 3h post γ-irradiation when 
compared to control cell lines, nor did accumulation of 53BP1 at the DSB sites in the DYRK1A-
KO cell lines increase at 6h post γ-irradiation, as both DYRK1A-KO cell lines continued to 
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display a significantly decreased 53BP1 IRIF recruitment compared to controls (Figure 12D, E, 
F). 
U-2 OS cell lines have only one copy of DYRK1A (Menon et al., 2019). It is possible that these 
cell lines have intrinsically reduced DYRK1A expression resulting from loss of one copy of 
the DYRK1A gene. Therefore, we further validated our findings described above using mouse 
NIH-3T3 fibroblasts in which Dyrk1a was similarly knocked out using a CRISPR-Cas9 
approach. In the case of NIH-3T3 cells, accumulation of 53BP1 foci reaches its peak at 1h post 
γ-irradiation (3Gy), and then starts to decrease at 3h (data not shown). Using these experimental 
conditions, we again observed a decreased 53BP1 IRIF formation in two independent, clonal 
NIH-3T3 Dyrk1a-KO cell lines compared to control cells. Indeed, while a majority of the control 
and Dyrk1a-KO NIH-3T3 cells contained more than ten 53BP1 foci at 1h post γ-irradiation, the 
average number of 53BP1 IRIF per nucleus was significantly lower in the Dyrk1a-KO cells 
compared to control (Menon et al., 2019). Moreover, at 3h post γ-irradiation, the number of 
53BP1 foci per nucleus decreased by approximately 50% in both the control and Dyrk1a-KO cell 
lines, indicative of a similar rate of resolving the lesions and removal of 53BP1 foci in these cells 
lines (Menon et al., 2019). 
To further confirm that the phenotype of the DYRK1A-KO U-2 OS cells was specific to a loss of 
DYRK1A protein and kinase activity, we re-introduced either active DYRK1A or kinase-
inactive K188R-DYRK1A (KD) mutant into one of our knockout clones and created stable cell 
lines. Indeed, we observed that expression of wild-type DYRK1A, but not the kinase inactive 
mutant, resulted in a complete rescue of the 53BP1 IRIF defect in these cells (Figure 13A, B). 
These results strongly support the role of DYRK1A in regulation of 53BP1 recruitment to the 




Figure 12: DYRK1A-deficient cells have impaired recruitment of RNF169 and 53BP1 to 
the DSBs. 
(A) WB confirms absence of the full length DYRK1A protein expression in two different U-2 
OS DYRK1A-KO clones. (B, C) Quantification of HA-RNF169 IRIF in U-2OS cells transiently 
expressing HA-RNF169 or GFP-RNF169 after 3h post-irradiation (5Gy) of the parental, control 
(non-targeting sgRNA clone) or DYRK1A-KO U-2 OS cell lines from three biological 
replicates. Red and black dots indicate counts by two independent observers. Here and below, 
the error bars show standard deviation. For statistical analysis, cell lines were compared to the 
parental U-2 OS cells using a Student’s two tailed t-test; p-values are shown on the graphs. (D, 
E, F) Representative images 3h post γ-irradiation and graphs show quantification of 53BP1 IRIF 
from the cell lines processed for staining 3h or 6h post γ-irradiation (5Gy). Graph show values 
obtained from three biological replicates. For statistical analysis, each cell line was compared to 





Figure 13: Rescue of the 53BP1 foci formation in DYRK1A-KO cells by re-expression of 
active DYRK1A. 
(A) Representative images of the 53BP1 staining in parental U-2 OS cells, control sgRNA clone, 
the DYRK1A-KO clone #1 (KO), and the KO clone #1 before or after stable re-expression of the 
wild type (KO + WT) or kinase-inactive mutant (K188R) DYRK1A (KO + KD). Scale bar, 10 
μm. (B) Quantification of the 53BP1 IRIF from three independent experiments using cell lines 
described in A. For statistical analysis, each cell line was compared to the parental U-2 OS line 
(gray bars) using a Student’s t-test and p-values are shown on the graphs. Error bars indicate 
standard deviation. Lower Panel: WB shows levels of DYRK1A in the cell lines used in this 
experiment.  Slower gel migration of the recombinant DYRK1A alleles is due to the presence of 




Further, we investigated if DYRK1A was required for overexpressed RNF169 to displace 53BP1 
from IRIF. Overexpression of GFP-RNF169 in the DYRK1A-KO U-2 OS cells also resulted in 
inhibition of the 53BP1 recruitment to DSBs. The differences between the GFP and GFP-
RNF169-expressing cells were highly significant in all cell lines, p- value < 0.001 (Figure 14A-
C). This result was consistent with our findings that RNF169 was able to inhibit 53BP1 IRIF 
formation in cells treated with DYRK1A inhibitor Harmine. Furthermore, recruitment of 53BP1 
foci was significantly lower in both the GFP- and GFP-RNF169-transfected DYRK1A-KO cells 
compared to the corresponding control cell lines (Figure 14A-C).  This suggested that knockout 
of DYRK1A in U-2 OS cells could impair 53BP1 IRIF formation independent of RNF169.  
2.2.5. Depletion of RNF169 does not fully rescue the 53BP1 recruitment defect in 
DYRK1A-KO cells 
To determine whether the effect of DYRK1A loss on 53BP1 is mediated by RNF169 or not, we 
depleted RNF169 in U-2 OS cell lines using siRNA transfection. Interestingly, RNF169 depleted 
DYRK1A KO cells still had a reduced recruitment of 53BP1 as compared to their respective 
controls. The 53BP1 was not completely rescued with RNF169 depletion (Figure 14D, E). This 
phenotype was unlike what we observed with DYRK1A overexpressing cells. This result 
suggests that the 53BP1 recruitment defect in the absence of DYRK1A is not likely due to a 
more efficient displacement by RNF169. Together, our data support the conclusion that 
DYRK1A regulates the recruitment of 53BP1 to damaged chromatin in an RNF169-dependent as 




Figure 14: Impaired 53BP1 IRIF formation in DYRK1A-KO cells is RNF169 independent. 
(A, B) Representative images and quantification of GFP-RNF169 (green) and 53BP1 (red) foci 
3h after γ-radiation (5 Gy). Indicated U-2 OS cell lines were transiently transfected with GFP or 
GFP-RNF169 and stained using 53BP1 antibody and DAPI. Graphs show values from 3 
biological replicates. Red and black dots indicate counts by two independent observers. Here and 
below, the error bars indicate standard deviation. Data were analyzed using ANOVA with 
Dunnett’s multiple comparisons test (p-values shown). All comparisons between the 
corresponding GFP-transfected and GFP-RNF169-transfected samples were significant (p < 
0.01, indicated by an asterisk). (C) WB showing the expression levels of RNF169 and DYRK1A 
in the representative experiment analyzed in panels (D) and (E). (D, E) Quantification of the 
53BP1 IRIF in control or DYRK1A-KO U-2 OS cell lines after siRNA knockdown of RNF169 
from three biological replicates. Statistical significance was calculated using Student’s two tailed 




To address the mechanism of the 53BP1 recruitment defect in DYRK1A-KO cells, we analyzed 
the expression of several DNA damage response markers during DNA repair. First, we looked at 
the early markers of the DNA damage response by WB analysis. There was no change in the 
induction of p53 or γH2AX in the DYRK1A-KO cells compared to control (Menon et al., 2019). 
Analysis of the ubiquitylation of histones and accumulation of γH2AX and at the DNA damage 
sites also appeared to be unchanged in the DYRK1A-KO cells compared to controls (Menon et 
al., 2019). This suggests that the initial DNA damage response was similar in control and 
DYRK1A KO cells. Furthermore, we analyzed if loss of DYRK1A in U-2 OS affected the DNA 
damage checkpoint. Cell cycle analysis revealed accumulation of cells in G1 and G2 phases after 
γ-irradiation indicating that loss of DYRK1A in U-2 OS cells did not affect the DNA damage 
checkpoint (Menon et al., 2019). An increase in 53BP1 and BRCA1 protein levels was observed 
in the DYRK1A KO cells with or without induction of DNA damage (Menon et al., 2019). Since 
accumulation of both 53BP1 and BRCA1 at the DSB sites requires the activity of RNF168 and 
RNF8 E3 ubiquitin ligases, we also analyzed the recruitment of BRCA1 in these cells and found 
it was unchanged in the DYRK1A-KO cells (Menon et al., 2019). Therefore, we were able to 
conclude that decreased recruitment of 53BP1 to the damage sites was likely not because of 
abnormal DNA damage signaling or histone ubiquitylation in the DYRK1A-KO cells. 
2.2.6. Loss of DYRK1A promotes HRR and DNA repair 
There is evidence that 53BP1 suppresses HR-mediated DNA repair by blocking end resection 
(Canny et al., 2018; Durocher & Pelletier, 2016). Since loss of DYRK1A decreased 
accumulation of 53BP1 at DSB sites, we investigated the effect of DYRK1A loss on DNA repair 
pathway choice, using control and DYRK1A-KO U-2 OS cell lines stably expressing the direct 
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repeat (DR) GFP reporter for the HR repair pathway (Pierce et al., 1999). In this model system, 
I-SceI restriction nuclease is used to generate a DSB by cleavage of the non-functional GFP gene 
fragment. If the generated DSB is repaired by NHEJ, there would be no GFP protein expression. 
However, if the DSB is repaired by HRR, using the downstream GFP sequence, a GFP protein is 
expressed (Menon et al., 2019). Consistent with reduced recruitment of 53BP1 to DSBs in the 
DYRK1A-KO cells, we observed an approximately two-fold increase in the percentage of GFP-
positive cells after I-SceI expression (Menon et al., 2019). The same trend was observed with 
both DYRK1A-KO clones. As compared to the control U-2 OS cells, this result was statistically 
significant with one of the DYRK1A-KO clones but not with the second U-2 OS DYRK1A-KO 
clone because of high variability between biological replicates. 
2.3. DISCUSSION AND FUTURE DIRECTIONS 
Through the results discussed in this chapter, we provide functional characterization of the 
DYRK1A-RNF169 interaction. Our study revealed the role of DYRK1A in the DNA damage 
pathway by regulating one of the key response factors to DNA DSB lesions - 53BP1 (Panier & 
Boulton, 2014). Overexpression of RNF169 prevents the accumulation of 53BP1 at DSBs, 
resulting in increased HR-mediated DNA repair efficiency due to a more efficient resection of 
the DNA ends (J. Chen et al., 2012; Poulsen et al., 2012). However, the mechanism by which 
RNF169 regulates 53BP1 accumulation, as well as the factors that regulate RNF169 recruitment 
and dissociation from the DSB sites are still not known. Our study not only validated the role of 
RNF169 as a negative regulator of 53BP1 accumulation but also supported the role of DYRK1A 
as an RNF169 effector that positively regulates its activity through both direct and indirect 
mechanisms.  Since the publication of our study, two other groups also reported the DYRK1A-
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RNF169 interaction and its role in the DNA damage response (Guard et al., 2019; Roewenstrunk 
et al., 2019).  
Previous studies found that a high-affinity ubiquitin-binding MIU domain in RNF169 is required 
for its ability to inhibit 53BP1 accumulation at the damage sites (J. Chen et al., 2012; Q. Hu et 
al., 2017; Poulsen et al., 2012). Our study shows that the binding of RNF169 to ubiquitin may be 
necessary, but not sufficient, to fully prevent the accumulation of 53BP1 at DSB sites. Indeed, 
the phosphorylation-deficient RNF169 mutants show reduced ability to displace 53BP1 from the 
DSBs despite almost normal recruitment to these sites. Interestingly, several ATM-regulated 
phosphorylation sites in 53BP1 are required for interaction with its key effector RIF1 but 
dispensable for its recruitment to the damage sites (Escribano-Díaz et al., 2013; Isono et al., 
2017). It is possible that DYRK1A phosphorylation of RNF169 serves to recruit an additional 
factor that is essential for displacing 53BP1, or for stabilizing the binding of RNF169 to 
ubiquitylated chromatin. The phosphomimetic DD mutant of RNF169 also showed a reduced 
ability to displace 53BP1 from DSBs. One possibility is that this mutant does not accurately 
represent the constitutively active form of RNF169. Another possibility is that the RNF169 DD 
mutant causes a dominant negative effect. An RNF169 dimer could be responsible for inhibiting 
53BP1 foci formation, wherein one molecule of RNF169 is in the phosphorylated form and the 
other is not phosphorylated. Thus, when the AA mutant is expressed, there is an excess of un-
phosphorylated RNF169, which may dimerize and cause inhibition of 53BP1 recruitment. When 
the phosphomimetic mutant is present in excess, a possibility is that there is not enough 
unphosphorylated RNF169 to form the active dimer and therefore, there is reduced 53BP1 
recruitment. Moreover, the constitutive presence of the DYRK1A-RNF169 complex both in the 
intact cells and after damage, as well as the estimated size of the DYRK1A-RNF169 complex 
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also indicate that other factor(s) is/are likely present in this complex that could be regulated by 
DNA damage signaling. Further proteomic studies of the RNF169-DYRK1A complex in the 
cells before and after DNA damage will help to identify such a factor. Of note, our analysis of 
the DYRK1A interactome detected an interaction with USP7, a ubiquitin-specific protease that 
has been recently shown to bind directly to RNF169 and increase the stability of 53BP1, 
RNF169 and RNF168 (An et al., 2018; X. Liu et al., 2016; Zhu et al., 2015). Although disruption 
of the DYRK1A phosphorylation sites in RNF169 did not influence its interaction with USP7, 
the role of USP7 in the DYRK1A-RNF 169 mediated regulation of 53BP1 should be further 
investigated.  
In our study, DYRK1A overexpression or depletion both caused a decrease in 53BP1 IRIF. 
Interestingly, while increased expression of DYRK1A appears to attenuate the displacement of 
53BP1 from the DSBs by RNF169, the 53BP1 DSB recruitment defect in DYRK1A-depleted 
cells appears to be, at least in part, RNF169-independent. This is because 53BP1 IRIF 
accumulation was not completely rescued with RNF169 depletion in DYRK1A-KO cells. 
Indeed, DYRK1A-KO cell lines displayed decreased RNF169 IRIF formation. Recent studies 
have revealed that in addition to the histone H2A-K15ub mark, 53BP1 recognizes and binds to 
the H4K20Me2 mark via its conserved Tudor domain, and this process is regulated by several 
factors including histone methyltransferases SETD8 and MMSET, as well as Polycomb proteins 
L3MBTL1 and JMJD2A that occupy these marks in the absence of DNA damage [reviewed in 
(Panier & Boulton, 2014)]. Furthermore, in S/G2 phases of the cell cycle, BRCA1 plays an 
active role in removing 53BP1 from chromatin around damage sites by a mechanism that is not 
fully understood, requiring CDK activity and CtIP (Chapman et al., 2012; Escribano-Díaz et al., 
2013; Isono et al., 2017). It will be interesting to investigate in the future whether changes in 
 
 35 
these 53BP1-regulating factors are responsible for the phenotypes observed in the DYRK1A-KO 
cells.  
There is also a possibility that there is another kinase capable of phosphorylating RNF169 at the 
same sites as DYRK1A, and this kinase is inhibited when DYRK1A is present in optimum 
amounts. When DYRK1A is present in excess, there could be an increased phosphorylation of 
RNF169 leading to decreased 53BP1 recruitment. On the other hand, when DYRK1A is 
depleted, the alternate kinase may phosphorylate RNF169 leading to decreased 53BP1 
recruitment. Although further studies will be needed to determine if this is true, it is important to 
note that there are several examples of redundant kinases phosphorylating a single substrate in 
the DNA damage response, such as ATM and DNA-PK kinases that are both capable of 
phosphorylating H2AX (Stiff et al., 2004). 
Since BRCA1 gene expression could be regulated by DYRK1A through recruitment of the 
DREAM repressor complex (Litovchick et al., 2011; Yakovlev, 2013), the relationship between 
DYRK1A expression levels and the outcomes of the DNA damaging therapy in cancer should be 
further investigated. Importantly, loss of 53BP1 can rescue the HR defects associated with 
inactivation of BRCA1, and is one of the factors responsible for the acquired resistance of the 
BRCA1-mutant tumors to PARP inhibitor therapy (Jaspers et al., 2013). Therefore, future studies 
will be needed to establish the exact role of DYRK1A in the context of cellular processes that 
regulate the recruitment of 53BP1 to the DSBs, and to validate the significance of DYRK1A as a 






CHAPTER 3: CHARACTERIZATION OF NOVEL DYRK1A INTERACTING 
PROTEINS 
 
3.1 INTRODUCTION TO THE CHAPTER 
Of the DYRK1A interacting proteins we reported earlier, we validated its interaction with 
DCAF7, LZTS1, LZTS2, FAM117B, RNF169 and TROAP (Menon et al., 2019) in human cells. 
Although we did not validate the interaction of LZTS3 with DYRK1A, its close relationship with 
LZTS1 and 2 lead us to review the literature on LZTS3 as well. In this chapter we will focus on 
the biochemical and functional characterization of all of these DYRK1A interactors. 
Below is a review of current literature on each of these DYRK1A interacting proteins except 
RNF169 (described in detail in Chapter 2).  
3.1.1. DCAF7 
Similar to DYRK1A, the DCAF7 gene is conserved in evolution. DYRK family of protein kinases 
includes members from yeast to humans. Interestingly, out of all the top human DYRK1A 
interacting proteins in our study only DCAF7 has an orthologue in yeast- Saccharomyces 
cerevisiae (genecards.org) and according to the BioGrid database, an interacting partner of the 
founding member of the DYRK sub-family member Yak1 includes the yeast DCAF7 orthologue 
YPL-247. The DCAF7 orthologue in plants, AN11 was originally identified as a gene in petunia 
located in a locus that controls the pigmentation of flowers by stimulating the transcription of 
anthocyanin biosynthetic genes (de Vetten et al., 1997) The orthologues of this gene have been 
identified in many species, including humans (Jin et al., 2006). In vertebrates this gene is also 
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known as WDR68 (WD-repeat protein 68) or DCAF7 (DDB1 and Cullin Associated Factor 7) 
(Lee & Zhou, 2007). 
The DCAF7 ortholog in Drosophila, CG14614 (official gene symbol wap, wings apart, also 
called riq, riquiqui), is essential for normal wing-vein patterning and development of the adult 
jump muscle (Morriss et al., 2013).. Interestingly, CG14614 associates with MNB in Drosophila, 
and both genes were shown to control normal wing and leg growth by modulating the Salvador-
Wart-Hippo (SWH) pathway (Degoutin et al., 2013). Thus, there is evidence of the importance 
of the DYRK1A-DCAF7 interaction for development in different organisms. DCAF7 is also 
involved in craniofacial development in zebrafish where it plays a role upstream of the EDN1 
(Endothelin-1) pathway (Nissen et al., 2006). This is of particular interest as DYRK1A itself is 
involved in development and DS patients have certain craniofacial abnormalities. Interestingly, 
nuclear access of DCAF7 is required for normal craniofacial development in zebrafish (B. Wang 
et al., 2013). This is important as DCAF7 is mainly a cytosolic protein. However, DCAF7 binds 
DYRK1A and this binding induces the nuclear translocation of DCAF7 (Miyata & Nishida, 
2011). On the other hand, the localization of DYRK1A has not been found to be dependent on 
DCAF7 binding (Glenewinkel et al., 2016; Miyata & Nishida, 2011).  
Structurally, DCAF7 and its orthologues all encode a protein with several WD40 domains. These 
domains are characterized by tryptophan-aspartate (WD) dipeptide repeats that are 44-60 amino 
acids in length (Stirnimann et al., 2010; Wu et al., 2012). These WD40 repeats fold and organize 
into circularized β- propeller structures and can facilitate protein-protein interactions (Stirnimann 
et al., 2010; Wu et al., 2012). DCAF7 is predicted to act as a substrate receptor for the DDB1- 
Cullin complexes although this function has not been experimentally demonstrated till date (Jin 
et al., 2006; Lee & Zhou, 2007). Interestingly, DCAF7 acts as a scaffold receptor to control 
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HIPK2 and MEKK1 kinase functions (Ritterhoff et al., 2010). DCAF7 is also required for 
efficient binding of E1A to DYRK1A, DYRK1B and HIPK2 (Glenewinkel et al., 2016; Skurat & 
Dietrich, 2004).  
There is evidence that DCAF7 could be required for cellular proliferation (Miyata & Nishida, 
2011; Ritterhoff et al., 2010). Both DYRK1A and DCAF7 bind to the C-terminal region of 
oncoprotein E1A (Komorek et al., 2010; Zemke & Berk, 2017). This region of E1A is 
responsible for restraining its oncogenic and transforming abilities. It was found that an E1A 
mutant defective in binding DYRK1A and DCAF7 showed a robust increase in proliferation, 
transformation and tumor formation as compared to wildtype E1A (Komorek et al., 2010). This 
suggests that E1A interaction with DYRK1A and DCAF7 could inhibit cell proliferation. 
DCAF7 is also required to maintain normal levels of DYRK1A and DYRK1B in C2C12 and 
HeLa cell lines (Yousefelahiyeh et al., 2018). 
We and others have detected DCAF7 as a binding partner of DYRK1A (Glenewinkel et al., 
2016; Guard et al., 2019; Komorek et al., 2010; Menon et al., 2019; Miyata & Nishida, 2011; 
Morita et al., 2006; Roewenstrunk et al., 2019; Skurat & Dietrich, 2004; Varjosalo et al., 2013). 
Furthermore, it was found that the interaction between DYRK1A and DCAF7 is evolutionarily 
conserved (Glenewinkel et al., 2016), as shown in Figure 15. Interestingly, WD40 repeats of 
DCAF7 alone are not sufficient for the binding of DCAF7 to DYRK1A but the N- and C- 
termini of DCAF7 are also required (Miyata & Nishida, 2011). It was determined that the 
minimal region in DYRK1A required for DCAF7 binding is located in the N-terminus and spans 
amino acids 93-104 of human DYRK1A (Glenewinkel et al., 2016; Miyata & Nishida, 2011).  
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Additional functions of DCAF7 include a role in the osmotic stress response (Ritterhoff et al., 
2010) and control of GLI1 transcriptional activity through interaction with mDia1 (DIAPH1) 
(Morita et al., 2006). Additionally, it has been reported that DCAF7 is required for nucleotide 
excision repair by maintaining the cellular levels of ERCC1-XPF (Kawara et al., 2019). This is 
the first report suggesting a direct role of DCAF7 in regulation of a DNA repair pathway and is 
interesting given the role of DYRK1A in DNA repair (Guard et al., 2019; Menon et al., 2019; 
Roewenstrunk et al., 2019). DCAF7 was also recently shown to regulate stability of DNA ligase 
I (LIG1), one of the key enzymes in the DNA replication and repair of DNA DSBs (Z. Peng et 
al., 2016). Another DCAF7 interacting protein detected in multiple studies is the molecular 
chaperone TRiC/CCT. It was shown that molecular chaperone TRiC/CCT binds to DCAF7 and 
promotes its folding, binding to DYRK1A and nuclear accumulation (Miyata et al., 2014).  
Finally, DCAF7 has also been reported to have functions in transcription that will be discussed in 





Figure 15: The DYRK1A-DCAF7 interaction is conserved across evolution. 
(A) Consensus sequence of the DCAF7 binding motif in class 1 DYRKs created by analyzing 19 
representative sequences from Class I DYRKs from the animal kingdom. (B) Phylogenetic 
relationship of the DYRKs and HIPKs that interact with DCAF7 [Adopted from (Glenewinkel et 
al., 2016)]. 
3.1.2. LZTS proteins  
In our MudPIT analysis of DYRK1A, we identified PSD-Zip70 (or LZTS1), LAPSER1 (or 
LZTS2) and ProSAPiP1 (LZTS3), which all belong to a ‘Fezzin’ family of proteins (Wendholt et 
al., 2006). Along with the characteristic Fez1 domain/s, LZTS1 and LZTS2 also have a coiled-
coil region with an internal leucine zipper motif in the center part of the protein and a PDZ 
domain at their C-terminus (Wendholt et al., 2006). These proteins can form homo or hetero-
oligomers (Schmeisser et al., 2009; Wendholt et al., 2006). Note that LZTS1 is also referred to as 
FEZ1 in some studies. The function of this family of proteins is not fully understood. 
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Interestingly, LZTS1, LZTS2 and LZTS3 were identified as Post Synaptic Density (PSD) 
proteins (Dolnik et al., 2016; Schmeisser et al., 2009; Wendholt et al., 2006), and they all bind 
directly to the signal-induced proliferation associated (SIPA) family of proteins that includes 
SIPA1, 2, and 3, also known as SPARs or spine-associated RapGAPs. SPARs are GTPase 
activating proteins (GAPs) in the brain (Dolnik et al., 2016; Reim et al., 2016; Wendholt et al., 
2006). The expression profile of LZTS1 detected in mouse and chick embryos revealed that it is 
localized to regions involved in neuronal development (Kropp & Wilson, 2012). LZTS1 knock 
out mice show cognitive and behavioral defects due to abnormal Rap2 activity (Mayanagi et al., 
2015), suggesting that the LZTS proteins may be associated with behavioral disorders. A recent 
publication suggests a previously unknown role of LZTS1 during mammalian cerebral 
development. This study showed that LZTS1 controls neuronal delamination and outer radial 
glial-like cell generation (Kawaue et al., 2019). Furthermore, LZTS2 could serve as a negative 
regulator in regulation of β-catenin localization from the synapse to nucleus, leading to decreased 
transcription of β-catenin target genes (Schmeisser et al., 2009). 
It is not known if there is a functional connection between DYRK1A and the LZTS family in 
neurological disorders. Interestingly, DYRK1A also phosphorylates proteins that bind to clathrin 
coated vesicles and inhibits clathrin-mediated endocytosis in neurons (Murakami et al., 2009, 
2012). Moreover, DYRK1A may also be regulated by Wnt signaling (Granno et al., 2019). 
Hence DYRK1A-LZTS interactions in this regard will be an interesting avenue of study. 
3.1.3. Role of LZTS proteins in cancer 
As suggested by the name (LZTS stands for Leucine Zipper Tumor Suppressor), LZTS1, LZTS2 
and LZTS3 have tumor suppressive functions. Indeed, Lzts1-/- mice develop tumors with diverse 
histogenetic backgrounds and LZTS1 expression is frequently lost in various types of cancers 
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(Ishii et al., 1999; Vecchione et al., 2007) suggesting that it acts as a major tumor suppressor 
gene in multiple cell types. Reintroduction of LZTS1 into cancer cells that lack its expression 
suppresses cell proliferation by cell cycle arrest at the G2/M phase of the cell cycle, and this 
effect is thought to be mediated by its interaction with mitotic kinase CDK1 (Ishii et al., 1999; 
Vecchione et al., 2007). LZTS1 expression is reduced in hepatocellular carcinoma (Y. He & Liu, 
2015; Zhang et al., 2015), and there is evidence of LZTS mediated suppression of proliferation 
by impairing the PI3K/Akt pathway in hepatocellular carcinoma (Y. He & Liu, 2015). Down 
regulation of LZTS1 is associated with poor prognosis and causes increased metastasis in breast 
cancer (L. Chen et al., 2009; W. Chen et al., 2007; Lovat et al., 2014; X.-X. Wang et al., 2011, 
2015). LZTS1 is lost or silenced in various other cancers including uveal melanoma (Onken et 
al., 2008), prostate cancer (Cabeza-Arvelaiz et al., 2001; Ishii et al., 1999), squamous cell 
carcinoma (Olasz et al., 2015), lung cancer (Lin et al., 2013; Nonaka et al., 2005; Toyooka et al., 
2002) and ovarian cancer (Arnold et al., 2006; Califano et al., 2010; Ishii et al., 1999).  
Similar to LZTS1, LZTS2 is also frequently deleted in cancer. LZTS2 has been mapped to a sub-
region of human chromosome 10q24.3, near the PTEN locus (Cabeza-Arvelaiz et al., 2001; 
Wendholt et al., 2006). In laryngeal squamous cell carcinoma, LZTS2 promoter methylation has 
been reported (Z. Shen et al., 2018). Loss of LZTS2 in mice leads to renal abnormalities and an 
increased incidence of cancer (Johnson et al., 2013; Y. Peng et al., 2011). Overexpression of 
LZTS2 cDNA strongly inhibits cell proliferation and the colony forming efficiencies of some 
cancer cell lines (Cabeza-Arvelaiz et al., 2001). Increased nuclear localization of β-catenin due to 
aberrant activation of the Wnt pathway contributes to cancer, and LZTS2 binds to β-catenin and 
promotes its nuclear exclusion, thus increasing the cytosolic pool of β-catenin (Thyssen et al., 
2006). It was recently demonstrated that PTEN and LZTS2 both control β-catenin mediated 
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transcription (E.-J. Yu et al., 2017). Interestingly, a connection between DYRK1A and β-catenin 
was recently reported where activation of Wnt signaling altered the sub-cellular localization of 
DYRK1A by an unknown mechanism (Granno et al., 2019). Furthermore, LZTS2 was seen to 
inhibit cell proliferation and regulate Lef/Tcf-dependent transcription through the Akt/GSK3β 
signaling pathway in lung cancer (Cui et al., 2013). LZTS2 inhibits PI3K/AKT activation in 
nasopharyngeal carcinoma as well (Xu et al., 2018). Finally, the protein interaction network of 
the mammalian Hippo pathway revealed interaction of LZTS2 with LATS2 (Couzens et al., 
2013). Thus, this particular DYRK1A-interacting protein found through the proteomic analysis 
could provide a connection between cancer-related cellular signaling pathways and DYRK1A. 
The role of LZTS3 in cancer has been studied to a lesser extent. Like LZTS1 and LZTS2, it is 
thought to have a tumor suppressive function (J. He et al., 2018; Teufel et al., 2005).  
3.1.4. FAM117B 
FAM117B (Family with sequence similarity 117, member B) is a poorly studied but potentially 
important DYRK1A interacting protein. A study conducted in 215 individuals with either 
Autism spectrum disorder (ASD) or intellectual disability reported the presence of several gene 
copy number changes. In this study, FAM117B was one of the 46 genes located in a region of 7.8 
Mb chromosomal deletion at 2q33.1 to q34. This suggests that FAM117B could also be involved 
in ASD or intellectual disability and it will be interesting to see if it has a link with the 
involvement of DYRK1A in neurological conditions (Roberts et al., 2014). Interestingly, a 
GWAS study recently found that FAM117B was one of the genes associated with cerebral small 
vessel disease. Further, using two independent single cell RNA sequencing datasets from the 
anterior temporal lobe of adult human brains and cerebrovascular cells of adult mouse brains, 
researchers found that FAM117B was expressed in various cell types that included astrocytes, 
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neurons and oligodendrocytes (Chung et al., 2019). This further suggests that FAM117B could 
play an important role in neurological processes and since it is a DYRK1A-interacting protein, 
FAM117B could be dependent on or influence DYRK1A’s function in neurological conditions. 
3.1.5. TROAP  
Tastin was initially described as a protein that forms a complex with trophinin and bystin, hence 
it was renamed as TROphinin Associated Protein or TROAP. The TROAP-trophonin-bystin 
complex is required for the initial adhesion of the blastocyst to uterine epithelial cells at the time 
of embryo implantation (Fukuda & Nozawa, 1999). Although TROAP expression is absent in 
most adult tissues (Nadano et. al., 2002), higher levels of expression are observed in testis, bone 
marrow and thymus, as well as human cancer cell lines such as HeLa and Jurkat cells (Genomics 
Institute of the Novartis Research Foundation [GNF] database). In mammalian cells, TROAP is 
thought to associate with microtubules (Nadano et al., 2002). Levels of TROAP increase in the 
G2/M phase of the cell cycle and it has been found to be required for maintaining bipolar 
spindles and the integrity of the centrosome during mitosis (Yang et al., 2008). Ectopically 
expressed TROAP in COS7 cells forms fibers that localize to the microtubular cytoskeleton and 
binds to cytoplasmic dynein in HEK293T cells (Nadano et al., 2002). The role of TROAP in 
cancer has been studied by several groups. TROAP was found to be pro-tumorigenic in lung 
adenocarcinoma (Z. Chen et al., 2019), non-small cell lung cancer (Huang et al., 2019), breast 
cancer (Kai Li et al., 2019), ovarian cancer (Godoy et al., 2013), colorectal cancer (X. Ye & Lv, 
2018), gastric cancers (Jing et al., 2018) and prostate cancer (J. Ye et al., 2019). In breast cancer, 
lung adenocarcinoma and gastric cancers, higher expression of TROAP was found to correlate 
with lower survival (Z. Chen et al., 2019; Jing et al., 2018; Kai Li et al., 2019). However, 
TROAP may play a dual role and both promote and suppress tumorigenesis in hepatocellular 
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carcinoma (H. Hu et al., 2019; Jiao et al., 2019; Lian et al., 2018). In breast cancer cells, TROAP 
depletion was found to cause cell cycle arrest in the G1/S phase of the cell cycle (Kai Li et al., 
2019). Depletion of TROAP in gastric and colorectal cancer cells also leads to an arrest in the 
G0/G1 phase of the cell cycle (Jing et al., 2018; X. Ye & Lv, 2018). In NSCLC, expression of 
TROAP along with certain other genes was found to be deregulated in pre-cancerous lesions and 
was gradually altered with disease progression suggesting that TROAP may be involved during 
tumorigenesis (Huang et al., 2019). These findings suggest that TROAP could be a therapeutic 
target in several cancer types, and provide the rationale for further research.  
3.2. RESULTS 
3.2.1. MudPIT proteomic analysis of DYRK1A interacting proteins 
In our earlier study, we reported the interaction of DYRK1A with RNF169, FAM117B, LZTS1, 
LZTS2 and TROAP. MudPIT proteomic analysis of DYRK1A revealed that DCAF7 interacts 
stoichiometrically with DYRK1A, suggesting that it is a major DYRK1A interacting protein. 
Since DCAF7 is a known scaffolding protein, we hypothesized that some of these proteins could 
form multi-protein complexes, which could be important for understanding the function of 
DYRK1A. We also hypothesized that DCAF7 acts as a scaffold to bring all these proteins 
together. In order to identify multi-protein complexes, we decided to first analyze the 
interactome of DCAF7 in T98G cells in a similar way as we did for analyzing the DYRK1A 
interactome. We detected 55 proteins that reproducibly bound DCAF7 in at least 2 out of 3 
replicate experiments. Unexpectedly, we found only a small overlap with DYRK1A interacting 
proteins (indicated by a black outline, Figure 16). Several known interactors of DCAF7 were 
also detected, including components of PRC1.3/5 (will be discussed in Chapter 4) and the 
 
 46 
chaperone TRiC/CCT complex that binds to DCAF7 and promotes its folding (Miyata et al., 
2014).  
Next, we similarly analyzed the interactomes of other novel DYRK1A interacting proteins to see 
if there is any overlap with DYRK1A and DCAF7 interactomes. RNF169, FAM117B, LZTS2, 
LZTS1 and TROAP reproducibly pulled down 28, 113, 183, 678 and 17 proteins respectively in 
at least 2 out of 3 biological replicates (Appendix tables and Figure 17A-E), including known, as 
well as novel, interactors for each of these proteins. As LZTS2, LZTS1 and FAM117B bound a 
large number of proteins, we sorted these reproducible interactors by their dNSAF score (relative 
abundance compared to all proteins detected), to identify the top enriched 50 interacting proteins 
detected in at least 2 biological replicates. We observed that, except for of RNF169, the 
interactomes of FAM117B, LZTS1, LZTS2 and TROAP did not show major overlap with 
DYRK1A (Appendix tables and Figure 17). Interestingly, all these proteins did pull down 
DCAF7 (Figures 17 and 18). Only a few proteins detected in these analyses also bound DCAF7 
(shown by yellow labels in Figures 17 A-E and indicated in bold in Appendix tables). In 
summary, our MudPIT proteomic analysis revealed that while there were no apparent multi-
subunit complexes with our novel DYRK1A interacting proteins, all of these proteins bound both 
DYRK1A and DCAF7 (Figures 17 and 18). This could support a model that DCAF7 plays a 
scaffolding role to promote these interactions. 
3.2.2. DYRK1A interacting proteins bind DCAF7 
Next, we wanted to validate if the DYRK1A binding proteins bound DCAF7. Using T98G cell 
lysates we carried out IP/WB analysis with antibodies against RNF169, FAM117B, LZTS2, 
LZTS1 and TROAP. Consistent with our previously observed result, all of these proteins bound 
DYRK1A. Furthermore, consistent with our new mass spec data, all of these DYRK1A 
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interacting proteins also bound DCAF7 (Figure 19, A-E). Next, we wanted to confirm our 
finding that these proteins apparently do not form a multi-subunit complex. Therefore, using 
T98G cells we carried out IP analysis of RNF169, FAM117B, LZTS1, LZTS2, TROAP and 
DYRK1A followed by WB analysis with DCAF7, DYRK1A and each bait protein. Indeed, we 
detected both DYRK1A and DCAF7 in all immunoprecipitates, but did not find interaction 
between most of the pulled-down proteins, thus confirming our results obtained by MudPIT 
proteomic analysis, suggesting that these proteins were not all present in a single complex 
(Figure 19F). One exception to this was previously reported binding between LZTS1 and LZTS2 
(Figure 19F).  Although our LZTS1 MudPIT analysis detected TROAP, we were unable to 






Figure 16: Analysis of the DCAF7-interacting protein network. 
(A) Purification of DCAF7 for MudPIT proteomic analysis. Top: Representative western blot 
showing levels of DCAF7 in T98G cells expressing HA- Flag tagged GFP (GFP-FH) or HA-
Flag-tagged DCAF7 (DCAF7-FH). Arrow indicates epitope tagged DCAF7. Values show band 
density relative to Vinculin (control). Bottom: representative silver stained gel containing 10% of 
HA-peptide eluted control (GFP) or DCAF7-FH IP samples analyzed by MudPIT. Green arrow 
indicates DCAF7 (B) Graph shows relative enrichment (dNSAF) of proteins detected in two or 
all three DCAF7 MudPIT experiments. DCAF7 is shown as a green circle whereas red and blue 
circles correspond to interacting proteins either listed in the BioGrid database, or new DCAF7-
binding proteins, respectively. Black arrow points to DYRK1A. (C) Hierarchical network of 
interactions (CytoScape) involving DCAF7-binding proteins identified in this study was 
constructed using MetaScape analysis tool. Colors, same as in (B). Larger nodes correspond to 
proteins detected in all three replicates and smaller nodes correspond to proteins detected in two 
biological replicates. Unconnected nodes are not known to interact with other factors. Black 
outline indicates an overlap with our previous DYRK1A dataset (detected in at least 2 out of 4 









Figure 17: Analysis of protein networks of DYRK1A interacting proteins. 
Hierarchical networks of interactions (CytoScape) for (A) LZTS2, (B) LZTS1, (C) FAM117B, 
(D) RNF169 and (E) TROAP were constructed using MetaScape analysis tool. Larger nodes 
correspond to proteins detected in all three replicates while smaller nodes correspond to proteins 
detected in two biological replicates. Unconnected nodes are not known to interact with other 
factors. Bait protein is shown in green whereas red and blue circles correspond to interacting 
proteins either listed in the BioGrid database, or new-RNF169 binding proteins, respectively. 
Black outline indicates an overlap with our previous DYRK1A dataset (detected in at least 2 out 
of 4 biological DYRK1A pull down experiments). Yellow label indicates an overlap with our 
DCAF7 dataset (Detected in at least 2 out of 4 biological DCAF7 pull down experiments). Note: 
Overlap with BioGrid database was analyzed in May 2019, which was before the inclusion of 












Figure 19: DYRK1A interacting proteins bind DCAF7 but do not form a single complex. 
(A-F) T98G lysates were used to perform immunoprecipitation analysis with the indicated 
antibodies or with non-reactive IgG control antibody followed by WB analysis for detection of 
the indicated proteins. As RNF169, FAM117B, TROAP and LZTS2 have similar molecular 
weights, Figure 21F is a composite figure made from 4 independent IP/WB experiments in order 
to avoid any residual overlapping signal from different antibodies during the WB analysis. 
DCAF7 and DYRK1A were detected in each IP/WB experiment as controls, and looked identical 




In order to identify if these complexes were mainly present in the nucleus or in the cytoplasm, 
we carried out cyto-nuclear fractionation of T98G cells and subjected the cytoplasmic and 
nuclear extracts to IP/WB analysis (Figure 20). Consistent with its role in DNA damage repair, 
we found that RNF169 is mainly a nuclear protein and that the RNF169-DYRK1A-DCAF7 
complex is also mainly nuclear in the cell [Figure 20A, (An et al., 2018; J. Chen et al., 2012; 
Guard et al., 2019; Menon et al., 2019; Poulsen et al., 2012; Roewenstrunk et al., 2019)]. 
Interestingly we also observed that the cytoplasmic RNF169 also binds both DYRK1A and 
DCAF7 (Figure 20A). We also observed that nuclear RNF169 migrates slower as compared to 
the cytoplasmic form, which could indicate the presence of a post translational modification in 
the nuclear compartment. Unlike the RNF169-DYRK1A-DCAF7 complex, FAM117B, LZTS2 
and LZTS1 complexes were mainly cytoplasmic (Figure 20A-D). Interestingly, we observed that 
two isoforms of TROAP are present in the cytoplasm whereas only the longer isoform is present 
in the nucleus, and that the TROAP-DYRK1A-DCAF7 complex was detected mainly in the 
cytoplasm, but is also present in the nucleus (Figure 20E). 
3.2.3. DCAF7 is not a scaffolding protein for DYRK1A tertiary complexes  
Next, we investigated if DCAF7 is required for the interaction of DYRK1A with RNF169, 
FAM117B, LZTS2, LZTS1 and TROAP (Figure 21 A-E). We carried out IP/WB analysis in U-2 
OS control or shDCAF7 cell lines in which DCAF7 was depleted by two different shRNA 
hairpins. Interestingly, we observed that depletion of DCAF7 reduced the levels of DYRK1A. 
This is consistent with a previous report suggesting that DCAF7 is required to maintain levels of 
DYRK1A (Yousefelahiyeh et al., 2018). Furthermore, it was found that DCAF7 is not required 
for RNF169, FAM117B or TROAP to bind DYRK1A but it might be needed for LZTS1/2-




Figure 20: Nucleo-cytoplasmic distribution of the tertiary complexes including DYRK1A 
and DCAF7. 
(A-E): T98G cells were fractionated into nuclear and cytoplasmic compartments followed by IP/ 
WB analysis with the indicated antibodies. Tubulin and Lamin were used to confirm the 






Figure 21: DCAF7 is not required for RNF169, FAM117B, TROAP to bind DYRK1A but it 
might be needed for LZTS1/2-DYRK1A binding. 
(A-E) Lysates from U-2 OS control or shDCAF7 cells were subjected to IP/WB analysis with 
indicated antibodies. IgG represents non-specific, control antibody. Arrows point to bands of 
interest and asterisk indicates non-specific band. DYRK1A band density in the IP lanes was 
quantified relative to bait protein using ImageJ analysis. Numbers indicate DYRK1A band 
density values relative to input.  
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Next, we sought to analyze if DYRK1A is required for mediating the interaction of RNF169, 
FAM117B, LZTS1, LZTS2 or TROAP with DCAF7 (Figure 22). We used U-2 OS control or U-
2 OS cell line in which DYRK1A has been knocked out using the CRISPR-Cas9 approach (KO 
#1 used in Chapter 2). As an additional control, we used a rescue DYRK1A KO cell line in 
which recombinant DYRK1A was stably re-expressed (same cell line used in Chapter 2). 
Interestingly, we found that the interaction of RNF169, FAM117B, LZTS1, LZTS2 and TROAP 
with DCAF7 was reduced in the absence of DYRK1A, but restored in the rescue cell line (Figure 
22A-E). Therefore, we can conclude that DYRK1A is required for the interaction of RNF169, 
FAM117B, LZTS1, LZTS2 and TROAP with DCAF7. Of note, we have consistently observed 
that FAM117B migrates higher in the presence of DYRK1A than in DYRK1A-KO cells 
indicating the presence of a post-translational modification. This difference was recapitulated 
using siRNA knockdown of DYRK1A in T98G cells. Using λ-phosphatase treatment in cell 
lysates from U-2 OS cells, we were able to confirm that this modification was indeed due to 
phosphorylation (Figure 23A, B).  
It has been reported that the amino acids 93-104 of DYRK1A are required for its interaction with 
DCAF7 (Glenewinkel et al., 2016). We wanted to determine if the DCAF7 binding site in 
DYRK1A was also required for its interaction with RNF169, FAM117B, LZTS2 and TROAP 
(Figure 24). We transiently transfected either GFP (negative control) or GFP-DYRK1A N-
terminal deletion constructs or rescue constructs expressing only certain N-terminal regions of 
DYRK1A (Figure 24A), followed by a GFP-pull down and WB analysis of DYRK1A interacting 
proteins (Figure 24B). We confirmed that DCAF7 bound to DYRK1A through the 93-104 amino 
acids (Figure 24A-B; indicated with red boxes), and found that RNF169, LZTS2 or FAM117B 
were not able to bind DYRK1A when the DCAF7 binding domain was deleted. This suggests 
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that the DCAF7 binding domain in DYRK1A is required for its interaction with RNF169, 
LZTS2 and FAM117B. Further, as previously shown, a GFP-DYRK1A fragment comprised of 
the first 103 amino acids was sufficient for DCAF7 binding (Figure 24A-B; indicated with red 
boxes). However, this construct did not bind RNF169, FAM117B, or LZTS2. This suggested that 
the DCAF7 binding region in DYRK1A was necessary but not sufficient for its interaction with 
RNF169, FAM117B or LZTS2. Interestingly, the minimal region of DYRK1A that binds 
RNF169, FAM117B and LZTS2 was found to encompass amino acids 77-136 of DYRK1A. Of 
note, RNF169, FAM117B and LZTS2 bound DYRK1A 77-136 more strongly than DYRK1A 1-
176, which also harbors the minimal binding region within it (Figure 24 A-B; indicated with red 
boxes). Interestingly, a different pattern of binding was observed for TROAP, which bound 
DYRK1A Δ93-104 even in the absence of DCAF7 binding. However, the deletion of the first 
134 amino acids at the N-terminus of DYRK1A was also able to abolish its binding with TROAP 
while none of the DYRK1A N-terminal rescue fragments were able to bind to TROAP. We 
therefore used DYRK1A C-terminal constructs and carried out a similar experiment in order to 
further map the TROAP binding region (Figure 25A-B). Deletion of most of the kinase domain 
of DYRK1A (DYRK1A Δ174-487) reduced the binding of TROAP to DYRK1A, while a kinase 
inactive mutant DYRK1A Y321F was able to bind TROAP indicating that the kinase domain but 







Figure 22: DYRK1A is required for DCAF7 interaction with RNF169, FAM117B, LZTS2, 
LZTS1 and TROAP. 
(A-E) Lysates from U-2 OS control, DYRK1A KO or DYRK1A KO rescue cell line with 
expression of recombinant DYRK1A were used for IP/WB analysis for indicated proteins. IgG 





Figure 23: DYRK1A phosphorylates FAM117B. 
(A) T98G cell lysates were treated with non-targeting siRNA or siRNA against DYRK1A 
followed by WB analysis for indicated proteins. (B) Indicated T98G cell lysates were incubated 
with or without λ-phosphatase followed by WB analysis.   
 
3.2.4. Effect of DYRK1A on localization of its interacting proteins 
Since binding to DYRK1A was required for novel DYRK1A interacting proteins to bind 
DCAF7, we wanted to investigate whether loss of binding was due to a change in sub-cellular 
localization in DYRK1A-KO cells. We used U-2 OS cells stably expressing epitope-tagged 
RNF169, FAM117B, LZTS2, LZTS1 or TROAP, followed by immunofluorescence staining 
using anti-HA antibody and confocal microscopy. Consistent with our cyto-nuclear fractionation, 
we observed RNF169 to be nuclear, however, its localization did not change in the absence of 
DYRK1A. All the other DYRK1A interacting proteins were cytoplasmic both in the presence 
and in the absence of DYRK1A. However, we observed increased FAM117B accumulation in 
the peri-nuclear space in the absence of DYRK1A. Further studies will be required to confirm 






Figure 24: DCAF7 binding domain in DYRK1A is necessary but not sufficient for 
interaction with RNF169, FAM117B, LZTS2 and is not involved in binding TROAP. 
(A) Schema of GFP-DYRK1A constructs used in B. (B) T98G cells were transfected with 
indicated DYRK1A constructs and used for IP with GFP-trap beads followed by a WB for 
proteins of interest. A composite figure was created from four different IP/WB experiments in 
order to avoid any overlapping signals from residual antibodies. The GFP and DCAF7 pull 





Figure 25: TROAP binding requires the kinase domain of DYRK1A. 
(A) Schema of GFP-DYRK1A constructs used in B. (B) T98G cells were transfected with 
indicated DYRK1A constructs and used for IP with GFP-TRAP beads followed by a WB 
analysis for proteins of interest. (C) Schema depicting the regions of DYRK1A required for 














Figure 26: Localization of DYRK1A interacting proteins in the presence or absence of 
DYRK1A 
U-2 OS control or DYRK1A KO cells stably expressing (A) HA-RNF169, (B) FAM117B-FH, 
(C) FH-LZTS2, (D) FH-LZTS1, (E) FH-DCAF7 and (F) FH- TROAP were plated on coverslips, 
fixed and stained with an anti-HA antibody followed by immunofluorescence analysis.  Left WB 






3.2.5. Effect of DCAF7 on DYRK1A mediated growth suppression 
Overexpression of DYRK1A causes inhibition of cell proliferation and G0/G1 cell cycle arrest in 
several cell lines, including U-2 OS (Litovchick et al., 2011). Since DCAF7 is a major DYRK1A 
interacting protein that also binds other DYRK1A interactors, we first analyzed if DCAF7 is 
involved into DYRK1A mediated growth suppression. We transiently transfected U-2 OS cells 
with either full length or DYRK1A deletion mutant deficient in binding DCAF7 (GFP- 
DYRK1A Δ93-104), or GFP alone as a control. This was followed by fixing and staining the 
cells with anti- Ki67 antibody. Ki67 is a protein that is present in all active phases of the cell 
cycle but absent in the resting G0 phase. Therefore, it is an excellent marker for measuring the 
percentage of actively cycling cells (Scholzen & Gerdes, 2000). U-2 OS cells transfected with 
GFP-DYRK1A had a significantly reduced fraction of Ki67-positive cells as compared to cells 
transfected with GFP alone (Figure 27B). Cells transfected with GFP- DYRK1A Δ93-104 also 
had significantly reduced Ki67 positive cells as compared to the GFP alone (Figure 27). This 
suggests that DYRK1A is able to inhibit proliferation of cells even when unable to bind DCAF7. 
Moreover, GFP-DYRK1A or GFP-DYRK1A Δ93-104 similarly suppressed proliferation of U-2 
OS cell lines stably overexpressing DCAF7 (Figure 27B). This suggests that even when DCAF7 
is present in excess, it does not overcome the growth suppressive function of DYRK1A (Figure 
27A-B). Overexpression of DYRK1A leads to cell cycle arrest in the G0/G1 phase of the cell 
cycle (Litovchick et al., 2011). Therefore, we wanted to characterize the cell cycle profile of the 
cells arrested upon expression of the DYRK1A mutant deficient in binding DCAF7.  For 
additional confirmation, we also used another mutant that lacked the N- terminus of DYRK1A 
(DYRK1A Δ1-134). We used the GFP-negative cells within each sample as our control. As 
compared to GFP negative cells in the same samples, cells transfected with GFP-DYRK1A or 
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GFP-DYRK1A deletion mutants were able to cause a G0/G1 cell cycle arrest (compare orange 
bars in Figure 28A). Further, DYRK1A overexpression in shDCAF7 cell lines also led to a 
G0/G1 cell cycle arrest (Figure 28B). These data collectively suggest that DYRK1A does not 
require DCAF7 for its ability to induce G0/G1 arrest (Figures 27,28). Since RNF169, LZTS2, 
FAM117B also bind through the N-terminus of DYRK1A, it is likely that they do not play a role 
in the growth suppressive function of DYRK1A. 
 
 
Figure 27: Role of DCAF7 in DYRK1A-mediated inhibition of proliferation. 
(A) WB indicating U-2 OS parental and DCAF7-FH cell lines transfected with GFP or GFP-
DYRK1A constructs. (B) Graph shows a fraction of GFP (+)/Ki67 (+) cells in the indicated cell 
lines measured by FACS analysis. Graph indicates average of 3 biological replicates and error 
bars indicate standard deviation. p-values were obtained using two tailed Student’s t-test and are 






Figure 28: Role of DCAF7 in DYRK1A-mediated growth arrest. 
U-2 OS cells or derivatives expressing sh control or sh DCAF7 were transfected with indicated 
GFP-DYRK1A constructs followed by cell cycle analysis using PI staining of DNA. (A) Left 
panel shows representative WB indicating expression of GFP or GFP-DYRK1A in U-2 OS 
parental cells. Graph shows average distribution of GFP DYRK1A (-) or GFP-DYRK1A (+) 
cells in each cell cycle phase from 2 biological repeats. Here and below, the error bars indicate 
standard deviation. (B) Left panel shows representative WB indicating expression of DCAF7 in 
sh control or DCAF7 knockdown (two independent clones) cell lines used for cell cycle analysis. 
Right panel indicates average counts of cells in each cell cycle phase from GFP DYRK1A (-) or 




The experiments described above analyzed the growth suppressive function of DYRK1A after a 
transient transfection. We wanted to determine whether DCAF7 could influence the growth 
suppressive effect of DYRK1A overexpression for an extended time period. We used U-2 OS 
cells capable of inducible expression of wild type or kinase dead DYRK1A (DYRK1A K188R) 
under the control of a doxycycline responsive promoter (Himpel et al., 2001; Litovchick et al., 
2011), with and without overexpression of DCAF7 in the same background (Figure 29C). We 
induced DYRK1A expression using doxycycline in U-2 OS control or DCAF7-overexpressing 
cells for a period of 8 days, and analyzed cell proliferation using crystal violet assay (Figure 
29A-B). Consistent with published results, a significant reduction in cellular proliferation was 
observed with extended overexpression of wildtype DYRK1A but not the kinase dead mutant, as 
compared to their uninduced controls (Litovchick et al., 2011). However, this effect was 
observed to a lesser extent in cells over expressing DCAF7 (Figure 29A-B). This suggests that 
DCAF7 and DYRK1A can have opposing effects on maintenance of cell cycle arrested state.  
3.2.6. Effect of DYRK1A interacting proteins on DYRK1A activity towards LIN52 
DYRK1A is required for phosphorylation of the LIN52 subunit of the MuvB core leading to the 
assembly of the DREAM complex (Litovchick et al., 2011). We therefore wanted to analyze if 
DCAF7 and other DYRK1A-interacting proteins affected DYRK1A activity towards LIN52 
phosphorylation. Briefly, lysates from U-2 OS control, or DCAF7 depleted cells or 
overexpressing cells were incubated with GST-LIN52 and ATP for 0, 30 or 60 minutes. 
Consistent with lack of effect on G0/G1 arrest function, knockdown or overexpression of 




Figure 29: Role of DCAF7 in DYRK1A-mediated growth arrest 
U-2 OS control or DCAF7 overexpressing cells were induced with Doxycycline to express 
DYRK1A WT or DYRK1A KR followed by crystal violet staining, dissolving the dye and 
colorimetric quantification. (A) Representative images of crystal violet stained plates (B) Graph 
indicating proliferation of Doxycycline-treated cells relative to untreated control from three 
biological replicates. Statistical significance was calculated using two-tailed Student’s t-test and 







Figure 30: DCAF7 does not influence DYRK1A activity towards LIN52 
(A) Cell lysates from U-2 OS control or shDCAF7 cell lines were incubated with GST-LIN52, 
kinase buffer and ATP for an in-vitro kinase assay for different time points, and analyzed by WB 
Representative WB from one experiment is shown. (B) U-2 OS GFP-FH or DCAF7-FH cell 
lysates were used for an in-vitro kinase assay as in (A) and analyzed by WB. Representative WB 
from one experiment is shown. (C) Graphs depict ImageJ densitometry analysis of p-LIN52 
signal relative to GST (average from three independent experiments). Error bars show standard 




Next, we used the same approach to analyze if any of the other DYRK1A interacting proteins 
including RNF169, FAM117B, TROAP, LZTS1 or LZTS2 regulated the activity of DYRK1A 
towards LIN52. Transient depletion or overexpression of RNF169, FAM117B and TROAP did 
not have an effect on LIN52 phosphorylation (Figure 31 A-C). Since there was no significant 
effect, we only report here the quantifications of data for these assays. On the other hand, 
knockdown of either LZTS1 or LZTS2 led to a decrease in DYRK1A-mediated LIN52 
phosphorylation (Figure 33A and 32A). We confirmed this result using an additional siRNA 
against LZTS1 (Figure 33B), and two different shRNA clones against LZTS2 (Figure 32B). Note 
that the extent of decrease in LIN52 phosphorylation correlated with the level of LZTS2 
knockdown [compare shLZTS2 (1) to shLZTS2 (2) in Figure 32B].  
From our biochemical experiments, we know that LZTS1 and LZTS2 bind each other. Therefore, 
we wanted to analyze if LZTS1 and LZTS2 have a combined effect towards LIN52 
phosphorylation or if they have redundant functions. We transiently knocked down LZTS1 in U-
2 OS control or the two shLZTS2 cell lines and analyzed the effect on DYRK1A mediated 
LIN52 phosphorylation (Figure 34). Like in Figures 32 and 33, single knockdown of LZTS1 or 
LZTS2 did lead to a reduction in LIN52 phosphorylation. However, combined knockdown of 
LZTS1 and LZTS2 failed to completely inhibit DYRK1A activity towards LIN52. Of note, 
knocking down LZTS1 in the cell line expressing shLZTS2 (2) gives a better inhibition of 
DYRK1A activity as compared to the control but it was still not a complete inhibition. 
Therefore, we can conclude that LZTS1 and LZTS2 regulate DYRK1A activity together and not 
redundantly. Of note that knock down of LZTS1 in shLZTS2 cell lines tends to further reduce 




Figure 31: Depletion of RNF169, FAM117B or TROAP does not influence DYRK1A 
activity towards LIN52 
(A-C) Cell lysates from U-2 OS control or indicated siRNA depleted proteins or overexpressed 
proteins were used for an in-vitro kinase assay as explained in Figure 30 and analyzed by WB 
with LIN52 S28-phospho specific antibody as described in- (Litovchick et al., 2011). GST-
LIN52 signal was quantified using ImageJ analysis. Graphs show average p-LIN52 band density 
relative to GST band density from three independent experiments. Error bars indicate standard 
deviation. No statistically significant differences were found using 2-way ANOVA to compare 





Figure 32: Depletion of LZTS2 decreases DYRK1A activity towards LIN52 
(A, B) Cell lysates from U-2 OS control or siRNA/shRNA mediated LZTS2 depleted cell lines 
or were used for an in-vitro kinase assay as described in Figure 30. Representative WB’s from 
one experiment are shown. Graphs show average p-LIN52 band density relative to GST band 
density from three independent experiments. Error bars indicate standard deviation. Statistical 
significance was calculated using 2-way ANOVA to compare test groups to untransfected (A) or 





Figure 33: Depletion of LZTS1 decreases DYRK1A activity towards LIN52. 
(A, B) Cell lysates from U-2 OS control or two different siRNA mediated LZTS1 depleted cell 
lines were used for an in-vitro kinase assay as described in Figure 30. Representative WB from 
one experiment are shown. Graphs show average p-LIN52 band density relative to GST band 
density from three independent experiments. Error bars indicate standard deviation. Statistical 
significance was calculated using 2-way ANOVA to compare test groups to untransfected 




Figure 34: Depletion of both LZTS1 and LZTS2 does not completely abolish DYRK1A 
activity towards LIN52. 
(A) Cell lysates from U-2 OS control or shLZTS2 cell lines treated with control siRNA or 
siRNA against LZTS1 were used for an in-vitro kinase assay for 60 minutes as described earlier. 
Graphs show average p-LIN52 band density relative to GST band density from three 
independent experiments. Error bars indicate standard deviation. Statistical significance was 
calculated using a two tailed Student’s t-test and p-values are indicated on the graph. 
 
Next, we analyzed if transient knockdown of LZTS1, LZTS2 or both had an effect on GFP-
DYRK1A mediated inhibition of proliferation. We analyzed this by transiently knocking down 
LZTS1, LZTS2 or both in U-2 OS cells followed by GFP or GFP DYRK1A transfection (Figure 
35A). The number of GFP (+)/Ki67 (+) cells were scored after immunostaining for Ki67. We 
observed that as compared to the GFP controls, GFP-DYRK1A was able to inhibit proliferation 
to a similar extent even with depletion of LZTS1 or LZTS2 or both. Therefore, LZTS1 or LZTS2 
do not significantly contribute to the growth suppressive function of DYRK1A under 
overexpressed conditions (Figure 35 A-B). Note that the levels of LZTS1 and LZTS2 are higher 
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when GFP-DYRK1A is overexpressed, suggesting that DYRK1A regulates the levels of 
LZTS1/2.  
 
Figure 35: Effect of LZTS1 and LZTS2 on DYRK1A mediated inhibition of proliferation. 
(A) Representative WB indicating knockdown of LZTS1 or LZTS2 or both in U-2 OS cell lines 
expressing GFP or GFP-DYRK1A.  These cells were fixed and immunostained with anti-Ki67 
antibody. (B) Manual quantification of at least 100 GFP+/Ki67+ cells was performed for each 
repeat. Graphs show average values obtained from 3 biological replicates. Error bars indicate 
standard deviation. Statistical significance was calculated using a two tailed Student’s t-test and 
significant p-values are shown on the graph. 
 
Next, we investigated the effect of overexpression of LZTS1 or LZTS2 on DYRK1A activity in 
cell extracts, and found that neither protein affected DYRK1A activity towards LIN52 (Figure 
36B). However, we noticed that the migration of both DYRK1A and LZTS2 was altered with 
time in LZTS2 overexpressing cells, suggesting that these proteins were post translationally 
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modified (Figure 36A). Interestingly, such changes were not observed in LZTS1- overexpressing 
cells (Figure 36B).  
 
Figure 36: Effect of LZTS2 or LZTS1 overexpression on DYRK1A activity towards LIN52. 
(A and B) Cell lysates from control or from cells overexpressing LZTS2 (A) or LZTS1 (B) were 
used for an in-vitro kinase assay as in Figure 30 followed by WB analysis for the indicated 
proteins. WB shown is from one experiment (Left panels). Graphs depict average values 
obtained following ImageJ densitometry analysis of p-LIN52 signal relative to GST signal from 
three independent experiments. Error bars indicate standard deviation (Right panels). No 




3.2.7. Post translational modification of DYRK1A in LZTS2 overexpressing cells is a 
phosphorylation 
Next, we explored if the modification of DYRK1A and LZTS2 in LZTS2-overexpressing cells 
was due to phosphorylation. We carried out immunoprecipitation of DYRK1A from control or 
LZTS2 overexpressing cells followed by treatment of the beads with λ-phosphatase. WB 
analysis indicated that as compared to the untreated control, λ-phosphatase treatment abrogated 
the gel shift of DYRK1A in LZTS2 overexpressing cells, suggesting that it was indeed a 
phosphorylation (Figure 37A). This was also confirmed by WB analysis using a PhosTag gel 
(Figure 37B). This experiment also revealed that LZTS2 itself was also phosphorylated (Figure 
37A). 
 
Figure 37: DYRK1A and LZTS2 in LZTS2 overexpressing cells are modified by 
phosphorylation. 
(A) Immunoprecipitation of DYRK1A from U-2 OS GFP-FH (control) or LZTS2-FH cell lysates 
was performed followed by incubation of the indicated sample with λ-phosphatase and WB 
analysis. Inputs and 1/3rd of IP samples were loaded in (A). (B) The remaining IP samples were 




Next, we investigated if DYRK1A phosphorylation in LZTS2 overexpressing U-2 OS cells is 
caused by autophosphorylation. We treated cell lysates with Harmine or with another DYRK1A 
inhibitor CX4945, before performing an in-vitro kinase assay (Göckler et al., 2009; H. Kim et 
al., 2016; Walte et al., 2013). Untreated lysates or lysates treated with DMSO were used as a 
control. The gel shift of DYRK1A or LZTS2 was not abolished by inhibition of the kinase 
activity of DYRK1A, while LIN52 phosphorylation was completely blocked in the same assay 
(Figure 38A). Moreover, HA-tagged LZTS2 migrated in a similar way in control and DYRK1A-
KO cell lines (Figure 38B). Thus, DYRK1A and LZTS2 are phosphorylated by a kinase other 
than DYRK1A itself in U-2 OS cells overexpressing LZTS2 (Figure 38A, B).  
3.2.8. Summary 
Through biochemical experiments carried out in this chapter we found that DYRK1A, along with 
DCAF7, exists in several hetero trimeric complexes rather than a single multi-protein complex. 
We also identified that DYRK1A, and not DCAF7, is required for the formation of these 
different complexes. We have also mapped the region of DYRK1A to which its interacting 
proteins bind. Through the functional characterization carried out in this chapter, we have 





Figure 38: Effect of DYRK1A loss on DYRK1A or LZTS2 phosphorylation. 
(A) Lysates from U-2 OS GFP-FH cells (control) or U-2 OS LZTS2-FH cells were treated with 
DMSO, Harmine or CX4945 followed by in-vitro kinase assay and WB analysis of indicated 
proteins. (B). Lysates from U-2 OS control FH-LZTS2 or U-2 OS DYRK1A KO FH-LZTS2 
were incubated with ATP followed by WB analysis of indicated proteins. 
 
3.3 DISCUSSION AND FUTURE DIRECTIONS 
3.3.1 MudPIT proteomic analysis of DYRK1A interacting proteins reveals novel 
interactors that could help understand the regulation and substrates of DYRK1A 
Except DCAF7 and RNF169, the interactome of other DYRK1A interacting proteins was not 
characterized in previous studies. Importantly, this study characterized the interactome of 
DYRK1A-interacting proteins in the T98G cell line derived from human glioblastoma, which is 
not transformed by viral oncoproteins that could influence protein interaction networks. Apart 
from DCAF7, our MudPIT proteomic analysis also provided several potential directions to 
elucidate and understand the function of DYRK1A in the future studies. For example, the LZTS2 
interactome shows the presence of known LZTS interactors belonging to the signal-induced 
proliferation associated family of proteins (SIPA), including SIPAL1, 2 and 3, also known as 
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SPARs, which in turn regulate RAP1 signaling. It is not known if DYRK1A contributes to the 
function of SPARs or is regulated by RAP1. Furthermore, MudPIT proteomic analysis of 
FAM117B shows the presence of proteins involved in the splicing machinery like SRSF2 and 
SRSF3, as well as ribosomal proteins RPS15, RPL24, RPL31, RPL37A and eukaryotic 
translation initiation factors EIF2S1, EIF2S2 and EIF3G, suggesting that FAM117B could be 
involved in translation. Interestingly, five of the mitochondrial ribosomal proteins (for example: 
MRPS31, MRPS38) were also found in our FAM117B pull-down analysis. As we have shown 
that DYRK1A phosphorylates FAM117B, it will be interesting to determine if FAM117B plays a 
role in mitochondrial ribosomal function, translation or RNA splicing, and if DYRK1A mediated 
phosphorylation of FAM117B regulates these functions.  
RNF169 did pull down several DNA binding proteins, which could point us towards further 
understanding the mechanism of DYRK1A and RNF169 mediated regulation of DNA repair. 
Interestingly RNF169 also pulled down some proteins that could be involved in transcription and 
translation. These include RPL10A, ILF2, LARP1 and ELAVL1. This suggests that DYRK1A 
and RNF169 could have roles in the cell apart from DNA repair.  
The TROAP interactome contained the smallest number of proteins as compared to all the other 
DYRK1A interacting proteins, possibly because of the cell type used. Therefore, characterization 
of the TROAP interactome in a physiologically-relevant cell type, including breast or ovarian 
cancer cells, will help elucidate the function of the TROAP-DYRK1A complex.  
In contrast to this, both LZTS1 and LZTS2 pulled down multiple proteins, in fact more than 
usually expected. This could be because of the high abundance of LZTS1 and LZTS2 in our cell 
lines or because of LZTS binding to a cellular compartment such as intracellular vesicles. We 
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also analyzed if there are any mutations in the construct used for LZTS1 and LZTS2 expression, 
but this was ruled out. Like DYRK1A, the interactomes of DCAF7, LZTS1, LZTS2 and 
FAM117B also show the presence of certain 14-3-3 proteins. Since it has been shown that 
DYRK1A activity can be regulated by 14-3-3 protein (Alvarez et al., 2007; D. Kim et al., 2004), 
it will be interesting to analyze if DCAF7, LZTS1, LZTS2 or FAM117B play a role in this 
function of the 14-3-3 proteins towards DYRK1A. 
3.3.2 DYRK1A interacting proteins exist in different protein complexes 
Through this study we have shown that although the DYRK1A interacting proteins bind DCAF7, 
they do not form larger multiprotein complexes. Our data so far also indicates that only a fraction 
of DCAF7 in the cell is bound to RNF169, LZTS1, LZTS2, FAM117B and TROAP. However, 
since all of these proteins bind both DYRK1A and DCAF7, it is important to study these 
complexes separately because they could be responsible for specific functions of DYRK1A. 
Moreover, unlike the RNF169-DYRK1A-DCAF7 complex that is observed in the nucleus, other 
proteins form a complex with DYRK1A and DCAF7 in the cytoplasm. This finding indicates 
that understanding the function of these different complexes of DYRK1A and DCAF7 will help 
in better understanding the nuclear and cytoplasmic functions of DYRK1A or the functions of 
DYRK1A in different sub-cellular compartments. 
3.3.3 DYRK1A is required for the interaction of DCAF7 with DYRK1A binding partners 
It is known that DCAF7 acts as a scaffold receptor to control HIPK2 and MEKK1 kinase 
functions (Ritterhoff et al., 2010). We therefore analyzed if DCAF7 is required for RNF169, 
FAM117B, LZTS1, LZTS2 or TROAP to bind DYRK1A. In contrast, our study demonstrated a 
role of DYRK1A as a scaffolding protein. In part, the requirement of DYRK1A for these 
proteins to bind DCAF7 could be explained by the region of DYRK1A that these proteins bind to 
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which is different from the DCAF7 binding region in DYRK1A.  Although we have observed 
this role in both U-2 OS and T98G cells (T98G data not shown), it is still unknown if 
overexpression of DYRK1A causes more binding of these proteins to DCAF7.  
An interesting result we observed was that amino acid residues 77-136 of DYRK1A were 
sufficient for LZTS2, FAM117B and RNF169 binding. In fact, the 77-136 fragment bound 
LZTS2, FAM117B and RNF169 much more tightly than the 1-176 fragment. Both of these 
polypeptides have an intact nuclear localization sequence. However, if the DYRK1A 1-176 is 
more localized in the nucleus than DYRK1A 77-136 in the cell, it is possible that DYRK1A 1-
176 also binds other nuclear proteins, which interfere with binding of primarily cytoplasmic 
proteins LZTS2 and FAM117B to DYRK1A 1-176. In case of RNF169 which is nuclear, the 
nuclear proteins that bind DYRK1A 1-176 may be binding close to the RNF169 binding region 
in DYRK1A, causing lower binding. Another possibility is that the 1-176 fragment may fold in a 
different way than 77-136 fragment, leading to masking of certain epitopes required for 
DYRK1A interactions.  
Finally, it has been shown that DYRK1A binds to DCAF7 and induces its nuclear localization 
(Miyata & Nishida, 2011). Interestingly, in our study DYRK1A did not dramatically influence 
the localization of its interactors, including DCAF7.  
3.3.4 DCAF7 does not affect DYRK1A mediated growth suppression 
Though DCAF7 is a major DYRK1A interacting protein, it does not appear to affect DYRK1A’s 
activity towards LIN52 or its ability to induce growth arrest. However, we observed that when 
DYRK1A is induced in DCAF7 overexpressing cells for a longer time, its ability to maintain 
growth arrest was lower compared to that in control cells. This indicates that DCAF7 could 
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oppose DYRK1A in this function. TCGA analysis of DCAF7 by Dr. Mikhail Dozmorov 
(Appendix Figure 1) revealed that high expression of DCAF7 correlates with lower survival in 
breast cancer. It could be possible that DCAF7 can sequester DYRK1A, thus reducing the pool 
of available DYRK1A that is involved in the growth suppression function. 
On screening several breast cancer cell lines for DCAF7 expression, we were able to determine 
that DCAF7 indeed is overexpressed in multiple breast cancer cell lines (Appendix figure 1). It 
would be interesting to determine if DCAF7 is required for proliferation and metastasis of these 
breast cancer cells and if all of DYRK1A in these cells is bound to DCAF7, thus inhibiting the 
tumor suppressive function of DYRK1A. 
3.3.5 LZTS1 and LZTS2 are novel regulators of DYRK1A  
Our study identified two novel DYRK1A interacting proteins LZTS1 and LZTS2 that could 
regulate DYRK1A activity. We observed that knockdown of LZTS1 or LZTS2 caused a 
reduction in DYRK1A kinase activity towards LIN52. However, depletion of both LZTS1 and 
LZTS2 did not completely abolish DYRK1A activity towards LIN52, suggesting that their 
functions are not redundant. Our results indicate that the LZTS proteins could be working 
together as a part of the same complex and influence DYRK1A activity. In support of this model, 
LZTS proteins form heterodimers (Schmeisser et al., 2009; Wendholt et al., 2006), and we have 
also confirmed that LZTS1 and LZTS2 bind to each other. Further studies will be required to 
analyze if disruption of the binding between LZTS1 and LZTS2 also causes the same effect on 
LIN52 phosphorylation. Another point to note is that we have not analyzed the effect of another 
DYRK1A interacting protein LZTS3 on DYRK1A activity. The residual activity of DYRK1A 
after LZTS1 or LZTS2 knockdown may be due to the presence of LZTS3, or some other protein 
which may function independent of the LZTS proteins to regulate DYRK1A activity. 
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Alternatively, LZTS could regulate DYRK1A in a certain subcellular compartment, for example, 
only in the cytoplasm. 
DYRK1A mediated LIN52 phosphorylation is required for the formation of the DREAM 
complex, which in turn causes growth suppression (Litovchick et al., 2011). However, depletion 
of LZTS1/2 did not affect the ability of DYRK1A to cause growth arrest. This apparent 
discrepancy could be due to the specifics of the in-vitro kinase assay used in our study. This 
assay measures the ability of DYRK1A to phosphorylate a substrate, in whole cell extracts, and 
in this case the substrate was LIN52. This result need not necessarily match the effect of LZTS 
on endogenous LIN52 phosphorylation. Moreover, this result could indicate that LZTS1/2 does 
not affect the function of DYRK1A in the nucleus. Since LZTS1/2 bind DYRK1A in the 
cytoplasm, fractionating cells and carrying out in-vitro kinase assays will be helpful. If LZTS1/2 
depletion only reduces DYRK1A kinase activity in cytoplasmic lysates but not in the nuclear 
lysates, this would support this model. It would also be interesting to analyze if inhibition of 
LZTS1/2 in the cytoplasm is able to completely inhibit DYRK1A activity as opposed to the 
partial inhibition observed with the whole cell lysates. The effect of LZTS proteins on DYRK1A 
activity can further be validated using cell lines, which have lost LZTS1 or LZTS2. We analyzed 
a panel of ovarian cancer cell lines for changes in LZTS2 or LZTS1 expression (Appendix 
Figure 2). Several cell lines had losses in LZTS1 expression (including TOV112D, SKOV3, 
TOV21G, OVCA420) and a few cell lines had slightly lower expression of LZTS2 (Appendix 
Figure 2). A DYRK1A kinase activity screen using these cell lines will be essential to validate 
our model. 
We also observed that the overexpression of LZTS2 leads to phosphorylation of DYRK1A. It is 
possible that DYRK1A is required to maintain normal levels of LZTS1 and LZTS2 in the cell. 
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When LZTS2 is overexpressed, there may be a feed-back loop that triggers phosphorylation of 
DYRK1A by another kinase (our experiments have ruled out autophosphorylation). Future 
experiments will be needed to determine the kinase that phosphorylates DYRK1A when LZTS2 


















CHAPTER 4: UNDERSTANDING THE ROLE OF DYRK1A and DCAF7 IN 
TRANSCRIPTION 
 
A closer look at the DCAF7 interactome shown in Figure 16, Chapter 2 of the dissertation, 
revealed the presence of several Polycomb complex subunit proteins. These proteins were not 
present in our previously identified DYRK1A interactome [Chapter 1, Figure 5 and (Menon et 
al., 2019)]. Moreover, using an exhaustive immunoprecipitation experiment, we had identified 
that not all DCAF7 in the cell is bound to DYRK1A (Appendix Figure 3) suggesting that 
DCAF7 could have functions towards this complex independent of DYRK1A. Since we were 
able to detect the DYRK1A-DCAF7 complexes with other proteins both in the cytoplasm and 
nucleus (Chapter 2, Figure 20), we wanted to analyze if DYRK1A-DCAF7 together play a role 
in this complex formation or regulation. Before proceeding to the results obtained in this chapter, 
the following introduction to the chapter explains the Polycomb repressive complexes and gives 
a brief account about the known roles of DYRK1A and DCAF7 in transcription. 
4.1 INTRODUCTION TO THE CHAPTER 
4.1.1 Polycomb group proteins and repressive complexes 
Polycomb group proteins (PcG) were first identified in Drosophila as regulators of appropriate 
body segmentation through Hox gene repression (Kennison, 1995; Lewis, 1978; Struhl, 1981). 
PcG are essential for many biological processes in mammals, including development, stem cell 
maintenance and differentiation, and tumor suppression (Jaenisch & Young, 2008; Margueron & 
Reinberg, 2011; Morey & Helin, 2010; Müller & Verrijzer, 2009; Rajasekhar & Begemann, 
2007; Schuettengruber & Cavalli, 2009; Schwartz & Pirrotta, 2007; Simon & Kingston, 2013; 
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Sparmann & van Lohuizen, 2006; Q. Wang et al., 2018). PcG proteins assemble into multi-
subunit nuclear complexes with various biochemical functions, including recognition and 
modification of histone posttranslational modifications (PTMs) and chromatin compaction 
(Simon & Kingston, 2013).  The two well studied types of complexes are the Polycomb 
Repressive Complex 1 (PRC1) and Polycomb Repressive Complex 2 (PRC2) (Jaenisch & 
Young, 2008; Raphaël Margueron & Reinberg, 2011; Morey & Helin, 2010; Müller & Verrijzer, 
2009; Rajasekhar & Begemann, 2007; Schuettengruber & Cavalli, 2009; Schwartz & Pirrotta, 
2007; Simon & Kingston, 2013; Sparmann & van Lohuizen, 2006) As their names suggest, these 
complexes are required to maintain repressive chromatin through epigenetic mechanisms and/or 
chromatin compacting (Cao et al., 2002; de Napoles et al., 2004; Müller et al., 2002; H. Wang et 
al., 2004) The PRC 1 and 2 complexes exhibit distinct enzymatic activities: PRC2 is responsible 
for di- and tri-methylation of histone H3 at lysine 27 catalyzed by the EZH1/2 methyltransferases 
(Ferrari et al., 2014; Raphael Margueron et al., 2008; X. Shen et al., 2008), whereas PRC1 is 
responsible for monoubiquitination of histone H2A at lysine 119 (H2AK119ub1) catalyzed by 
the E3 ligase RING1A or RING1B (de Napoles et al., 2004; Endoh et al., 2008).  For the purpose 
of this thesis, we concentrated on the PRC1 complex because of its relevance to DYRK1A and 
DCAF7 that will be discussed below. 
 The core PRC1 complex in Drosophila contains Polycomb (Pc) (Saurin et al., 2001; Shao et al., 
1999), a chromodomain-containing protein that binds to H3K27me3 (Fischle et al., 2003; Min et 
al., 2003); Posterior sex combs (Psc), responsible for chromatin compaction in-vitro (Francis et 
al., 2004); Polyhomeotic (Ph) and dRing, the enzyme responsible for H2A ubiquitination (H. 
Wang et al., 2004). Mammalian PRC1 complexes are very heterogeneous compared to 
Drosophila because each subunit has several homologues in the human genome and they can 
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associate in a combinatorial fashion (Gao et al., 2012). In mammals, several chromodomain 
proteins (CBX) are homologous to Pc, RING1A and RING1B are enzymes similar to dRing, 
several Ph homologs (PHC1-3) exist, and six Psc homologs, collectively known as Polycomb 
group RING fingers (PCGFs) are present (Simon & Kingston, 2013). Different combinations of 
these homologues in addition to other factors give rise to several distinct mammalian PRC1 
complexes.  
Proteomic and functional studies have enhanced the understanding of these complexes and 
characterized at least six distinct groups of mammalian PRC1 complexes, PRC1.1–1.6, each 
comprising one of six Polycomb group RING fingers (PCGFs), and the E3 ligase 
RING1A/B (Gao et al., 2012; Hauri et al., 2016; Kloet et al., 2016; Sanchez-Pulido et al., 
2008).  These PRC1 subtypes can be grouped into canonical and non-canonical complexes. 
PRC1.2 and PRC1.4 containing CBX proteins with chromodomains fall under canonical PRC1 
complexes based on H3K27me3 recognition deposited by PRC2 (Cao et al., 2002; Fischle et al., 
2003; Gao et al., 2012; Min et al., 2003; Scelfo et al., 2015), and Figure 39. The other complexes 
are termed as non-canonical (Figure 39). How the non-canonical sub-complexes are recruited to 
chromatin is not understood, but RYBP containing-PRC1 complexes adopt a PRC2/H3K27me3-
independent mechanism for targeting chromatin. There are two molecular functions attributed to 
PRC1, including chromatin compaction (Levine et al., 2002; Shao et al., 1999) and 




Figure 39: Schematic representation of the different PRC1 complexes. 
[Adopted from (Gao et al., 2012)]. The PRC1.3/5 complex is highlighted with a pink outline. 
  
4.1.2 PRC1.3/5 
PCGF3 and PCGF5 form a distinct type of PRC1 complex which contain AUTS2 (Gao et al., 
2012). From here on in the thesis, we will refer to this complex as PRC1.3/5.  In contrast to the 
repressive functions of canonical PRC1, it has been found that PRC1.3/5 could mediate 
transcriptional activation (Gao et al., 2014). This conversion from repressive to activating 
function is mediated by AUTS2 (Gao et al., 2014). 
Autism susceptibility candidate 2 (AUTS2) maps to chromosome 7q11.2 and encodes a nuclear 
protein (Bedogni et al., 2010). Studies in mice revealed that AUTS2 localizes to regions of the 
brain both during development and in adults (Bedogni et al., 2010). In mice, homozygous 
neuron-specific deletion of the full-length Auts2 isoform display abnormalities in motor skills 
(Gao et al., 2014). Furthermore, mice with heterozygous disruption of Auts2 display impaired 
emotional control and cognitive memory (Hori et al., 2015). Loss of function studies of 
zebrafish auts2 using morpholinos showed that auts2 knockdown leads to abnormalities 
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including microcephaly, reduction of neural cells and movement disorders, as well as 
craniofacial dysmorphisms (Beunders et al., 2013; Oksenberg & Ahituv, 2013). Furthermore, the 
gene AUTS2 is reportedly disrupted in individuals with neurological disorders, including autism 
spectrum disorders (ASD) (Hori et al., 2015; Oksenberg & Ahituv, 2013; Sultana et al., 2002). 
Similar involvement of AUTS2 and DYRK1A in neurological diseases makes the PRC1.3/5 
complex especially interesting for our study. Molecular studies have revealed that AUTS2 
interacts with the promoters/enhancers of various genes that are involved in brain development 
and/or associated with neurological disorders (Oksenberg & Ahituv, 2013). AUTS2 is 
responsible for the recruitment of histone acetyl transferase p300 which turns the complex into a 
transcriptional activator, and CK2 protein kinase which inhibits the repressive function of PRC1 
(Gao et al., 2014; Hori et al., 2015). However, the exact molecular mechanisms that mediate the 
function of PRC1.3/5 are not well known. 
4.1.3 DCAF7 and PRC1.3/5 
Proteins with WD40 repeats have been shown to associate with chromatin modifying complexes 
that include the polycomb repressive complex 1 and complex 2 (Gao et al., 2014; Stirnimann et 
al., 2010). Using proteomic studies, Gao et al., showed that both AUTS2 and PCGF5; two of the 
components of the PRC1.3/5 complex, pulled down DCAF7 (Gao et al., 2014). Using 
immunoprecipitation of the PRC1.3/5 component AUTS2 followed by glycerol gradient analysis 
of HEK 293T cells, it has been confirmed that DCAF7 is indeed a part of the PRC1.3/5 complex 
(Q. Wang et al., 2018). Furthermore, using a GAL4-luciferase reporter system, DCAF7 was 
found to be required for PRC1.3/5 mediated transcriptional activation (Q. Wang et al., 2018). 
Indeed, loss of DCAF7 led to a decreased expression of genes involved in neuronal 
differentiation in mouse embryonic fibroblasts (Q. Wang et al., 2018).  
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4.1.4 DYRK1A in transcription 
DYRK1A is also thought to play a role in transcription. A chromatin-wide profiling of DYRK1A 
revealed that DYRK1A could act as a RNA Polymerase II CTD kinase in order to facilitate 
transcription of certain RNA Polymerase II target genes. DYRK1A appears to be recruited to its 
target genes after recognizing the motif TCTCGCGAGA however it is not known how this 
binding is mediated. This is followed by phosphorylation of the C-terminal domain (CTD) of 
RNA Pol II at Ser2 and Ser5 (Di Vona et al., 2015). DCAF7 mediates the binding between RNA 
Pol II and DYRK1A (D. Yu et al., 2019). DYRK1A was also found to phosphorylate histone H3 
in a recent study (Jang et al., 2014). Interestingly, DYRK1A interacts with histone acetyl 
transferases CBP and p300 in 293T cells, and DYRK1A overexpression hyper phosphorylates 
CBP and p300 (S. Li et al., 2018). Analysis of published ChIP-seq datasets in T98G and HeLa 
cells (Di Vona et al., 2015) and validation of some genes with ChIP in HEK293 cells revealed 
that DYRK1A indeed localizes to regions of enhancers along with CBP and p300 (S. Li et al., 
2018). 
However, the roles of DCAF7 or PRC1.3/5 in DYRK1A-mediated transcriptional responses are 
not known. 
4.2. RESULTS 
In order to better understand the functional relationship between DYRK1A and DCAF7, we 
employed MudPIT proteomic analysis of DCAF7 in T98G cells. We observed that DCAF7 
immunoprecipitated several proteins that were also detected in our DYRK1A MudPIT proteomic 
analysis. We also observed the presence of known DCAF7 binding proteins. Importantly, we 
observed that DCAF7 co-precipitated all previously published components of PRC1.3/5 
including PCGF3/5, RING1/2, AUTS2, FBRS, FBRSL1, CK2α, CK2α′, CK2β, YAF2 and 
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RYBP (Figure 40). FBRS and FBRSL1 are homologs of AUTS2. Of note, our DYRK1A 
proteomic analysis did not show the presence of any of the PRC1.3/5 components (Figure 40). 
4.2.1 DCAF7 is a part of PRC1.3/5 but DYRK1A does not bind components of the complex. 
First, using T98G cells, we validated that DCAF7 is indeed a part of PRC1.3/5 (Figure 41). We 
used an antibody against FBRS, a paralog of AUTS2 (genecards.org), for IP followed by WB 
analysis. We were able to co-immunoprecipitate DCAF7, RING1B, RING1A and CK2α with 
FBRS. As expected, FBRS did not bind to DYRK1A.  For a reverse pull down, we used cell 
lysates from T98G cells stably expressing Flag and HA tagged DCAF7 (FH-DCAF7) and we 
immunoprecipitated DCAF7 using an anti-HA antibody. Indeed, FH-DCAF7 did bind to 
RING1B, RING1A, CK2α, FBRS and DYRK1A (Figure 41). Using CRISPR-Cas9 technology, 
we had previously generated DYRK1A KO T98G cells in the laboratory (Iness et al., 2019). In 
order to analyze if DYRK1A depletion had an effect on PRC1.3/5 assembly, we carried out an 
FBRS pull down in DYRK1A KO cells (Figure 41). PRC1.3/5 components were pulled down at 
levels similar to those observed in the control cell line suggesting that loss of DYRK1A did not 
affect the interaction between these subunits. Similar to the depletion of DYRK1A, DYRK1A 
overexpression also had no effect on FBRS being able to pull down components of PRC1.3/5. 
We also observed that FH-tagged DYRK1A was able co-immunoprecipitate DCAF7 but not any 




Figure 40: Summary of MudPIT proteomic analysis of DCAF7. 
Proteins specifically detected in at least 2 out of 3 replicates are ranked by relative enrichment in 
DCAF7 IP samples. The number of times each protein was detected in DCAF7 
immunoprecipitation is indicated. Proteins with a blue color in the DCAF7 column are known 
DCAF7 binding proteins (a).  Comparison of DYRK1A dataset to the DCAF7 dataset resulted in 
overlaps indicated with peach colored boxes in the DYRK1A column [b indicates (Menon et al., 
2019)]. DCAF7 was detected as a component of the PRC1.3/5 complex with 




Figure 41: DCAF7 but not DYRK1A binds the components of the PRC1.3/5 complex. 
IP using FBRS antibody was carried out using lysates from the indicated T98G cell lines 
followed by WB analysis for indicated proteins. IP analysis with an HA antibody was used as a 
control to show FH-DCAF7 and FH-DYRK1A pull downs followed by WB analysis for 
indicated proteins. 
4.2.2. DYRK1A could affect the molecular composition of the PRC1.5 complex 
Next, we analyzed the effect of DYRK1A on the molecular size of PRC1.3/5 using sucrose 
gradient ultracentrifugation. Nuclear lysates from T98G control or DYRK1A KO cell lines were 
loaded on top of a 10-40% sucrose gradient with 5% glycerol added for better separation, and 
subjected to ultracentrifugation. Following this, a total of twenty-two fractions were collected 
from the top of the gradient and WB analysis was performed. We observed that components of 
PRC1.3/5 co-fractionated together, indicating that they are present in a single complex (Figure 
42). Though DYRK1A did not bind any of the PRC1.3/5 components, we observed that 
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DYRK1A also co-fractionated with the components of PRC1.3/5 in several fractions. Moreover, 
we observed that in the absence of DYRK1A, PRC1.3/5 components were present in the heavier 
fractions (Figure 42B compared to 42A) suggesting that DYRK1A could affect the PRC1.3/5 
complex composition. Of note, we were only detecting those PRC1.3/5 components for which 
we were able to obtain and validate the antibodies. PRC1.3/5 also has other components that we 
did not detect in our WB analysis. Moreover, some of the components like RING1A/B are 
involved in several PRC1.3/5 complexes. Thus, it is possible that DYRK1A inhibits the 
formation of a more complete complex but further studies will be required to confirm this.  
4.2.3. DYRK1A and DCAF7 negatively regulate the PRC1 function of monoubiquitination 
of H2A at K119  
The only known enzymatic function of PRC1 is monoubiquitination of histone H2A at lysine 
119, which is associated with a repressive chromatin state (H. Wang et al., 2004). We thus 
decided to analyze the effect of DYRK1A and DCAF7 on this monoubiquitination mark (H2A-
K119-Ub1). Using WB analysis, we observed that overexpression of DCAF7 resulted in 
decreased H2A-K119-Ub1 in T98G cells (Figure 43A). This suggested that DCAF7 could be a 
negative regulator of PRC1 function towards H2A-K119-Ub1. Though DYRK1A does not bind 
PRC1.3/5 components, we evaluated the role of DYRK1A on H2A-K119-Ub1. Interestingly, we 
observed that DCAF7 overexpression in T98G DYRK1A-KO cells did not inhibit H2A-K119-
Ub1 (Figure 43A). We further confirmed this result by transiently knocking down DYRK1A in 
T98G cells overexpressing DCAF7, where we observed a similar result. Indeed, siRNA-
mediated DYRK1A depletion in T98G cells with DCAF7 overexpression led to an increase in 
H2A-K119-Ub1 signal (Figure 43A). This could be interpreted in two ways: either DCAF7 
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requires DYRK1A for the negative regulation of PRC1 function, or that DYRK1A and DCAF7 
together inhibit H2A-K119-Ub1. 
 
Figure 42: DYRK1A could affect the molecular size of the PRC1.3/5 complex 
(A) Nuclear lysates from T98G control or (B) DYRK1A KO cells were loaded on top of a 
sucrose gradient followed by ultracentrifugation to separate protein complexes. Fractions were 
collected and analyzed using WB analysis for detection of indicated proteins. Differences in the 




We further analyzed the effect of inhibition of DYRK1A kinase activity on PRC1 function using 
the DYRK1A inhibitor Harmine. T98G cells were serum starved for 48 hours and released in 
serum containing medium for 6, 12, 18 or 24 hours (Figure 43B). PRC1 is known to play a role 
in chromatin compaction which could be increased in quiescent cells (Levine et al., 2002; Shao 
et al., 1999). Our WB analysis of H2A-K119-Ub1 correlated with this function. An increased 
signal was observed in serum starved cells compared with a lower signal in cycling cells (Figure 
43B). Interestingly, we observed that inhibition of DYRK1A with Harmine resulted in an 
increased H2A-K119-Ub1 signal (Figure 43B). This observation further supports that DYRK1A 
could play a role in regulation of PRC1 function. Of note, monoubiquitination of H2A at K119 is 
a collective function of all PRC1 complexes. With these experiments we could conclude that 




Figure 43: DYRK1A and DCAF7 regulate monoubiquitination of H2A at K119. 
(A) WB analysis indicates effect of DYRK1A and DCAF7 on the known PRC1 function towards 
mono ubiquitination of H2A at K119 in the indicated T98G cell lines/conditions. (B) T98G cells 
were serum starved for 48hours followed by release with serum containing media for the 
indicated time points. WB analysis indicates the effect of inhibition of DYRK1A using 10μM 
Harmine on monoubiquitination of H2A at K119.  DMSO was used as a vehicle control. (C) 
Schema indicating that DYRK1A and DCAF7 could inhibit the function of PRC1 towards 





4.2.4. DYRK1A is required for the transcriptional activity of DCAF7 
T98G cell lines were used for our proteomic studies of DYRK1A and DCAF7 as well as for 
ChIP-seq analysis by another group (Di Vona et al., 2015). The effects of DYRK1A and DCAF7 
on H2A-K119 Ub1 were also observed in T98G cells. Therefore, to determine the role of 
DYRK1A and DCAF7 in transcription, we performed RNA-seq analysis using T98G control and 
DYRK1A KO cell lines with or without DCAF7 overexpression (Figure 44A, B). Cells 
overexpressing GFP in the presence or absence of DYRK1A were used as controls (Figure 44A, 
B). In order to minimize batch effects, five replicate samples were collected for each cell line at 
the same time. This was followed by RNA isolation and analysis of the quality of RNA. All 
twenty samples had an RNA integrity (RIN) value of greater than 9. We also analyzed 
expression of DCAF7 in each sample using RT-qPCR analysis before submission, as a quality 
control test (data not shown). We then submitted the samples for RNA-seq analysis. The 
sequencing led to the generation of approximately 30 million, 150bp single-end reads per 
sample. The data was analyzed for us by Dr. Mikhail Dozmorov (Department of Biostatistics and 
Massey Cancer Center, VCU). Principal component analysis of the RNA-seq data revealed that 
either loss of DYRK1A or overexpression of DCAF7 caused significant perturbations in the 
transcriptome (Figure 44C, D). However, overexpression of DCAF7 in the absence of DYRK1A 
caused relatively minor changes in global gene expression. This suggests that DYRK1A could be 







Figure 44: Summary of RNA seq analysis 
(A) WB shows levels of DCAF7 and DYRK1A in the cell lines used for RNA seq analysis. 
Arrow indicates Flag-HA-tagged DCAF7 (B) Design of RNA-seq experiment using T98G cells 
to determine the effect of DYRK1A and DCAF7 on transcription. (C) Graph shows principal 
component analysis of the RNA-seq data. (D) Venn diagram showing overlaps of significantly 






4.2.5. DYRK1A and DCAF7 regulate a common subset of genes  
First, we only looked at genes that were upregulated or down regulated when DYRK1A was 
knocked out or when DCAF7 was overexpressed. There were multiple genes that were 
differentially regulated in each comparison relative to GFP control (Figure 44D). The expression 
of a total of 4904 genes were upregulated and 4721 were down regulated when DYRK1A was 
knocked out (False Discovery Rate FDR 0.05). Overexpression of DCAF7 lead to 1726 genes 
being upregulated and 1880 genes being downregulated as compared to the GFP control (FDR 
0.05, Figure 44D). Comparison of these gene sets revealed a significant overlap (Figure 44). All 
overlap comparisons are highly significant (Fisher t test <0.001). This suggests that DYRK1A 
and DCAF7 may co-regulate a common subset of genes. Gene Set Enrichment Analysis (GSEA) 
was used for a biological interpretation of DEGs between conditions. This analysis revealed that 
both DYRK1A and/or DCAF7 regulated gene sets were significantly enriched in several 
functional categories (Figure 45A). Some of the categories were cell proliferation, neurological 
development and neurodegeneration. Furthermore, since previous studies found that DYRK1A is 
required for the DREAM complex assembly, it is expected that DREAM target genes should be 
up-regulated in DYRK1A KO cells. Indeed, ~800 target genes were up-regulated in the 
DYRK1A-KO cells. This result further supported the role of DYRK1A in DREAM function 
(Figure 45B).  
In-order to confirm the RNA seq results, we used the same cell lines that we used for RNA seq 
analysis and performed a RT-qPCR for some of the DREAM target genes. We were able to 
validate the up-regulation of DREAM target genes including E2F2, ID3, ARHGAP11B, BUB1B 
and MYBL2 in the DYRK1A-KO samples using RT-qPCR (Figure 45C). GSEA analysis also 
revealed upregulation of DREAM targets with overexpression of DCAF7 (Figure 45A). 
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However, we were unable to find the effect of DCAF7 on the gene set upregulated by loss of 
DYRK1A. Since the DREAM complex represses the expression of several genes, it is possible 
DYRK1A KO and DCAF7 overexpression regulate the expression of the different subsets of 
DREAM target genes. Another possibility is that DCAF7 causes a very subtle effect on the genes 
validated by RT-qPCR and therefore an effect was not observed. 
 
Figure 45: DYRK1A and DCAF7 affect genes in different functional categories and 
DREAM target genes are upregulated in DYRK1A KO samples. 
(A) Table shows top functional categories identified using MSigDB Gene set enrichment 
(GSEA) tool for each indicated dataset (B) Heatmap showing changes in DREAM target gene set 
in DYRK1A KO data set as compared to control from four biological replicates. (C) RT-qPCR 
validation of DREAM target genes from T98G GFP-FH or T98G KO GFP-FH cell lines. Graph 
shows average of three biological repeats. Error bars show standard deviation. Statistical 




Figure 46: DCAF7 requires DYRK1A for its effect on transcription of a subset of genes. 
(A) Average RNA-seq Log Fold change (FC) values of DEGs regulated by both DYRK1A and 
DCAF7 showing lack of response to DCAF7 overexpression in the absence of DYRK1A (red 
boxes). (B) RT-qPCR validation of the indicated genes regulated by both DYRK1A and DCAF7 
confirms the lack of response to DCAF7 overexpression in the absence of DYRK1A (compare 
red boxes). 
 
Further, we identified a set of DEGs for further validation. These genes were altered in both 
DYRK1A and DCAF7 analyses with LogFC at least ± 1.0, and having a role in neurological 
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disease or cancer. These genes could be divided into 4 major categories: 1) genes that were 
upregulated with DYRK1A loss or DCAF7 overexpression; 2) genes that were downregulated 
with DYRK1A loss or DCAF7 overexpression; 3) genes that were up regulated with DYRK1A 
loss but downregulated with DCAF7 overexpression and 4) genes that were down regulated with 
DYRK1A loss but upregulated with DCAF7 overexpression (Figure 47). Looking at the average 
FC values obtained by RNA seq analysis for a subset of these genes, we were able to conclude 
that DCAF7 requires DYRK1A for its transcriptional activity (Figure 46A). We also confirmed 
this using RT-qPCR analysis for a subset of genes regulated by both DYRK1A and DCAF7 
(Figure 46B).  
We performed RT-qPCR analysis for the validation set to analyze the DYRK1A and DCAF7- 
regulated expression of these genes. This was carried out in the same cell lines as the RNA seq 
analysis. We were able to validate the expression of all selected DEGs (Figure 48). We were 
therefore able to conclude that DYRK1A and DCAF7 could regulate gene expression in the same 




Figure 47: DYRK1A and DCAF7 co-regulate a common subset of genes. 
Differentially expressed genes are shown in both DYRK1A and DCAF7 analyses that are 
implicated in neurological disease or cancer. The four different expression categories are 





Figure 48: DYRK1A and DCAF7 regulate a common subset of genes that have relevance in 
disease. 
RT-qPCR validations of genes indicated in Figure 47 using T98G GFP-FH, T98G DYRK1A KO 
GFP-FH or T98G DCAF7-FH cell lines. Graphs indicate average of three biological replicates. 
Error bars show standard deviation. Statistical significance was calculated using two tailed 
Student’s t-test. P-values: *≤0.05; ** ≤ 0.01; *** ≤ 0.001; **** ≤ 0.0001 (A) Genes upregulated 
in both DYRK1A KO and DCAF7 overexpression conditions. (B) Genes downregulated in 
DYRK1A KO and upregulated in DCAF7 overexpression conditions. (C) Genes upregulated 
with DYRK1A KO but down regulated with DCAF7 overexpression. (D) Genes down regulated 





4.2.6. There is an overlap between DEGs and published DYRK1A ChIP-seq datasets 
DYRK1A has been shown to play a role in transcription (Di Vona et al., 2015). In this study Di 
Vona et al., carried out ChIP-seq analysis in order to identify the genomic regions that DYRK1A 
binds to under cycling or serum starved conditions in T98G cells. Since our RNA-seq analysis 
was also carried out using T98G cells, we analyzed if there is an overlap of DYRK1A bound 
genes from the ChIP-seq dataset with the DEGs identified through our RNA-seq analysis. 
Indeed, there was an overlap of genes that were both up and down regulated with DYRK1A-KO 
(Figure 49 and Appendix tables 7,8). Out of the ~4905 genes that were upregulated in DYRK1A-
KO cells, the genomic regions of 306 genes were bound by DYRK1A (Figure 49A, Appendix 
table 7). Out of the ~4722 genes downregulated when DYRK1A is knocked out, 240 genes had 
DYRK1A bound genomic regions (Figure 49B, Appendix table 8). This suggests that DYRK1A 
binds to the genomic regions of these genes and could possibly regulate expression by direct 
binding. 
Interestingly, we also observed an overlap with genes that were up and down regulated with 
DCAF7 overexpression (Figure 50, Appendix table 9). Out of ~1727 genes upregulated with 
DCAF7 overexpression; 91 genes were directly bound by DYRK1A (Di Vona et al., 2015). 
Further 106 of the ~1881 genes downregulated with DCAF7 overexpression were also directly 
bound by DYRK1A. These results give us a starting point for the future ChIP validations in 
order to further understand the mechanism by which DYRK1A and DCAF7 regulate the 
expression of these genes.  
There were also published ChIP-seq datasets available for AUTS2. However, this study was 
carried out in HEK293T cells (Gao et al., 2014). Even though the cell types are different, we 
observed a considerable overlap between genes bound by AUTS2 and genes bound by 
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DYRK1A, and identified a total of 65 genes bound by both AUTS2 and DYRK1A (Figure 51, 
Appendix table 10). Further analysis of these genes will help us understand the influence of 
DYRK1A on the PRC1.3/5 regulated genes. 
 
Figure 49: Overlap of DYRK1A regulated genes with DYRK1A ChIP-seq datasets 
(A) Overlap of Genes Up in DYRK1A KO with DYRK1A bound genes under cycling and serum 
starved conditions. (B) Overlap of Genes Down in DYRK1A KO with DYRK1A bound genes 
under cycling and serum starved conditions [ChIP-seq dataset obtained from (Di Vona et al., 




Figure 50: Overlap of DCAF7 regulated genes with DYRK1A ChIP-seq datasets 
(A) Overlap of Genes Up in DCAF7 overexpression with DYRK1A bound genes under cycling 
and serum starved conditions (B) Overlap of Genes down in DCAF7 overexpression with 
DYRK1A bound genes under cycling and serum starved conditions [ChIP-seq dataset obtained 






Figure 51: Overlap of genes bound by AUTS2 and genes bound by DYRK1A under cycling 
and serum starved conditions. 
[DYRK1A ChIP-seq dataset obtained from (Di Vona et al., 2015); AUTS2 ChIP-seq dataset was 
obtained from (Gao et al., 2014)]. Refer Appendix Table 10 for the list of the overlapping genes. 
 
4.3. DISCUSSION AND FUTURE DIRECTIONS 
4.3.1 DCAF7 is a part of PRC1.3/5 but DYRK1A does not bind components of the complex 
Proteomic studies by our lab and others revealed that DCAF7 bound several proteins belonging 
to the PRC1.3/5 complex (this dissertation and the BioGrid database, Figure 16). However, only 
our study investigated the DCAF7 interactome in T98G cells. The presence of PRC1.3/5 
components in DCAF7 proteomic analysis from different cell types across different studies 
demonstrates that DCAF7 is indeed a part of this complex. Moreover, out of the several PRC1 
complexes, DCAF7 only pulls down components of the non-canonical PRC1.3/5 complex, 
suggesting a possible specific function of DCAF7 in this type of PRC1 complex.    
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Indeed, we confirmed the interaction of DCAF7 with components of the PRC1.5-AUTS2 
complex in T98G cells. Although DYRK1A and DCAF7 interact stoichiometrically, our results 
indicated that DYRK1A is not a part of the PRC1.3/5 complex. Using exhaustive 
immunoprecipitation to deplete DYRK1A from T98G cells lysates we have observed that not all 
of the DCAF7 in the cell is bound to DYRK1A (Appendix Figure 3). This suggests that DCAF7 
could have protein interactions independent of DYRK1A.  
4.3.2. DYRK1A affects the molecular size of AUTS2-PRC1  
Although DYRK1A did not bind PRC1.3/5 components, its absence altered the molecular size of 
the complex. It is important to note that we did not detect all the components of the complex due 
to limited availability of antibodies. It is possible that some of the AUTS2-PRC1 components 
that we did not detect can be phosphorylated and regulated by DYRK1A. One angle to the future 
studies would be to analyze if any of the AUTS2-PRC1 components are phosphorylated by 
DYRK1A, leading to their degradation. This would explain the formation of a more stable and 
complete complex in the absence of DYRK1A.  
4.3.3. DYRK1A and DCAF7 regulate PRC1 function 
The only known function of the PRC1.3/5 complex is to catalyze H2A-K119 
monoubiquitylation, which mediates transcriptional repression. This monoubiquitylation is 
inhibited by CK2 mediated phosphorylation of RING1B, leading to transcriptional activation 
(Gao et al., 2014). We observed that inhibition of DYRK1A by Harmine leads to an increase in 
H2A-K119 monoubiquitylation. Since this is a readout of global PRC1 function and not AUTS2-
PRC1 alone, it is possible that DYRK1A phosphorylates and inhibits some component of PRC1. 
It will also be important to analyze the extent of global PRC1 function that is affected by 
DYRK1A. Moreover, since DYRK1A and CK2 are phylogenetically similar (Aranda et al., 
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2011; Kannan & Neuwald, 2004), it will be important to analyze if they are redundant with 
respect to their function towards PRC1. Harmine inhibits only DYRK1A and DYRK1B while 
CX4945 is primarily a CK2 inhibitor that was also found to potently inhibit DYRK1A (H. Kim 
et al., 2016). Thus, comparing the effect of CX4945 to effect of other DYRK1A inhibitors on 
PRC1 function, we can determine if inhibition of both CK2 and DYRK1A causes a further 
increase in PRC1 function.  
Our results also indicated that overexpression of DCAF7 led to a decrease in AUTS2-PRC1 
function and this decrease was dependent on DYRK1A. This points to the possibility that 
DYRK1A and DCAF7 could regulate a common subset of genes that are also regulated by 
PRC1.3/5. Although the regulatory regions bound by DYRK1A are known, ChIP-seq analysis 
will be needed to analyze the genomic region bound by DCAF7. Further, ChIP- seq analysis to 
determine AUTS2 bound regions in the same cell type followed by an overlap of all of these 
datasets would be helpful to understand the mechanism through which DYRK1A and DCAF7 
regulate PRC1.3/5 function. 
4.3.4. DYRK1A and DCAF7 regulate a common subset of genes 
Interestingly, our RNA-seq analysis and RT-qPCR validations indicated that DYRK1A and 
DCAF7 regulate a common sub-set of genes. Interestingly, several genes co-regulated by both 
DYRK1A and DCAF7 are implicated in neurological disorders and cancer. This is important 
because DYRK1A itself is implicated in both of these disease conditions. We have already 
shown that DYRK1A is required for the transcriptional role of DCAF7 but the mechanism of this 
regulation needs to be studied.  
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Moreover, many of the genes regulated by DYRK1A or DCAF7, or both DYRK1A and DCAF7 
overlap with genes to whose genomic regions DYRK1A is known to bind. It could be possible 
that both DYRK1A and DCAF7 bind to the regulatory regions of these genes or it could be 
possible that one recruits the other. Due to its WD-40 repeats, it is also possible that DCAF7 has 
scaffolding functions bringing together DYRK1A and certain other transcriptional regulators. 
Given a large number of genes influenced by both DYRK1A and DCAF7, it is possible that 
these proteins may act as regulators of gene expression, for example as enhancers or activators. 
There is a study that analyzed published DYRK1A datasets to find that DYRK1A indeed 
localizes to regions of enhancers along with CBP and p300 (S. Li et al., 2018). Therefore, future 














CHAPTER 5: PERSPECTIVES AND IMPACT 
 
Although DYRK1A is implicated in human neurological conditions and in cancer, the functions 
and regulation of DYRK1A in the cell are not very well understood hence making it difficult to 
target DYRK1A for therapy. The findings presented in this dissertation significantly advance our 
understanding of DYRK1A function by characterizing the extended network of its protein-
protein interactions and by detailed analysis of the functional interaction between DYRK1A and 
its most significant partners in the cell. Significantly, we found that DYRK1A (and its 
stoichiometric partner DCAF7) are involved in numerous distinct tertiary complexes that are 
involved in different cellular processes both in the nucleus and in the cytoplasm. Further studies 
will characterize the role of DYRK1A-DCAF7 in these cellular pathways. 
In Chapter 2, we describe a novel role of DYRK1A in the DNA damage response pathway. 
Genomic instability is a major hallmark of cancer, and the ability of the genome maintenance 
systems to sense and repair damaged DNA is crucial for the homeostasis of the cell. Defects in 
these repair systems cause an increase mutation burden, driving tumorigenesis. Indeed, some 
familial cancer syndromes results from germline mutations in DNA repair genes, whereas most 
cancers have acquired alterations in DNA damage and repair pathways. Moreover, development 
of resistance to current chemotherapeutics is a direct function of genomic instability and is a 
major therapeutic challenge that requires further research before it can be overcome. Apart from 
cancer, several neurological disorders also result from defects in DNA repair genes. Our finding 
that DYRK1A levels can influence DNA repair will help us better understand the DNA damage 
response and DNA repair pathways and allow us to modulate these processes.  
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Sustained proliferative advantage remains one of the most important and fundamental features in 
cancer. The ability to regulate cell cycle progression in a controlled manner is lost in cancer cells 
and as a result, this deregulation allows them to evade cell cycle checkpoints, leading to 
sustained and aberrant proliferation. DYRK1A is a cell cycle regulator that prevents the 
uncontrolled proliferation of cells by promoting cell cycle exit and entry into quiescence. This 
important function must be considered when DYRK1A is targeted for therapy of conditions 
associated with its gain-of-function, such as Down syndrome and Alzheimer’s disease.  Through 
the work in Chapter 3 of this dissertation, we have identified several DYRK1A-interacting-
proteins, and their respective protein interactomes, which could not only be utilized in future 
studies to better understand the regulation and substrates of DYRK1A, but also be used to 
characterize the function of the DYRK1A interacting proteins in different cellular pathways, 
including regulation of cell proliferation. Understanding of the physiological role of the 
DYRK1A complexes in the cell will help to design more precise inhibitors of only its desired 
functions. We have also identified a previously unknown scaffolding function of DYRK1A in 
the protein complexes identified in our study. If this scaffolding function of DYRK1A is 
required in different cellular pathways, it could help us better understand the phenotypic effect of 
DYRK1A dosage in different diseases.   
We also identified LZTS1 and LZTS2 as novel regulators of DYRK1A activity. DYRK1A is a 
multifunctional kinase that phosphorylates numerous substrates in the cell. Therefore, targeting 
DYRK1A for therapy becomes difficult. However, if we are able to understand the mechanism 
by which LZTS1 and LZTS2 regulate DYRK1A kinase activity, we could potentially target 
LZTS1 and LZTS2 proteins in conditions where there is increased DYRK1A activity, like in 
Down syndrome.   
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Through Chapter 4 in the dissertation we have identified that DYRK1A and DCAF7 could 
inhibit the function of the PRC1 complex. By understanding the mechanism through which 
DYRK1A and DCAF7 affect the global PRC1 activity, we better understand the regulation of 
this complex which is perturbed in several developmental disorders and cancer. Further, our 
RNA-seq data has revealed that DYRK1A and DCAF7 could influence a common sub-set of 
genes implicated in neurological disorders or cancer. This was previously unknown and can be 
















CHAPTER 6: MATERIALS AND METHODS 
 
5.1. Cell lines 
Human glioblastoma T98G, osteosarcoma U-2OS, HEK293T, Phoenix cells (modified 
HEK293T), were obtained from ATCC and used from early passage master stocks. Human 
ovarian cancer cell lines were obtained from ATCC or were a gift from Dr. Ronny Drapkin. 
Human Breast cancer cell lines were a gift from Dr. Jennifer Koblinski.  All cell lines were 
cultured according to ATCC specifications and regularly checked for mycoplasma contamination 
using PCR assay and DAPI staining. T98G and U-2 OS cells stably expressing Flag-HA (FH) 
epitope tagged DYRK1A, GFP, DCAF7, LZTS2, LZTS1, TROAP or FAM117B were 
established using pMSCV retroviral vectors and puromycin selection as described in (Litovchick 
et al., 2011). U-2 OS cells stably expressing shRNA’s against DCAF7 (Mission shRNA 
Millipore sigma, Catalog# SHCLNG-NM_005828; clones TRCN0000147504 and 
TRCN0000149770) or LZTS2 (Mission shRNA Millipore Sigma, Catalog # SHCLNG-
NM_032429; clones TRCN0000419617 and TRCN0000412326) or non-targeting control (gift 
from Dr. Steven Grossman) were established using pLKO1 lentiviral vectors followed by 
puromycin selection. U-2 OS cell lines expressing DYRK1A in a doxycycline-inducible fashion 
were also used (Himpel et al., 2001; Litovchick et al., 2011). 
DYRK1A-KO U-2 OS (Menon et al., 2019) and T98G cell lines (Iness et al., 2019) were 
established using GeneArt CRISPR Nuclease vector with OFP reporter (Life Technologies) 
harboring human or mouse DYRK1A-specific guide sequences. The control cell line was 
similarly established using a non-targeting construct provided with the kit. Briefly, cells were 
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transfected with sgRNA-CRISPR plasmids, FACS-sorted for OFP expression and grown as 
single-cell clones in 96-well plates that were screened for DYRK1A expression using 
immunoblotting. Two independent clones lacking DYRK1A expression were expanded and 
validated using antibodies against different epitopes in DYRK1A as well as genomic sequencing 
of the nested PCR-amplified fragment surrounding the sgRNA-targeted region. T98G cell lines 
have more than one copy of DYRK1A. Therefore, to verify that we had obtained single cell 
clones of DYRK1A KO cell lines, the nested amplified genomic regions were purified, cloned 
into Promega pGEM®-T Easy vector. Multiple DNA clones were sequenced to confirm the 
presence of mutations and the absence of the wild type sequences.  
Table 1: Sequences of guiding RNA used to create indicated DYRK1A KO cell lines 
 
5.2. MudPIT proteomic analysis 
MudPIT proteomic analysis was performed as described previously in (Florens & Washburn, 
2006; Litovchick et al., 2007) using Finnigan LTQ linear ion trap mass spectrometer equipped 
with an electrospray ionization source. T98G cells stably expressing either Flag-HA tagged 
DYRK1A, DCAF7, LZTS2, LZTS1, FAM117B, TROAP or GFP (control) were used for 
immunoprecipitations with anti-HA antibody agarose beads (clone HA7, Sigma, 
Catalog#A2095). For RNF169, U-2 OS cells stably expressing HA-RNF169 were used for 
immunoprecipitation as described for the other proteins. Proteins were eluted from beads using 
HA peptide (Sigma, Catalog #I2149), concentrated and digested with trypsin. Tryptic peptides 
were resolved using Quaternary Agilent 1100 series HPLC and microcapillary multi-dimensional 
C18-SCX-C18 matrix using fully automated 10-step chromatography run and electrosprayed into 
Cell line Top strand (5′-3′) Bottom  (5′-3′)




mass spectrometer. Full MS spectra were recorded on the peptides over a 400 to 1,600 m/z 
range, followed by five tandem mass (MS/MS) events sequentially generated in a data-dependent 
manner on the first to fifth most intense ions selected from the full MS spectrum (at 35% 
collision energy). SEQUEST (Eng et al., 1994) was used to match MS/MS spectra to peptides in 
a database of 58622 amino acid sequences, consisting of 29147 human proteins (non-redundant 
entries from NCBI 2011-08-16 release). To estimate relative protein levels, spectral counts were 
normalized using Normalized Spectral Abundance Factors (NSAFs) (Litovchick et al., 2007; 
Swanson et al., 2009). Average NSAFs were calculated from four biological replicate DYRK1A 
pull-down experiments. Average NSAFs for all other proteins were calculated from three 
biological experiments. The analysis was carried out at the Proteomics Core at the Proteomics 
center at Stowers institute (Selene Swanson, Laurence Florens and Michael Washburn).  
5.3. Immunoblotting and immunoprecipitation 
For immunoblotting, cells were lysed in EBC or RIPA buffers supplemented with protease 
inhibitors (Millipore-Sigma catalog#539131), phosphatase inhibitors (Millipore-Sigma catalog# 
524625) and β-ME for 10 min at 4°C and then centrifuged at 14,000g for 15 min at 4°C. Protein 
concentrations were determined by DC protein assay (BioRad). Protein samples were resolved 
using polyacrylamide gels (BioRad), transferred to a nitrocellulose membrane (GE Healthcare) 
and probed by specific antibodies, as recommended by manufacturer. For immunoprecipitation, 
cell extracts were incubated with appropriate antibodies (1 μg/ml) and Protein A Sepharose 
beads (GE Healthcare, Catalog #17078001) overnight at 4°C, washed five times with lysis buffer 
and re-suspended in 2X Laemmli sample buffer (BioRad, Catalog # 161-0737). Antibodies used 
in this study are listed in Table 2.  
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5.4. Cytonuclear fractionation 
Cells were seeded at desired densities followed by cyto-nuclear fractionation using a 
commercially available kit (Active Motif, Catalog# 40010) and following manufacturer’s 
instructions followed by IP/WB analysis. 
5.5. Chemicals and treatments 
To induce DNA damage, cells were exposed to gamma irradiation using MDS Nordion 
Gammacell 40 research irradiator with a 137Cs source (ON, Canada) as described in (Menon et 
al., 2019). Harmine (Sigma; catalog No. H8646) and CX4945 (Selleckchem, Catalog no. # 
S2248) dissolved in DMSO were used for cell treatments at 10 µM final concentrations. 
For phosphorylation assays, λ-phosphatase (NEB, Catalog # P0753S) was used either directly on 
immunoprecipitated sample or cell lysates according to manufacturer’s protocol followed by WB 
analysis. PhosTag Acrylamide reagent (NARD institute limited, catalog # AAL-107) was added 




Table 2: List of antibodies used in the thesis 
 
Antibody Species Source Purpose Catalog number
DYRK1A (clone 7D10) Mouse Sigma WB WH0001859MI
DYRK1A Rabbit Bethyl IP/WB A303-801A
RNF169 Rabbit Abcam WB ab188237
RNF169 Rabbit Bethyl IP/WB A304-097A
FAM117B Rabbit Bethyl WB BL19741
TROAP Rabbit Bethyl IP BL19735
TROAP Rabbit Proteintech IP/WB 13634-1-AP
DCAF7 Rabbit Abcam WB ab138490
LZTS2 Rabbit Bethyl IP/WB BL19733
LZTS2 Rabbit Invitrogen IP/WB PA5-60871
LZTS1 Rabbit Bethyl IP/WB BL19723
LZTS1 Rabbit Invitrogen IP/WB PA5-52274
RING1A Rabbit Bethyl WB A303-552A
RING1B/RNF2 Rabbit Bethyl WB A302-869A
FBRS Rabbit Invitrogen IP/WB PA5-60615
CK2α Rabbit Bethyl WB A300-198A
Ubiquityl-Histone H2A (Lys 119) Rabbit Cell Signaling WB D27C4
Ubiquitin (P4D1) Mouse Santacruz WB sc-8017
Ubiquitin (FK2) Mouse R&D BiosystemsIF A-106
USP7 Rabbit Bethyl WB A300-033A
BRCA1 Rabbit Bethyl WB A300-000A
p53 Mouse DO-1 WB sc-126
H2AX (pSer139)- 20E3 Rabbit Cell Signaling WB/IF 9718S
53BP1 (19/53BP1) Mouse BD BiosciencesIF/WB 612523
GFP (D5.1) Rabbit Cell Signaling WB 3724S
GFP-Trap agarose Chromotek IP gta-20
HA-Tag (HA.11) Mouse BioLegend WB/IF 16B12
HA-Tag (C29F4) Rabbit Cell Signaling WB/IF 3724
HA-agarose Mouse Sigma IP A2095
Ki67 Rabbit Millipore IF/FACS AB9260
p-LIN52 Rabbit Litovchick lab WB
GST (B14) Mouse Santacruz WB sc-138
Vinculin (hVIN-1) Mouse Sigma WB V9131
Tubulin Mouse Sigma WB SAB1411818
Lamin Rabbit Cell Signaling WB 29565
β-actin (13E5) Rabbit Cell Signaling WB 4970S
Normal Rabbit IgG Rabbit Millipore IP NI01-100VG
Anti-Mouse IgG Goat Jackson ImmunoResearchWB 115-035-003
Anti-Rabbit IgG Goat Jackson ImmunoResearchWB 111-035-003
Anti-Rabbit IgG Light Chain Mouse Jackson ImmunoResearch211-032-171
Anti-Rabbit Alexa Fluor 488 Rabbit Invitrogen IF A-11008
Anti-Mouse Alexa Fluor 594 Goat Jackson Immuno ResearchIF 115-585-146




5.6. RNAi and plasmids 
siRNA oligos used in this study were from Ambion/ Thermo Fisher Scientific as indicated in 
table 3. siRNA transfections were performed using Lipofectamine RNAiMAX (Invitrogen, 
catalog# 13778075) according to the manufacturer’s instructions. GFP-tagged rat Dyrk1a wild-
type and mutant constructs in pEGFP-C1 were a kind gift from Dr. Walter Becker (Glenewinkel 
et al., 2016). GFP-tagged mouse Dyrk1a wild-type and mutant constructs in pEGFP-N1 were a 
kind gift from Dr. Garriella D’Arcangelo (Yabut et al., 2010). HA-RNF169-pcDNA3 and GFP-
RNF169 constructs were a gift from Dr. Niels Mailand (Poulsen et al., 2012). The phosphosite 
mutants of RNF169 were generated using the QuikChange II XL site directed mutagenesis kit 
(Agilent Technologies, Catalog # 200521) and verified by sequencing. Plasmid transfections 
were performed using either TransIT-2020 transfection reagent (Mirus Bio, Catalog# MIR5400), 
BioT reagent (Bioland Scientific LLC, Catalog# B01-01) or polyethylenimine reagent 
(Polysciences Inc., Catalog#23966) that was prepared according to manufacturer’s protocol.  
Table 3: List of siRNAs used in the thesis 
 
 
Target Type Catalog ID Source
RNF169 Silencer select 4392420 s48512 Ambion/Thermofisher
FAM117B Silencer select 4392420 s45493 Ambion/Thermofisher
LZTS2 Silencer select 4392420 s39013 Ambion/Thermofisher
LZTS1 Silencer select 4392420 s22063, s22062 Ambion/Thermofisher
TROAP Silencer AM167908 16369 Ambion/Thermofisher
DYRK1A Silencer select 4390824 s4399 Ambion/Thermofisher
Negative control Silencer select 4390846 No. 2 Ambion/Thermofisher
Negative control Silencer AM4611 No. 1 Ambion/Thermofisher
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5.7. In-vitro kinase assays 
Cell extracts (0.8 mg/ml) were prepared using EBC buffer, supplemented with EDTA-free 
protease inhibitors (Roche Diagnostics, Catalog#11836170001), phosphatase inhibitors and β-
ME. Cell extract from a control cell line was treated with 10μM Harmine for 30 minutes on ice. 
The cell lysates and the Harmine treated control were then incubated with 1X kinase buffer (Cell 
Signaling Technologies, Catalog# 9802S), 10 mM MnCl2, 200μM ATP (Cell signaling 
Technologies Catalog# 9804), and incubated at 30°C with 300 ng GST-LIN52 in a 100 μL 
reaction volume. The reaction was allowed to proceed for different time periods (0, 30, 45 or 60 
minutes) and   reaction was terminated by adding SDS-PAGE loading buffer and heating at 95°C 
for 10 min. Phosphorylation of GST-LIN52 was analyzed by WB analysis. 
5.8. Immunofluorescence 
Cells were seeded on glass coverslips in 6-well dishes and allowed to attach for 24h. After 
washing in PBS three times, cells were fixed in 4% formaldehyde for 20 min, blocked and 
permeabilized with 0.2% Triton X-100 in PBS containing 5% BSA for 30 min followed by 
incubation with primary and secondary antibodies. The coverslips were mounted in Fluoroshield 
mounting medium with DAPI (Abcam) and viewed using Zeiss Axio AX10 Imager fluorescence 
microscope for DNA damage-based assays. Images were acquired at 60x magnification using 
AxioVision software. For foci counts, the images were analyzed using ImageJ FIJI software 
(Schindelin et al., 2012). Briefly, images in JPEG format were processed to find the total number 
of foci (maxima). A noise tolerance value of 20 or 30 was used, and it was the same for all 
samples within each comparison group. For 53BP1, average foci per cell and number of cells 
with greater than 10 foci were calculated. For HA-RNF169, average foci per HA-positive cell 
and number of HA-positive cells with greater than 5 or 10 foci were calculated. To analyze 
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53BP1 in HA-RNF169 expressing cell lines, 53BP1 foci were scored only in the HA-positive 
cells. At least three biological repeats, defined as independently plated and treated series of cell 
samples, were analyzed for each quantitative analysis. For each biological repeat, more than 100 
cells per experimental condition were typically scored. Some experiments were analyzed by two 
different observers, and all data were included in the analysis. The Zeiss Cell Observer Spinning 
Disc confocal microscope was used for capturing images for localization analysis; images were 
acquired at 63X magnification using ZEN 3.0 software (blue edition). 
5.9. Gradient centrifugation 
T98G cells were scraped using ice-cold PBS containing protease and phosphatase inhibitors, 
collected by centrifugation and extracted using buffer containing 10 mM HEPES, 2 mM MgCl2, 
10 mM KCl, 0.5% NP-40, 0.5 mM EDTA, 150 mM NaCl, H2O, 1 mM DTT, protease and 
phosphatase inhibitors. For glycerol gradient analysis, 200 µL of clarified cell lysate containing 
approximately 6 mg/ml of protein was loaded on top of a pre-formed glycerol gradient (5 ml, 5–
45% in lysis buffer made using a gradient maker). Another gradient was also loaded with protein 
weight markers (25 μg each) including bovine serum albumin (Sigma, Catalog# A8531), yeast 
alcohol dehydrogenase from yeast (Sigma, Catalog# A 8656), and bovine thyroglobulin (Sigma, 
Catalog# T9145). The samples were then centrifuged using SW55Ti rotor at 45,000 rpm at 4°C 
for 18h, after which 200 µL fractions were collected from the top of the gradient and analyzed by 
Western blotting or Coomassie staining (for markers). 
For sucrose gradient analysis, solutions of 45% sucrose (solution A), 5% sucrose (solution D), 
2:1 – 2 parts of solution A and 1 part of solution D (solution B) and 1:2- 1 part of solution A and 
2 parts of solution D were made (solution C) in lysis buffer. A volume of 1mL of solution A was 
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pipetted into the centrifuge tube and frozen followed by sequential layering and freezing of 
solutions B, C and D. Just before the gradients were ready to be run, the gradient was thawed at 
room temperature for 30 minutes and cell lysates were loaded followed by centrifugation using 
SW55Ti rotor at 40,000 rpm 4°C for 18h, and collection of fractions.  WB analysis was carried 
out as described for glycerol gradient analysis. 
5.10. DR-GFP assay 
DR-GFP reporter cell lines were established by transfecting the DR-GFP reporter construct [gift 
from Dr. Maria Jasin, Addgene plasmid # 26475; (Pierce et al., 1999)] into the control or 
DYRK1A-KO U-2 OS cells followed by puromycin selection as described (Yakovlev, 2013). 
The cells stably expressing the DR-GFP reporter were infected with adenovirus to express I-SceI 
at MOI =50. To monitor the HRR efficiency, GFP positive cells were detected 48h post-infection 
using flow cytometry as described (Pierce et al., 1999; Yakovlev, 2013) 
5.11. FACS analysis 
Cells were grown to desired densities, transfected with indicated constructs, trypsinized, 
collected by centrifugation and fixed overnight in 70% chilled ethanol.    The next day, cells 
were incubated with PI (50μg/mL) and RNase A solution (100μg/ml, Sigma, Catalog #R4642) 
made in PBS at room temperature for 1hour. The cells (at least 10,000 per condition) were then 
analyzed using FACS Canto II flow cytometer (Becton Dickinson, San Jose, CA, USA). 
For Ki67 staining, U-2 OS cells were plated followed by transfection with indicated constructs. 
72 hours post transfection, cells were trypsinized and fixed in 1% formaldehyde solution by 
incubating at room temperature for 20 minutes. This was followed by blocking and 
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permeabilization at room temperature for 20 minutes, followed by staining with primary 
antibody and secondary antibodies. FACS analysis was performed using BD LSR-Fortessa flow 
cytometer (Becton Dickinson, San Jose, CA, USA) with at least 10,000 cells per condition. 
5.12. Growth assay 
U-2 OS control or DYRK1A inducible cell lines were seeded at a density of 3500 cells per well 
of a 12 well plate. Cells were allowed to attach overnight followed by addition of Doxycyline 
(Sigma, Catalog#9891-5G) containing medium such that the final concentration of Doxcycline is 
1μg/mL. Cells were allowed to grow for 8 days and stained with crystal violet (Sigma, Catalog # 
HT 90132).  The relative cell density was quantified by dissolving the dye in 10% (v/v) glacial 
acetic acid (ACROS, Cat# 64-19-7) and measuring the absorbance at 590 nm, after which the 
ratio of cell density relative to the uninduced control was calculated. 
5.13. RNA-seq analysis 
Five replicates from each sample were collected in Trizol LS reagent (Invitrogen) followed by 
isolation of RNA using Qiagen RNeasy Mini Kit (Catalog # 74104). RNA integrity was analyzed 
using Agilent BioAnalyzer 2100 (Dr. Vladimir Lee, Genomics core- VCU) and samples were 
sent for RNA-seq analysis (Genome Sequencing Facility, UT Health- San Antonio). Briefly, 
RNA from five replicate samples were used to prepare mRNA libraries that were analyzed using 
Illumina Hi-Seq 2500. Resulting files containing single end reads were assessed for quality using 
FastQC tools and trimmed using Trimmomatic (Bolger et al., 2014). The reads were aligned to 
the latest assembly of the human genome (GRCh38/hg38) using Subread, and DEGs were 
determined using DESeq2 (Love et al., 2014) and Edge R (Robinson et al., 2010) packages using 
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a False discovery rate (FDR) of 0.05. The analysis of RNA seq data was performed by Dr. 
Mikhail Dosmorov. 
5.14. RT-qPCR assays 
RNA isolation was carried out using Trizol LS reagent (Invitrogen) followed by cDNA synthesis 
using sensiFAST cDNA synthesis kit (Bioline; Catalog #BIO-65053). Thermoscientific maxima 
SYBR Green/ Rox qPCR master mix (Catalog #K0222) was used for qPCR analysis along with 
gene specific primers (Table 4) and the reactions were run on an Eppendorf realplex 
mastercycler. Fold changes in mRNA expression were calculated relative to controls using the 2-
ΔΔCt method. 
5.15. Statistical analysis and bioinformatic tools 
For quantitation of cell-staining based experiments including foci counts and Ki67 staining, 100 
or more cells per conditions were typically scored. To calculate statistical significance, data from 
at least three biological replicates was analyzed using two-tailed Student’s t-test. For kinase 
assays, ImageJ quantifications from three biological replicates were analyzed using 2-way 
Anova. For analysis of differential gene expression, two tailed student’s t-test was used to 
calculate significance.  
For protein networks analysis, list of proteins detected in at least three out of four DYRK1A 
MudPIT analyzes or two out of four times for LZTS1, LZTS2, FAM117B, RNF169 and TROAP 
were analyzed using MetaScape web-based software (metascape.org) that integrates data from 
BioGrid (Chatr-Aryamontri et al., 2015) and other protein databases with custom datasets to 
build protein-protein interaction networks. Protein-protein interaction networks were custom 
formatted using Cytoscape_3.7.1 software. 
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Gene (Human) Forward (5'>3') Reverse (5'>3')
GABRQ TCCGCCTGAGACCGAATTTT TCTGTTCAATGCTCGTGACA
ADGRV1 TCTCATCAGGGAAAAGGGAACC CTGCCAGGGGGAAAGGTGATA 
ELAVL2 AGAAGGTATCCAGGACCGCT AAGCCATATTGAGCAGATTGTCC
PLXNA2 ACAGGCCTGGGAACCTAATC ACTACCAGGCTAAGCAACCG
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Appendix Figure 1: DCAF7 gene in human cancers 
(A) High expression of DCAF7 in breast cancer (red lines) negatively affects survival (TCGA 
data- Dr. Mikhail Dozmorov) (B) DCAF7 undergoes frequent amplifications in breast cancer 
(cBioPortal). (C) Expression of DCAF7 and DYRK1A in human breast epithelial (MCF10A) 




Appendix Figure 2: WB indicating levels of LZTS1 and LZTS2 in indicated ovarian cancer 
cell lines. T98G glioblastoma and U-2 OS osteosarcoma cell lines were used as controls. 
 
                                  
Appendix Figure 3: All DCAF7 in the cell is not bound to DYRK1A. 
T98G cell lysates were subjected to sequential immunoprecipitation with a non-specific control 
antibody (IgG) or with an antibody specific to DYRK1A. The supernatant (indicated as Sup1, 
Sup2) was collected after each round of immunoprecipitation and levels of DYRK1A and 















# Out of 3
GFP-CTAP 
Detected 
# Out of 3
DCAF7:GFP-
CTAP Locus Description NCBI_Gene Length MW pI
0.030677 3 0 ∞ gi|108936958|ref|NP_005819.3| DDB1- and CUL4-associated factor 7 DCAF7 342 38926 5.5
0.004271 3 0 ∞ gi|578836477|ref|XP_006724042.1| dual specificity tyrosine-phosphorylation-regulated kinase 1A DYRK1A 754 84557 8.8
0.003544 3 0 ∞ gi|768013459|ref|XP_011527477.1| casein kinase II subunit alpha CSNK2A2 391 45144 7.7
0.002912 3 0 ∞ gi|4502643|ref|NP_001753.1| T-complex protein 1 subunit zeta CCT6A 531 58024 6.7
0.002016 3 0 ∞ gi|23503295|ref|NP_001311.3| casein kinase II subunit beta CSNK2B 215 24942 5.6
0.001581 3 0 ∞ gi|51479192|ref|NP_002922.2| E3 ubiquitin-protein ligase RING1 RING1 406 42429 5.6
0.001502 3 0 ∞ gi|208431810|ref|NP_001129119.1| protein FAM53C FAM53C 392 43091 8.6
0.001216 3 0 ∞ gi|119395758|ref|NP_005210.3| protein diaphanous homolog 1 DIAPH1 1272 141347 5.4
0.001199 3 0 ∞ gi|767988718|ref|XP_011544217.1|  probable fibrosin-1 FBRS 980 103769 9.5
0.001158 3 0 ∞ gi|4503097|ref|NP_001887.1| casein kinase II subunit alpha CSNK2A2 350 41213 8.6
0.001124 3 0 ∞ gi|530401926|ref|XP_005266228.1| fibrosin-1-like protein isoform X3 FBRSL1 1085 115367 9.4
0.001065 3 0 ∞ gi|530427297|ref|XP_005272307.1|  polycomb group RING finger protein 3 PCGF3 242 28115 8.2
0.000992 3 0 ∞ gi|13376611|ref|NP_079345.1| zinc finger protein 703 ZNF703 590 58222 8.8
0.000946 3 0 ∞ gi|767947342|ref|XP_011514312.1| autism susceptibility gene 2 protein  AUTS2 1266 139763 9.4
0.000914 3 0 ∞ gi|38455427|ref|NP_006421.2| T-complex protein 1 subunit delta CCT4 539 57924 7.8
0.000889 3 0 ∞ gi|767910102|ref|XP_011508154.1| E3 ubiquitin-protein ligase RING2 RNF2 336 37655 6.8
0.000804 3 0 ∞ gi|767964062|ref|XP_011538574.1| polycomb group RING finger protein 5 PCGF5 236 27512 6.5
0.000776 3 0 ∞ gi|5453607|ref|NP_006420.1| T-complex protein 1 subunit eta CCT7 543 59367 7.6
0.000674 3 0 ∞ gi|300244514|ref|NP_001177906.1| YY1-associated factor 2 YAF2 138 15115 9.9
0.000652 3 0 ∞ gi|578823153|ref|XP_006719244.1| PREDICTED: tastin TROAP 868 93449 7.2
0.000476 3 0 ∞ gi|21464101|ref|NP_036611.2| 14-3-3 protein gamma YWHAG 247 28303 4.9
0.000454 3 0 ∞ gi|768057171|ref|XP_011547115.1| dual specificity tyrosine-phosphorylation-regulated kinase 1B DYRK1B 689 75127 9.4
0.000323 3 0 ∞ gi|112363092|ref|NP_036366.3| RING1 and YY1-binding protein RYBP 228 24822 9.6
0.000268 3 0 ∞ gi|24432032|ref|NP_116161.2| zinc finger protein 503 ZNF503 646 62555 8.7
0.000219 3 0 ∞ gi|530421618|ref|XP_005272744.1|  protein phosphatase 1 regulatory subunit 3F PPP1R3F 798 82726 4.6
0.000143 3 0 ∞ gi|148839382|ref|NP_001092108.1| E3 ubiquitin-protein ligase RNF169 RNF169 708 77194 9.1
0.000062 3 0 ∞ gi|374092020|ref|NP_006448.4| PDZ and LIM domain protein 5 PDLIM5 596 63975 8.2
0.001179 3 1 19.01612903 gi|48762932|ref|NP_006576.2| T-complex protein 1 subunit theta CCT8 548 59621 5.6
0.001003 3 2 11.39772727 gi|5453603|ref|NP_006422.1| T-complex protein 1 subunit beta CCT2 535 57488 6.4
0.002089 3 3 11.17112299 gi|57863257|ref|NP_110379.2| T-complex protein 1 subunit alpha TCP1 556 60344 6.1
0.000878 3 1 7.080645161 gi|63162572|ref|NP_005989.3| T-complex protein 1 subunit gamma CCT3 545 60534 6.5
0.000198 3 2 7.071428571 gi|301171345|ref|NP_001180343.1| tubulin alpha-8 chain TUBA8 383 42954 5.1
0.000807 2 0 ∞ gi|7705618|ref|NP_057134.1| 39S ribosomal protein L11, mitochondrial MRPL11 192 20683 9.9
0.000796 2 0 ∞ gi|393715117|ref|NP_004891.4| DNA dC-_dU-editing enzyme APOBEC-3B APOBEC3B 382 45951 6.3
0.000303 2 0 ∞ gi|13654278|ref|NP_112487.1| SRA stem-loop-interacting RNA-binding protein SLIRP 109 12349 10.2
0.000262 2 0 ∞ gi|4885413|ref|NP_005331.1| histidine triad nucleotide-binding protein 1 HINT1 126 13802 7
0.000254 2 0 ∞ gi|71772415|ref|NP_001025180.1| 40S ribosomal protein S15a RPS15A 130 14839 10.1
0.000252 2 0 ∞ gi|332634984|ref|NP_001091084.2| DNA-directed RNA polymerase II subunit RPB11-b2 POLR2J3 115 13074 6.3
0.000203 2 0 ∞ gi|5730023|ref|NP_006657.1| ruvB-like 2 RUVBL2 463 51157 5.6
0.0002 2 0 ∞ gi|68160937|ref|NP_005073.2| E3 ubiquitin/ISG15 ligase TRIM25 TRIM25 630 70974 8.1
0.000178 2 0 ∞ gi|110735439|ref|NP_000544.2| Werner syndrome ATP-dependent helicase WRN 1432 162460 6.3
0.000158 2 0 ∞ gi|4506753|ref|NP_003698.1| ruvB-like 1 RUVBL1 456 50228 6.4
0.000155 2 0 ∞ gi|530370210|ref|XP_005246543.1| mannose-1-phosphate guanyltransferase alpha GMPPA 420 46291 7.2
0.000143 2 0 ∞ gi|325301072|ref|NP_001191455.1| translocon-associated protein subunit delta SSR4 184 20213 5.8
0.000139 2 0 ∞ gi|289629265|ref|NP_001166216.1| protein transport protein Sec23B SEC23B 767 86479 6.9
0.000129 2 0 ∞ gi|164420685|ref|NP_073577.3| homeodomain-interacting protein kinase 2 HIPK2 1198 130965 8.4
0.000108 2 0 ∞ gi|157057543|ref|NP_443102.2| sorting nexin-18 SNX18 628 68895 5.7
0.000079 2 0 ∞ gi|767952979|ref|XP_011515331.1|  RNA-binding protein 12B RBM12B 1001 118103 6.8
0.000051 2 0 ∞ gi|767938662|ref|XP_011532966.1| calnexin isoform X2 CANX 646 73410 4.6
0.000026 2 0 ∞ gi|304555583|ref|NP_001123525.2| elongation factor 1-delta EEF1D 647 71422 6.4
0.000474 2 1 12.15384615 gi|13124875|ref|NP_074035.1| myosin-11 isoform SM2A MYH11 1938 223575 5.5
0.000432 2 1 9.818181818 gi|431822377|ref|NP_001258929.1| dedicator of cytokinesis protein 7 DOCK7 2100 238532 6.8
0.001578 2 2 7.205479452 gi|530383156|ref|XP_005248783.1| unconventional myosin-VI MYO6 1253 145015 8.6
0.000143 2 3 6.80952381 gi|116805348|ref|NP_055309.2| trinucleotide repeat-containing gene 6A protein TNRC6A 1962 210296 7














# Out of 3
GFP-CTAP 
Detected 





e Length MW pI
0.237479 3 1 969.302 gi|83267868|ref|NP_001032584.1| dynein light chain 1, cytoplasmic DYNLL1 89 10366 7.4
0.071217 3 0 ∞ gi|254910983|ref|NP_775782.2| protein FAM117B FAM117B 589 61968 9.8
0.057198 3 0 ∞ gi|767953588|ref|XP_011515591.1| 14-3-3 protein zeta/delta YWHAZ 245 27745 4.8
0.03839 3 1 238.4472 gi|21328448|ref|NP_647539.1| 14-3-3 protein beta/alpha YWHAB 246 28082 4.8
0.031779 3 2 46.6652 gi|5803227|ref|NP_006817.1| 14-3-3 protein theta YWHAQ 245 27764 4.8
0.014981 3 0 ∞ gi|108936958|ref|NP_005819.3| DDB1- and CUL4-associated factor 7 DCAF7 342 38926 5.5
0.010188 3 1 80.85714 gi|5803225|ref|NP_006752.1| 14-3-3 protein epsilon YWHAE 255 29174 4.7
0.009108 3 1 37.17551 gi|18087855|ref|NP_542408.1| dynein light chain 2, cytoplasmic DYNLL2 89 10350 7.4
0.008456 3 0 ∞ gi|4507951|ref|NP_003396.1| 14-3-3 protein eta YWHAH 246 28219 4.8
0.004821 3 0 ∞ gi|4506619|ref|NP_000977.1| 60S ribosomal protein L24 RPL24 157 17779 11.3
0.003545 3 0 ∞ gi|4506633|ref|NP_000984.1| 60S ribosomal protein L31 RPL31 125 14463 10.5
0.002811 3 0 ∞ gi|578836477|ref|XP_006724042.1| dual specificity tyrosine-phosphorylation-regulated kinase 1A DYRK1A 754 84557 8.8
0.002315 2 0 ∞ gi|4506643|ref|NP_000989.1| 60S ribosomal protein L37a RPL37A 92 10275 10.4
0.00123 3 0 ∞ gi|4506901|ref|NP_003008.1| serine/arginine-rich splicing factor 3 SRSF3 164 19330 11.6
0.000857 2 0 ∞ gi|4506687|ref|NP_001009.1| 40S ribosomal protein S15 RPS15 145 17040 10.4
0.000771 3 0 ∞ gi|767950480|ref|XP_011542667.1| paraneoplastic antigen Ma2 PNMA2 364 41509 4.8
0.000695 3 0 ∞ gi|148727341|ref|NP_009109.3| serine-threonine kinase receptor-associated protein STRAP 350 38438 5.1
0.00069 3 0 ∞ gi|66346679|ref|NP_001018077.1| plasminogen activator inhibitor 1 RNA-binding SERBP1 408 44965 8.6
0.000576 3 0 ∞ gi|77812674|ref|NP_001030005.1| H/ACA ribonucleoprotein complex subunit 2 NHP2 90 10071 10
0.000536 2 0 ∞ gi|7705618|ref|NP_057134.1| 39S ribosomal protein L11, mitochondrial MRPL11 192 20683 9.9
0.000531 3 0 ∞ gi|23503259|ref|NP_699170.1| tRNA pseudouridine synthase-like 1 PUSL1 303 33233 9.9
0.000481 2 0 ∞ gi|345197222|ref|NP_001230807.1| four and a half LIM domains protein 3 FHL3 172 18918 7.6
0.000427 3 0 ∞ gi|22907039|ref|NP_055323.2| DNA dC-_dU-editing enzyme APOBEC-3C APOBEC3C 190 22826 7.6
0.000383 3 0 ∞ gi|767904731|ref|XP_011539919.1| filamin-binding LIM protein FBLIM1 373 40670 6
0.000358 2 0 ∞ gi|4758256|ref|NP_004085.1| eukaryotic translation initiation factor 2 subunit 1 EIF2S1 315 36112 5.1
0.000355 2 0 ∞ gi|5922001|ref|NP_006475.1| dual specificity tyrosine-phosphorylation-regulated kinase 1B DYRK1B 601 66336 9.1
0.000327 2 0 ∞ gi|8922549|ref|NP_060624.1| histone chaperone ASF1B ASF1B 202 22434 4.6
0.000283 2 0 ∞ gi|51317376|ref|NP_001003796.1| NHP2-like protein 1 SNU13 128 14174 8.5
0.000274 2 0 ∞ gi|16554616|ref|NP_115865.1| 28S ribosomal protein S6, mitochondrial MRPS6 125 14227 9.3
0.000263 2 0 ∞ gi|521258690|ref|NP_001265585.1| small nuclear ribonucleoprotein Sm D3 SNRPD3 126 13916 10.3
0.000251 3 0 ∞ gi|68160937|ref|NP_005073.2| E3 ubiquitin/ISG15 ligase TRIM25 TRIM25 630 70974 8.1
0.000246 2 0 ∞ gi|767951904|ref|XP_011515883.1| transcription elongation factor B polypeptide 1 TCEB1 112 12473 4.8
0.000244 3 0 ∞ gi|768004861|ref|XP_011526754.1| kelch-like ECH-associated protein 1 KEAP1 624 69666 6.4
0.000237 3 0 ∞ gi|56118219|ref|NP_001007226.1| insulin-like growth factor 2 mRNA-binding protein 2 IGF2BP2 556 61843 8.3
0.000236 2 0 ∞ gi|7661730|ref|NP_054737.1| 28S ribosomal protein S28, mitochondrial MRPS28 187 20843 9.1
0.000219 3 0 ∞ gi|15147219|ref|NP_150093.1| transcriptional activator protein Pur-beta PURB 312 33241 5.4
0.000206 3 0 ∞ gi|87239981|ref|NP_003738.2| tankyrase-1 TNKS 1327 142039 7
0.000193 2 0 ∞ gi|306482646|ref|NP_001182356.1| serine/arginine-rich splicing factor 2 SRSF2 221 25476 11.9
0.000184 2 0 ∞ gi|18139549|ref|NP_085151.1| histone-lysine N-methyltransferase SETD7 SETD7 366 40721 4.6
0.000183 3 0 ∞ gi|49472822|ref|NP_003746.2| eukaryotic translation initiation factor 3 subunit G EIF3G 320 35611 6.1
0.000171 2 0 ∞ gi|169636418|ref|NP_115867.2| 39S ribosomal protein L38, mitochondrial MRPL38 380 44597 7.5
0.000169 3 0 ∞ gi|544346109|ref|NP_001269672.1| SPATS2-like protein SPATS2L 498 54945 9.7
0.000169 2 0 ∞ gi|530371187|ref|XP_005247022.1|  general transcription factor 3C polypeptide 3 GTF3C3 494 56384 6.6
0.000164 3 0 ∞ gi|13994259|ref|NP_114108.1| 28S ribosomal protein S5, mitochondrial MRPS5 430 48006 9.9
0.000164 3 0 ∞ gi|767985150|ref|XP_011520272.1| thrombospondin-1 THBS1 1170 129383 4.9
0.000162 3 0 ∞ gi|767974361|ref|XP_011536692.1| nucleosome assembly protein 1-like 1 NAP1L1 403 46832 4.5
0.000161 2 0 ∞ gi|29826335|ref|NP_003899.2|  eukaryotic translation initiation factor 2 subunit 2 EIF2S2 333 38388 5.8
0.000156 3 0 ∞ gi|186928854|ref|NP_005821.2| 28S ribosomal protein S31, mitochondrial MRPS31 395 45319 9.3
0.000133 3 0 ∞ gi|17402904|ref|NP_478126.1| exosome complex component MTR3 EXOSC6 272 28235 6.3
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0.010264 3 0 ∞ gi|108936958|ref|NP_005819.3| DDB1- and CUL4-associated factor 7 DCAF7 342 38926 5.5
0.005095 3 0 ∞ gi|578836477|ref|XP_006724042.1| dual specificity tyrosine-phosphorylation-regulated kinase 1A DYRK1A 754 84557 8.8
0.003806 3 0 ∞ gi|767912565|ref|XP_011542546.1| signal-induced proliferation-associated 1-like protein 2 SIPA1L2 1722 190436 6.8
0.002753 3 0 ∞ gi|767950531|ref|XP_011542689.1| leucine zipper putative tumor suppressor 1 LZTS1 596 66613 7.1
0.002222 3 0 ∞ gi|768007560|ref|XP_011524959.1|  signal-induced proliferation-associated 1-like protein 3 SIPA1L3 1781 194608 8.3
0.001475 3 0 ∞ gi|545746375|ref|NP_001271175.1| signal-induced proliferation-associated 1-like protein 1 SIPA1L1 1782 197407 8.3
0.001429 3 0 ∞ gi|122937500|ref|NP_001074002.1| protein unc-119 homolog B UNC119B 251 28137 5.7
0.001064 3 0 ∞ gi|768057171|ref|XP_011547115.1| dual specificity tyrosine-phosphorylation-regulated kinase 1B DYRK1B 689 75127 9.4
0.000723 3 0 ∞ gi|21464101|ref|NP_036611.2| 14-3-3 protein gamma YWHAG 247 28303 4.9
0.000697 3 0 ∞ gi|767935349|ref|XP_011541469.1|  protein Shroom1 SHROOM1 852 90786 6.1
0.000598 3 0 ∞ gi|115511046|ref|NP_009098.3| zinc finger MYM-type protein 6 ZMYM6 1325 148088 8.2
0.000582 3 0 ∞ gi|44890068|ref|NP_005086.2| zinc finger MYM-type protein 4 ZMYM4 1548 172787 6.8
0.000417 3 0 ∞ gi|530426085|ref|XP_005260950.1| leucine zipper putative tumor suppressor 3 LZTS3 673 71791 7.6
0.000189 3 0 ∞ gi|11321601|ref|NP_002618.1| ATP-dependent 6-phosphofructokinase, platelet type  PFKP 784 85596 7.6
0.000109 3 0 ∞ gi|4507729|ref|NP_001060.1| tubulin beta-2A chain TUBB2A 445 49907 4.9
0.038582 3 1 964.55 gi|530394499|ref|XP_005270281.1|  leucine zipper putative tumor suppressor 2 LZTS2 669 72759 6.5
0.012743 3 2 81.6859 gi|283436222|ref|NP_001164006.1| ATPase family AAA domain-containing protein 3A ATAD3A 586 66218 9.2
0.003093 3 3 20.21569 gi|14389309|ref|NP_116093.1| tubulin alpha-1C chain isoform c TUBA1C 449 49895 5.1
0.000641 3 2 19.42424 gi|237649019|ref|NP_001153682.1| calcium-binding mitochondrial carrier protein Aralar2 SLC25A13 676 74304 8.6
0.002162 3 2 19.13274 gi|217272849|ref|NP_001136067.1| prolyl 4-hydroxylase subunit alpha-1 P4HA1 534 61049 6
0.000742 3 3 14.26923 gi|18105007|ref|NP_004332.2| CAD protein CAD 2225 242981 6.5
0.019113 3 3 6.379506 gi|29788785|ref|NP_821133.1| tubulin beta chain  TUBB 444 49671 4.9
0.000594 3 1 5.881188 gi|426214088|ref|NP_001258766.1| reticulocalbin-2 RCN2 335 39139 4.5
0.042142 3 3 5.084087 gi|55956899|ref|NP_000217.2| keratin, type I cytoskeletal 9 KRT9 623 62064 5.2
0.001352 2 0 ∞ gi|75677353|ref|NP_114127.3| ATPase family AAA domain-containing protein 3B ATAD3B 648 72573 9.2
0.001095 2 0 ∞ gi|4827048|ref|NP_005139.1| protein unc-119 homolog A UNC119 240 26962 6.4
0.000964 2 0 ∞ gi|768037835|ref|XP_011529275.1| PDZ domain-containing protein 11 PDZD11 140 16131 7.2
0.000958 2 0 ∞ gi|187830777|ref|NP_001119584.1| cellular tumor antigen p53 TP53 393 43653 6.8
0.00079 2 0 ∞ gi|578810654|ref|XP_006714791.1| prolyl 4-hydroxylase subunit alpha-2 P4HA2 535 60902 5.7
0.000686 2 0 ∞ gi|7657257|ref|NP_055580.1| mitochondrial import receptor subunit TOM20 homolog TOMM20 145 16298 8.6
0.000651 2 0 ∞ gi|5802968|ref|NP_006809.1| protein AF1q MLLT11 90 10061 4.5
0.000633 2 0 ∞ gi|332634984|ref|NP_001091084.2| DNA-directed RNA polymerase II subunit RPB11-b2  POLR2J3 115 13074 6.3
0.00059 2 0 ∞ gi|23308693|ref|NP_689948.1| zinc finger and BTB domain-containing protein 9 ZBTB9 473 50602 6.8
0.000562 2 0 ∞ gi|530339647|ref|NP_001268861.1| condensin-2 complex subunit G2 NCAPG2 1143 130960 6.9
0.000528 2 0 ∞ gi|66529294|ref|NP_000296.2| serum paraoxonase/arylesterase 2 PON2 354 39381 5.6
0.000516 2 0 ∞ gi|530426780|ref|XP_005266156.1|  TNF receptor-associated factor 2 TRAF2 533 59135 7.5
0.000514 2 0 ∞ gi|578823153|ref|XP_006719244.1| tastin TROAP 868 93449 7.2
0.000513 2 0 ∞ gi|109689718|ref|NP_001035937.1| monoacylglycerol lipase ABHD12 ABHD12 398 45097 8.6
0.000478 2 0 ∞ gi|148368978|ref|NP_689512.2| condensin-2 complex subunit H2 NCAPH2 605 68227 4.7
0.000433 2 0 ∞ gi|157057543|ref|NP_443102.2| sorting nexin-18 SNX18 628 68895 5.7
0.000421 2 0 ∞ gi|31543831|ref|NP_001061.2| tubulin gamma-1 chain TUBG1 451 51170 6.1
0.000383 2 0 ∞ gi|767969890|ref|XP_011541020.1| condensin-2 complex subunit D3 NCAPD3 1498 168890 7.5
0.000377 2 0 ∞ gi|5730009|ref|NP_006501.1| zinc finger protein RFP TRIM27 513 58490 6.2
0.000367 2 0 ∞ gi|11386135|ref|NP_000700.1| 2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial BCKDHA 445 50471 8.3
0.000349 2 0 ∞ gi|153085461|ref|NP_001093138.1| HIG1 domain family member 1A, mitochondrial isoform HIGD1A 107 11770 9.4
0.000344 2 0 ∞ gi|767953588|ref|XP_011515591.1| PREDICTED: 14-3-3 protein zeta/delta YWHAZ 245 27745 4.8
0.000329 2 0 ∞ gi|4506189|ref|NP_002783.1| proteasome subunit alpha type-7 PSMA7 248 27887 8.5
0.000323 2 0 ∞ gi|4506753|ref|NP_003698.1| ruvB-like 1 RUVBL1 456 50228 6.4
0.000322 2 0 ∞ gi|187960098|ref|NP_001120800.1| medium-chain specific acyl-CoA dehydrogenase, mitochondrial isoform ACADM 425 47020 8.3
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0.079012 3 0 ∞ gi|767950531|ref|XP_011542689.1| leucine zipper putative tumor suppressor 1 LZTS1 596 66613 7.1
0.012714 3 0 ∞ gi|122937500|ref|NP_001074002.1| protein unc-119 homolog B UNC119B 251 28137 5.7
0.003781 3 0 ∞ gi|4827048|ref|NP_005139.1| protein unc-119 homolog A  UNC119 240 26962 6.4
0.003154 3 0 ∞ gi|21361647|ref|NP_006612.2| putative adenosylhomocysteinase 2 AHCYL1 530 58951 6.9
0.003012 3 0 ∞ gi|314122177|ref|NP_001186600.1| calumenin isoform c precursor CALU 323 38051 4.6
0.002244 3 0 ∞ gi|21464101|ref|NP_036611.2| 14-3-3 protein gamma YWHAG 247 28303 4.9
0.00222 3 0 ∞ gi|5730023|ref|NP_006657.1| ruvB-like 2 RUVBL2 463 51157 5.6
0.002135 3 0 ∞ gi|767924420|ref|XP_011532466.1| protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2 POMGNT2 580 66615 8.6
0.002091 3 0 ∞ gi|4506753|ref|NP_003698.1| ruvB-like 1 RUVBL1 456 50228 6.4
0.0019 3 0 ∞ gi|153085461|ref|NP_001093138.1| HIG1 domain family member 1A, mitochondrial HIGD1A 107 11770 9.4
0.001899 3 0 ∞ gi|530392883|ref|XP_005269499.1| PREDICTED: erlin-1 ERLIN1 348 39171 7.9
0.001663 3 0 ∞ gi|108936958|ref|NP_005819.3| DDB1- and CUL4-associated factor 7 DCAF7 342 38926 5.5
0.001579 3 0 ∞ gi|66529294|ref|NP_000296.2| serum paraoxonase/arylesterase 2 PON2 354 39381 5.6
0.001391 3 0 ∞ gi|17388799|ref|NP_490647.1| dnaJ homolog subfamily B member 6 DNAJB6 326 36087 9.1
0.001244 3 0 ∞ gi|530387549|ref|XP_005273449.1|  erlin-2 ERLIN2 339 37840 5.6
0.001171 3 0 ∞ gi|11321601|ref|NP_002618.1| ATP-dependent 6-phosphofructokinase, platelet type PFKP 784 85596 7.6
0.001041 3 0 ∞ gi|768044351|ref|XP_011544912.1|  ribonuclease inhibitor RNH1 461 49974 4.8
0.00103 3 0 ∞ gi|767948171|ref|XP_011514665.1| MICOS complex subunit MIC19 MIC19 232 26753 7.8
0.000998 3 0 ∞ gi|767935349|ref|XP_011541469.1| protein Shroom1 SHROOM1 852 90786 6.1
0.000972 3 0 ∞ gi|19923483|ref|NP_057406.2| ras-related protein Rab-14 RAB14 215 23897 6.2
0.000934 3 0 ∞ gi|5453559|ref|NP_006347.1| ATP synthase subunit d, mitochondrial ATP5H 161 18491 5.3
0.000907 3 0 ∞ gi|33239451|ref|NP_872590.1| proliferating cell nuclear antigen PCNA 261 28769 4.7
0.000864 3 0 ∞ gi|6912430|ref|NP_036537.1| protein-S-isoprenylcysteine O-methyltransferase ICMT 284 31938 8
0.000858 3 0 ∞ gi|578821561|ref|XP_006718676.1| protein phosphatase 6 regulatory subunit 3 PPP6R3 873 97669 4.6
0.000823 3 0 ∞ gi|11559927|ref|NP_071383.1| 28S ribosomal protein S14, mitochondrial MRPS14 128 15139 11.4
0.000817 3 0 ∞ gi|13654278|ref|NP_112487.1| SRA stem-loop-interacting RNA-binding protein, mitochondrial isoform SLIRP 109 12349 10.2
0.000782 3 0 ∞ gi|578836477|ref|XP_006724042.1| dual specificity tyrosine-phosphorylation-regulated kinase 1A DYRK1A 754 84557 8.8
0.000776 3 0 ∞ gi|225543166|ref|NP_056195.3| sorting and assembly machinery component 50 homolog SAMM50 469 51976 6.9
0.000757 3 0 ∞ gi|21359867|ref|NP_001907.2| cytochrome c1, heme protein, mitochondrial precursor CYC1 325 35390 9
0.00075 3 0 ∞ gi|13435356|ref|NP_006109.2| HCLS1-associated protein X-1 HAX1 279 31621 4.9
0.000727 3 0 ∞ gi|767953588|ref|XP_011515591.1| 14-3-3 protein zeta/delta YWHAZ 245 27745 4.8
0.0007 3 0 ∞ gi|31543831|ref|NP_001061.2| tubulin gamma-1 chain TUBG1 451 51170 6.1
0.00069 3 0 ∞ gi|89903012|ref|NP_001034891.1| cell division control protein 42 homolog CDC42 191 21259 6.5
0.000688 3 0 ∞ gi|530407434|ref|XP_005255087.1| cytosolic Fe-S cluster assembly factor NUBP2 NUBP2 130 13793 5.1
0.000679 3 0 ∞ gi|109689718|ref|NP_001035937.1| monoacylglycerol lipase ABHD12 ABHD12 398 45097 8.6
0.000676 3 0 ∞ gi|92110027|ref|NP_060129.2| glutaminyl-peptide cyclotransferase-like protein QPCTL 382 42924 9.8
0.000652 3 0 ∞ gi|169404009|ref|NP_003135.2| translocon-associated protein subunit alpha SSR1 286 32235 4.5
0.000633 3 0 ∞ gi|530395344|ref|XP_005252973.1|  rho-related GTP-binding protein RhoG RHOG 191 21308 8.1
0.000605 3 0 ∞ gi|187830777|ref|NP_001119584.1| cellular tumor antigen p53 TP53 393 43653 6.8
0.000605 3 0 ∞ gi|21361565|ref|NP_001679.2| ATP synthase F(0) complex subunit B1, mitochondrial precursor ATP5F1 256 28909 9.4
0.000556 3 0 ∞ gi|4502227|ref|NP_001168.1| ADP-ribosylation factor-like protein 1 ARL1 181 20418 5.7
0.000534 3 0 ∞ gi|521258690|ref|NP_001265585.1| small nuclear ribonucleoprotein Sm D3 SNRPD3 126 13916 10.3
0.000527 3 0 ∞ gi|4506613|ref|NP_000974.1| 60S ribosomal protein L22 proprotein RPL22 128 14787 9.2
0.000522 3 0 ∞ gi|46852178|ref|NP_064507.3| E3 ubiquitin-protein ligase KCMF1 KCMF1 381 41945 5.7
0.000497 3 0 ∞ gi|205830453|ref|NP_001128634.1| catechol O-methyltransferase isoform MB-COMT COMT 271 30037 5.5
0.000488 3 0 ∞ gi|530376692|ref|XP_005248174.1|  transmembrane protein 33 TMEM33 247 27978 9.7
0.000483 3 0 ∞ gi|15721937|ref|NP_114403.1| 28S ribosomal protein S24, mitochondrial precursor MRPS24 167 19015 9.4
0.000482 3 0 ∞ gi|20270303|ref|NP_620124.1| mitochondrial Rho GTPase 2 RHOT2 618 68118 5.9
0.000482 3 0 ∞ gi|530419305|ref|XP_005261210.1| putative ribonuclease YBEY 168 19436 8.1
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0.004144 3 0 ∞ RNF169 gi|767967816|ref|XP_011543191.1|  E3 ubiquitin-protein ligase RNF169 729 79394 9.1
0.002413 3 0 ∞ USP7 gi|150378533|ref|NP_003461.2| ubiquitin carboxyl-terminal hydrolase 7 isoform 1 1102 128302 5.6
0.000644 3 0 ∞ DCAF7 gi|108936958|ref|NP_005819.3| DDB1- and CUL4-associated factor 7 342 38926 5.5
0.000607 3 0 ∞ DYRK1A gi|768020356|ref|XP_011527785.1| dual specificity tyrosine-phosphorylation-regulated kinase 1A 763 85584 8.7
0.000344 3 0 ∞ ACTR1A gi|5031569|ref|NP_005727.1| alpha-centractin 376 42614 6.6
0.000693 3 0 ∞ SLC25A5 gi|156071459|ref|NP_001143.2| ADP/ATP translocase 2 298 32852 9.7
0.000267 3 0 ∞ ILF2 gi|24234747|ref|NP_004506.2| ILF2:interleukin enhancer-binding factor 2 390 43062 5.3
0.000951 3 0 ∞ RPL10A gi|15431288|ref|NP_009035.3| 60S ribosomal protein L10a 217 24831 9.9
0.000239 2 0 ∞ WDR6 gi|197927448|ref|NP_060501.3| WD repeat-containing protein 6 1151 125001 6.9
0.000028 2 0 ∞ SIPA1L1 gi|545746375|ref|NP_001271175.1| signal-induced proliferation-associated 1-like protein 1 1782 197407 8.3
0.000279 2 0 ∞ DYNLL2 gi|18087855|ref|NP_542408.1| dynein light chain 2, cytoplasmic 89 10350 7.4
0.000515 2 0 ∞ KPNB1 gi|19923142|ref|NP_002256.2| importin subunit beta-1 876 97170 4.8
0.000333 2 0 ∞ PSMC2 gi|4506209|ref|NP_002794.1| 26S protease regulatory subunit 7 433 48634 5.9
0.000099 2 0 ∞ MCM7 gi|33469968|ref|NP_005907.3| DNA replication licensing factor MCM7 719 81308 6.5
0.000106 2 0 ∞ LRCH3 gi|578807822|ref|XP_006713854.1| leucine-rich repeat and calponin homology domain-containing protein 3  777 86083 6.7
0.002086 2 0 ∞ SRSF9 gi|4506903|ref|NP_003760.1| serine/arginine-rich splicing factor 9 221 25542 8.6
0.000051 2 0 ∞ TARDBP gi|6678271|ref|NP_031401.1| TAR DNA-binding protein 43 414 44740 6.2
0.00016 2 0 ∞ ATP1A1 gi|21361181|ref|NP_000692.2| ATP1A1:sodium/potassium-transporting ATPase subunit alpha-1 1023 112896 5.5
0.000862 2 0 ∞ ELAVL1 gi|38201714|ref|NP_001410.2| ELAVL1:ELAV-like protein 1 326 36092 9.2
0.001085 2 0 ∞ RPS17 gi|4506693|ref|NP_001012.1| 40S ribosomal protein S17 135 15550 9.8
0.000869 2 0 ∞ TMOD1 gi|260763922|ref|NP_001159588.1| tropomodulin-1 359 40569 5.1
0.000021 2 0 ∞ DOCK7 gi|431822375|ref|NP_001258928.1| dedicator of cytokinesis protein 7 2129 241410 6.8
0.000634 2 0 ∞ FLG2 gi|62122917|ref|NP_001014364.1| FLG2:filaggrin-2 2391 248072 8.3
0.000062 2 0 ∞ LARP1 gi|39725634|ref|NP_056130.2| LARP1:la-related protein 1 1019 116465 9.1
0.000397 2 0 ∞ SMARCE1 gi|21264355|ref|NP_003070.3| SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1 411 46649 4.9
0.000155 2 0 ∞ ZNF185 gi|530422917|ref|XP_005274794.1| zinc finger protein 185 690 73613 7








# Out of 3
GFP-CTAP 
Detected 
# Out of 3
NTAP-
TROA:GFP-
CTAP Locus Description NCBI_Gene Length MW pI
0.003868 3 0 ∞ gi|578823153|ref|XP_006719244.1| tastin TROAP 868 93449 7.2
0.001995 3 3 13.03922 gi|14389309|ref|NP_116093.1| tubulin alpha-1C chain TUBA1C 449 49895 5.1
0.001886 3 0 ∞ gi|578836477|ref|XP_006724042.1| dual specificity tyrosine-phosphorylation-regulated kinase 1A DYRK1A 754 84557 8.8
0.001525 3 0 ∞ gi|108936958|ref|NP_005819.3| DDB1- and CUL4-associated factor 7 DCAF7 342 38926 5.5
0.000997 3 3 6.828767 gi|32698730|ref|NP_065823.1| nuclear fragile X mental retardation-interacting protein 2 NUFIP2 695 76121 8.7
0.014143 2 3 5.849049 gi|124494247|ref|NP_001074419.1| unconventional myosin-Ic MYO1C 1044 119628 9.5
0.003002 2 3 7.014019 gi|5453599|ref|NP_006127.1| F-actin-capping protein subunit alpha-2 CAPZA2 286 32949 5.8
0.001921 2 3 5.910769 gi|45359846|ref|NP_987100.1| ras GTPase-activating protein-binding protein 2 G3BP2 449 50817 5.4
0.001204 2 0 ∞ gi|4506633|ref|NP_000984.1| 60S ribosomal protein L31 RPL31 125 14463 10.5
0.001062 2 1 27.23077 gi|13124875|ref|NP_074035.1| myosin-11 isoform SM2A MYH11 1938 223575 5.5
0.000761 2 3 11.19118 gi|383792189|ref|NP_059867.3| ataxin-2-like protein ATXN2L 1062 112091 8.7
0.000693 2 2 10.04348 gi|227430301|ref|NP_001153059.1| CD109 antigen isoform 2 preproprotein CD109 1428 159695 5.8
0.000574 2 0 ∞ gi|16905517|ref|NP_473357.1| serine/arginine-rich splicing factor 10 SRSF10 262 31301 11.3
0.000292 2 0 ∞ gi|40807443|ref|NP_955445.1| protein regulator of cytokinesis 1 PRC1 606 70249 6.7
0.000141 2 0 ∞ gi|18379349|ref|NP_006364.2| synaptic vesicle membrane protein VAT-1 homolog VAT1 393 41920 6.3




Appendix table 7: Overlap of DYRK1A regulated genes (obtained by RNA-seq) with 
DYRK1A ChIP-seq dataset [under Serum starved or Cycling conditions (Di Vona et al., 
2015)]. Related to Figure 49A. 
Serum starved 
only (2 genes)
ADAT1 EXOC8 PUF60 ABCC10 HDAC6 PLEKHA6 SRP14 CNN2
AHCTF1 FAM76A PXMP2 ABHD18 HGH1 PLEKHG2 SRRT TMEM259
ALDH16A1 FBXL5 QRICH1 ABTB2 HMBOX1 PMF1 SUSD2
ASH2L FBXO31 R3HDM1 ACBD4 HOMER2 PNKP TAF6
ASXL1 FLNA RAB33B ADNP HOXC6 POLR1C TBL3
ATAD3A FOXC2 RBM15 ALKBH2 ICMT POLR3E TCF3
ATF2 FUBP1 RCC1 AP4E1 ID1 PPM1G THAP7
ATF4 GAS8 RFC5 ARHGAP32 IFRD1 PPOX TIA1
ATXN7L2 GGA3 RING1 ARHGEF18 IGFBP3 PPP1R10 TMEM183A
BANP GPATCH3 SCAMP5 ASF1B IL17RD PPP1R12A TMEM262
BAZ2B GRWD1 SEC22C BAK1 INTS9 PRDM11 TRIP6
BCAR3 HERC1 SENP7 BRF1 KANK1 PRKDC TROAP
BRI3BP HERPUD2 SETD5 CARMIL1 KIF24 PRMT5 TUBGCP6
C1orf74 HNRNPH3 SLC12A2 CDKN1B KIN PROSER3 UBALD1
C2orf68 HSD17B8 SLC25A4 CENPC KLC2 PRPF4 UBXN11
C6orf89 HUWE1 SMARCA5 CFAP45 LOXL2 PRPF40B UMAD1
CAND1 ILF2 SMG5 CFDP1 LRFN3 PRR14 UNG
CD2AP KIAA1191 SPDL1 CHMP1A LTA4H PRTG USP21
CDC20 LIN7C SPRTN CLASP1 LY6G5B PTGER4 USP54
CDC25B LUC7L2 SRCAP CLTB MAD2L1 R3HDM4 VAMP2
CDC5L MAD1L1 SRSF10 COL1A1 MCM4 RAB17 VPS37C
CENPB MAPK14 STRIP1 CYTH1 MDM4 RAD18 VPS51
CENPT MAU2 SUV39H1 DDX19A MED16 RGL2 WDR46
CEP350 MBTPS1 THAP11 DFFA MGRN1 RIC8B WDR59
CHAF1A MED22 TIPIN DIDO1 MPZL1 RPS15 WDR90
CIAPIN1 MGME1 TMEM209 DLX1 MRE11 SELENON YIPF3
COPB2 MRM2 TMEM79 DYRK1A MRI1 SEMA3B ZBTB25
COQ9 MTHFSD TMPO E2F2 MYBL2 SF1 ZDHHC5
CORO7 MYO19 TRAPPC2 EFHD1 NANS SIPA1L1 ZFP30
CSDE1 NANP TRIM7 EID2 NCL SIRT5 ZFPM1
CYGB NCAPG2 TTC23 EIF1AD NCOA7 SLC12A9 ZKSCAN2
DBNDD1 NDUFS7 TUBGCP5 EPOP NFATC2IP SLC4A3 ZNF136
DBR1 NFYC UBE2D3 FBRS NFIB SLC6A9 ZNF184
DCAF16 NKTR UHRF2 FDPS NMRAL1 SMARCAD1 ZNF790
DDHD2 NOL9 USP39 FKBPL NOA1 SMARCC2
DDX20 NOP14 WDR6 FMNL1 NPTN SMC1A
DENR NUDT1 WDR77 FUS NUDT5 SMC5
DHX37 OFD1 XPC GCAT NUP37 SMG7
DNAJA3 PFKFB2 YOD1 GDF7 PACS2 SNAP29
DNAJC27 PHF12 ZCCHC14 GDI2 PARP2 SNRNP70
DPP9 PIH1D1 ZFP91 GGT5 PDE12 SNRPC
EFHC1 POLDIP3 ZNF48 GID8 PEX14 SPATA33
EHD1 POLE ZNF500 GOLGA8B PFDN6 SPC25
EMD POLG ZNF839 GSN PHC2 SPTY2D1
ETFA POP7 ZNF850 HASPIN PI4KA SREK1
Serum starved + Cycling  (135 
genes) Cycling only (169 genes)




Appendix table 8: Overlap of DYRK1A regulated genes (obtained by RNA-seq) with 
DYRK1A ChIP-seq dataset [under Serum starved or Cycling conditions (Di Vona et al., 
2015)]. Related to Figure 49B. 
AKAP11 MKKS SSR1 ACADSB FTCD PPP1R2 UPF3A
ASPH MMS22L SURF2 ACO2 GPN3 PRDX4 ZNF286A
C5orf24 MRPL57 TMCO1 ADGRF1 GRB2 PSENEN ZNF697
C6orf120 MRPS7 TMEM245 ADGRG1 HARS2 PSMD10 ZNF792
CCDC77 MTFR1L TOPORS AHCY HES7 PTPN1
CCNC NAA35 UBC AIDA HIGD2A RAB27A
CCNG1 NAA38 VDAC3 AKT1S1 HINT1 RACK1
CCT8 NCOA4 VMP1 ANKRD49 HMGN5 RBM26
CDK12 NOL11 WDR27 ARCN1 ICAM1 RICTOR
CHST7 NPR3 ZBTB2 ATG4A IFT74 RIN1
CNP NRBF2 ZBTB6 B4GAT1 IKBKG RPS15A
COASY NSUN3 BCLAF1 IKZF5 RPS7
COX11 PAXBP1 BZW1 ITGA10 RPS9
CUL5 PBLD C11orf54 KCTD2 SACM1L
DCTN2 PGK1 C12orf57 LAMTOR4 SAP18
DHFR2 PIGN C20orf27 LIN37 SBDS
DNAJB4 PLOD2 CASTOR1 LSM14A SEC63
DNTTIP2 PPP4R3B CCNJ LYRM7 SEMA7A
ECHS1 PRDX1 CCR7 MAGT1 SH3BGRL
ERGIC2 PSMB3 CD320 MAP3K7 SLC39A9
ETF1 PSMD5 CDC26 MDH1B SMNDC1
FAM135A PTPRN2 CETN2 MLF2 SNRPG
FGFR1OP2 PTRH2 CETN3 MOB1A SP9
FMC1 PTTG1 CHUK MRPL19 SPTBN4
GGNBP2 RBPJ CHURC1 MRPL58 SSR4
GLCE RNF167 CLPX MRPS18B SUCLG1
GP1BA RPL10A CNPY2 MTHFD2L TAF1D
GPR19 RPL12 COL1A2 MTRF1L TAPBPL
HSD17B1 RPL13A COPS3 MYNN TBC1D17
HSPA4 RPL17 COQ3 NKAP TFPT
HSPH1 RPL23 COX7B NOP16 TFRC
IFT80 RPL26 DIS3 NPM1 TIMM17A
IMP3 RPL27A DRG1 NSDHL TMEM107
INTS13 RPL7A DSE NTMT1 TMEM11
IREB2 RPS6 DZIP3 NUDT19 TMEM127
KAZALD1 RRAGA EDRF1 NUDT2 TMEM132B
LAMP1 SEC62 EIF3L OST4 TRIM41
LPXN SFXN3 ENDOV PCMTD1 TSEN34
LRSAM1 SKA3 EXT2 PCYOX1 TSPYL1
LTV1 SLC39A7 F8 PHB TSPYL4
MAGOHB SLU7 FAM136A PIBF1 TTC14
MAP1LC3B SMIM10L1 FAM216A PLAA TTC30B
MAP3K7CL SMIM27 FASTKD2 PLCD3 TTC32
MATR3 SPAG16 FGF1 POFUT2 TXNDC9
MICU2 SRP19 FOXG1 POLR2H UBAC1
Serum starved + Cycling  (101 
genes) Cycling only (139 genes)




Appendix table 9: Overlap of DCAF7 regulated genes (obtained by RNA-seq) with 
DYRK1A ChIP-seq dataset [under Serum starved or Cycling conditions (Di Vona et al., 
2015)]. Related to Figure 50A and 50B. 
 
Appendix table 10: Overlap of genes bound by AUTS2 and genes bound by DYRK1A 
[under Cycling or Serum starved conditions (Di Vona et al., 2015)]. Related to Figure 51. 
Serum starved 
only (2 genes)
ADAT1 MAK16 ABCC10 KPNA2 SIRT5 CNN2 AGBL5 PTPRN2 ACADSB EIF3L RIN1
ASH2L MAPK14 CARMIL1 LOXL2 SLC44A1 GGH ALDH16A1 RC3H2 ADGRF1 EPHB3 RPS7
ASPH MICU2 CETN2 MAD2L1 SNRPC ATF4 RIMS3 AIDA FOXG1 SLC12A9
C1orf74 MRPL57 COL1A2 MRPS18B SPTY2D1 BANP RPL13A ATF7 GSN SLC39A9
C6orf89 MYO19 DHX8 MYBL2 TADA3 C2orf68 RPL27A B4GAT1 HDAC10 SMARCC2
CHAF1A NCAPG2 DIS3 NCOA7 TFRC CDC25B RPL4 C11orf54 HDAC6 SMARCD2
COPB2 NOP14 DZIP3 NOP16 TP53 CENPB RPL7A C12orf57 IKZF5 SMNDC1
DBR1 NPR3 FAM216A NUDT5 TRIM27 CHST7 RPS11 CAMK2D ITGA10 SNAI1
DCAF16 PGK1 FGF1 PDE12 UBXN11 CYGB RPS16 CCNJ LRFN3 TFPT
DHX37 PIGW FKBPL PFDN6 WDR46 ECHS1 SFXN3 CHUK LSM14A TIA1
EFHC1 PLOD2 FUS PHB WDR90 FAM135A SLC12A2 CLASP1 LY6G5C TMEM127
FLNA PTRH2 GDI2 POFUT2 ZNF697 FBXO31 SLC25A11 CNIH2 MBLAC1 TROAP
GMPPA SEC22C GOLGA8B POLR1C ZNF790 FOXC2 SNX33 CNPY2 NFIB TSPYL1
GORASP2 SETD5 HMGN5 PSMB2 GLCE SURF1 COL1A1 NUDT19 TSPYL4
HSD17B8 SKA3 IGFBP3 RAD18 HERC1 SURF2 CREBZF P2RX6 TTC32
HSPH1 SLC39A7 INTS9 RBM26 KAZALD1 YPEL4 CTNNBIP1 PCYOX1 TUBGCP6
LAMP1 SS18L2 KANK1 RFC3 LPXN DLX1 PHC2 U2AF1L4
LSM3 SSR1 KBTBD6 SAP18 LRRC28 DUSP4 PLCD3 UBAC1
MAGOHB TMEM79 KIF24 SEMA3B MIF4GD EBF1 PLEKHG2 VAMP1
PAOX EDRF1 PROSER3 ZFP36
PAXBP1 EFNA5 PSENEN ZNF792
PCGF2 EID2 PTCH2
POLDIP3 EID2B RAB27A
Up in DCAF7 overexpression and overlap with DYRK1A ChIP-seq 
dataset
Serum starved + 
Cycling  (39 genes) Cycling only (67 genes)
Dn in DCAF7 overexpression and overlap with DYRK1A 
ChIP-seq dataset
Serum starved + 
Cycling  (38 genes) Cycling only (51 genes)
Serum starved 
only (1 gene)
ALDH16A1 MED1 RPL17 ACTRT3 MTRNR2L1 RPS15 TRAPPC6B
ARF3 MED22 RPL17-C18orf32 BCLAF1 MYNN SMC5
ATF4 METTL16 RPL7A C19orf53 NDUFA11 SNRPG
C18orf32 MYO19 RPS16 CNPY2 NUDT19 TIMM17A
C5orf24 NCAPG2 RPS28 DRG1 PICK1 U2AF1L4
CCNG1 NDUFA7 SUPT5H DSE PKLR VMAC
CCT8 NOL9 TAS1R1 FDPS PLEKHG2 VPS8
DNTTIP2 PIGW TMEM245 GTF3C5 POLR1C YIPF3
IREB2 PIH1D1 UBC GUK1 PPM1G ZFP36
LRSAM1 PPCDC HOXC5 PSENEN ZNF345
MAP3K7CL RPL12 LIN37 PSMB2 ZNF790
Serum starved + Cycling  (31 genes) Cycling  only (33 genes)
Overlap of DYRK1A Chip-Seq dataset with AUTS2 ChIP-seq dataset
